0001816233-24-000111.txt : 20240509 0001816233-24-000111.hdr.sgml : 20240509 20240509171259 ACCESSION NUMBER: 0001816233-24-000111 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sharecare, Inc. CENTRAL INDEX KEY: 0001816233 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HEALTH SERVICES [8000] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 851365053 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39535 FILM NUMBER: 24931878 BUSINESS ADDRESS: STREET 1: 255 EAST PACES FERRY ROAD NE STREET 2: SUITE 700 CITY: ATLANTA STATE: GA ZIP: 30305 BUSINESS PHONE: (404) 671-4000 MAIL ADDRESS: STREET 1: 255 EAST PACES FERRY ROAD NE STREET 2: SUITE 700 CITY: ATLANTA STATE: GA ZIP: 30305 FORMER COMPANY: FORMER CONFORMED NAME: Falcon Capital Acquisition Corp. DATE OF NAME CHANGE: 20200626 FORMER COMPANY: FORMER CONFORMED NAME: Falcon Capital Corp I DATE OF NAME CHANGE: 20200625 10-Q 1 shcr-20240331.htm 10-Q shcr-20240331
000181623312/312024Q1falsehttp://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613MemberP6MP6Mhttp://www.sharecare.com/20240331#WarrantLiabilityxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureshcr:installment00018162332024-01-012024-03-310001816233us-gaap:CommonClassAMember2024-01-012024-03-310001816233shcr:RedeemableWarrantsMember2024-01-012024-03-3100018162332024-05-0600018162332024-03-3100018162332023-12-310001816233shcr:RedeemableConvertiblePreferredStockSeriesAMember2024-03-310001816233shcr:RedeemableConvertiblePreferredStockSeriesAMember2023-12-3100018162332023-01-012023-03-310001816233us-gaap:RedeemableConvertiblePreferredStockMember2023-12-310001816233us-gaap:CommonStockMember2023-12-310001816233us-gaap:AdditionalPaidInCapitalMember2023-12-310001816233us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001816233us-gaap:RetainedEarningsMember2023-12-310001816233us-gaap:NoncontrollingInterestMember2023-12-310001816233us-gaap:CommonStockMember2024-01-012024-03-310001816233us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001816233us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001816233us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001816233us-gaap:RetainedEarningsMember2024-01-012024-03-310001816233us-gaap:RedeemableConvertiblePreferredStockMember2024-03-310001816233us-gaap:CommonStockMember2024-03-310001816233us-gaap:AdditionalPaidInCapitalMember2024-03-310001816233us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001816233us-gaap:RetainedEarningsMember2024-03-310001816233us-gaap:NoncontrollingInterestMember2024-03-310001816233us-gaap:RedeemableConvertiblePreferredStockMember2022-12-310001816233us-gaap:CommonStockMember2022-12-310001816233us-gaap:AdditionalPaidInCapitalMember2022-12-310001816233us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001816233us-gaap:RetainedEarningsMember2022-12-310001816233us-gaap:NoncontrollingInterestMember2022-12-3100018162332022-12-310001816233us-gaap:CommonStockMember2023-01-012023-03-310001816233us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100018162332022-01-012022-12-310001816233us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-12-310001816233srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-12-310001816233us-gaap:NoncontrollingInterestMember2023-01-012023-03-310001816233us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001816233us-gaap:RetainedEarningsMember2023-01-012023-03-310001816233us-gaap:RedeemableConvertiblePreferredStockMember2023-03-310001816233us-gaap:CommonStockMember2023-03-310001816233us-gaap:AdditionalPaidInCapitalMember2023-03-310001816233us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001816233us-gaap:RetainedEarningsMember2023-03-310001816233us-gaap:NoncontrollingInterestMember2023-03-3100018162332023-03-310001816233us-gaap:RelatedPartyMember2023-12-310001816233us-gaap:RelatedPartyMember2024-03-310001816233srt:MinimumMember2024-01-012024-03-310001816233srt:MaximumMember2024-01-012024-03-310001816233shcr:EnterpriseMember2024-01-012024-03-310001816233shcr:EnterpriseMembersrt:MinimumMember2024-01-012024-03-310001816233shcr:EnterpriseMembersrt:MaximumMember2024-01-012024-03-3100018162332024-04-012024-03-310001816233shcr:EnterpriseMember2023-01-012023-03-310001816233shcr:ProviderMember2024-01-012024-03-310001816233shcr:ProviderMember2023-01-012023-03-310001816233shcr:LifeSciencesMember2024-01-012024-03-310001816233shcr:LifeSciencesMember2023-01-012023-03-310001816233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2024-03-310001816233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2024-03-310001816233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2024-03-310001816233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2024-03-310001816233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2024-03-310001816233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2024-03-310001816233us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2024-03-310001816233us-gaap:FairValueMeasurementsRecurringMember2024-03-310001816233shcr:WarrantPrivateMember2024-03-310001816233shcr:ContingentConsiderationLiabilityMember2023-12-310001816233shcr:ContingentConsiderationLiabilityMember2024-01-012024-03-310001816233shcr:ContingentConsiderationLiabilityMember2024-03-310001816233us-gaap:TechnologyBasedIntangibleAssetsMember2024-03-310001816233us-gaap:TradeNamesMember2024-03-310001816233us-gaap:CustomerRelationshipsMember2024-03-310001816233us-gaap:ComputerSoftwareIntangibleAssetMember2024-03-310001816233shcr:ComputerSoftwareProjectsInProcessIntangibleAssetMember2024-03-310001816233us-gaap:TradeNamesMember2024-03-310001816233shcr:WarrantLiabilityMember2024-03-310001816233shcr:WarrantEquityMember2024-01-012024-03-310001816233shcr:WarrantEquityMember2024-03-310001816233shcr:WarrantEquityMembersrt:MinimumMember2024-03-310001816233shcr:WarrantEquityMembersrt:MaximumMember2024-03-310001816233shcr:ContractualAndEarnoutArrangementsMember2024-03-3100018162332023-01-012023-12-310001816233us-gaap:RestrictedStockUnitsRSUMember2023-12-310001816233us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001816233us-gaap:RestrictedStockUnitsRSUMember2024-03-310001816233us-gaap:CostOfSalesMember2024-01-012024-03-310001816233us-gaap:CostOfSalesMember2023-01-012023-03-310001816233us-gaap:SellingAndMarketingExpenseMember2024-01-012024-03-310001816233us-gaap:SellingAndMarketingExpenseMember2023-01-012023-03-310001816233shcr:ProductAndTechnologyExpenseMember2024-01-012024-03-310001816233shcr:ProductAndTechnologyExpenseMember2023-01-012023-03-310001816233us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-03-310001816233us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001816233us-gaap:RestrictedStockUnitsRSUMember2023-05-310001816233us-gaap:RestrictedStockUnitsRSUMember2023-05-312023-05-310001816233shcr:SulAmricaServiosDeSadeSASulAmricaMembershcr:SharecareBrasilServiciosDeConsultoriaLtdaMember2024-03-310001816233shcr:CustomerMembershcr:SulAmricaServiosDeSadeSASulAmricaMember2024-01-012024-03-310001816233shcr:CustomerMembershcr:SulAmricaServiosDeSadeSASulAmricaMember2023-01-012023-03-310001816233shcr:CustomerBoardOfDirectorsRelatedMember2023-01-012023-03-310001816233shcr:CustomerBoardOfDirectorsRelatedMember2023-12-310001816233shcr:SeriesAPreferredStockHolderMember2023-01-012023-03-310001816233shcr:SeriesAPreferredStockHolderMember2023-12-310001816233shcr:DirectorAffiliatedCustomerMember2023-12-310001816233shcr:DirectorAffiliatedCustomerMember2023-01-012023-03-310001816233us-gaap:StockCompensationPlanMember2024-01-012024-03-310001816233us-gaap:StockCompensationPlanMember2023-01-012023-03-310001816233us-gaap:RedeemableConvertiblePreferredStockMember2024-01-012024-03-310001816233us-gaap:RedeemableConvertiblePreferredStockMember2023-01-012023-03-310001816233us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001816233us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310001816233us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001816233us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________
FORM 10-Q
_____________________________________________
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2024
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from     to
Commission file number 001-39535
SHARECARE, INC.
(Exact name of registrant as specified in its charter)
Delaware 85-1365053
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer Identification No.)
255 East Paces Ferry Road NE, Suite 700
Atlanta, Georgia
30305
(Address of Principal Executive Offices)(Zip Code)
(404) 671-4000
(Registrant's telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareSHCRThe Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per shareSHCRWThe Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filerx
Non-accelerated fileroSmaller reporting companyo
Emerging growth companyx
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x
As of May 6, 2024, there were 362,409,958 shares of the registrant’s common stock, par value $0.0001 per share, outstanding.

Sharecare, Inc.
Table of Contents
Page
i
Part I - Financial Information
ITEM 1. FINANCIAL STATEMENTS
SHARECARE, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share amounts)
As of March 31,
2024		As of December 31,
2023
Assets
Current assets:
Cash and cash equivalents$100,320 $128,187 
Accounts receivable, net (net of allowance for doubtful accounts of $8,348 and $8,544, respectively)
124,936 128,173 
Other receivables 2,213 2,262 
Prepaid expenses9,875 6,007 
Other current assets2,814 3,178 
Total current assets240,158 267,807 
Property and equipment, net2,751 3,375 
Other long-term assets13,599 13,863 
Intangible assets, net130,263 136,552 
Goodwill191,860 192,037 
Total assets$578,631 $613,634 
Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity
Current liabilities:
Accounts payable$45,530 $45,388 
Accrued expenses and other current liabilities (Note 3)55,516 65,706 
Deferred revenue5,735 5,517 
Total current liabilities106,781 116,611 
Warrant liabilities317 403 
Long-term debt 586 519 
Other long-term liabilities7,171 8,032 
Total liabilities114,855 125,565 
Commitments and contingencies (Note 7)
Series A redeemable convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of $50,000 as of March 31, 2024 and December 31, 2023
58,205 58,205 
Stockholders’ equity:
Common stock $0.0001 par value; 600,000,000 and 600,000,000 shares authorized; 358,572,273 and 353,430,357 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively
36 35 
Additional paid-in capital1,168,869 1,157,737 
Accumulated other comprehensive loss(2,551)(2,263)
Accumulated deficit(760,460)(725,373)
Total Sharecare, Inc. stockholders’ equity405,894 430,136 
Noncontrolling interest in subsidiaries(323)(272)
Total stockholders’ equity405,571 429,864 
Total liabilities, redeemable convertible preferred stock and stockholders’ equity$578,631 $613,634 

The accompanying notes are an integral part of these consolidated financial statements.
1

SHARECARE, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands, except share and per share amounts)
Three Months Ended
March 31,
20242023
Revenue
$90,861 $116,295 
Costs and operating expenses:
Costs of revenue (exclusive of depreciation and amortization)
51,121 67,890 
Sales and marketing13,558 15,348 
Product and technology14,544 20,808 
General and administrative34,907 34,121 
Depreciation and amortization13,331 14,781 
Total costs and operating expenses127,461 152,948 
Loss from operations(36,600)(36,653)
Other income:
Interest income1,274 1,680 
Interest expense(217)(430)
Other income
368 429 
Total other income
1,425 1,679 
Loss before income tax benefit (expense)
(35,175)(34,974)
Income tax benefit (expense)
31 (31)
Net loss(35,144)(35,005)
Net loss attributable to noncontrolling interest in subsidiaries(57)(346)
Net loss attributable to Sharecare, Inc.$(35,087)$(34,659)
Net loss per share attributable to common stockholders, basic and diluted $(0.10)$(0.10)
Weighted-average common shares outstanding, basic and diluted
354,208,908 352,923,217 
Net loss$(35,144)$(35,005)
Other comprehensive loss adjustments:
Foreign currency translation(282)307 
Comprehensive loss(35,426)(34,698)
Comprehensive loss (income) attributable to noncontrolling interest in subsidiaries
(51)(289)
Comprehensive loss attributable to Sharecare, Inc.$(35,375)$(34,409)

The accompanying notes are an integral part of these consolidated financial statements.
2
SHARECARE, INC.
CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
(In thousands, except share amounts)

Redeemable Convertible
Preferred Stock
Common Stock
Additional
Paid-In
Capital		Accumulated
Other
Comprehensive
Income (Loss)		Accumulated
Deficit		Noncontrolling
Interest		Total
Stockholders’ Equity
(Deficit)
SharesAmountSharesAmount
Balance at December 31, 20235,000,000 $58,205 353,430,357$35$1,157,737 $(2,263)$(725,373)$(272)$429,864 
Stock options exercised— — 40,278—24 — — — 24 
Common stock issued upon vesting of restricted stock units— — 7,674,8631(1)— — — — 
Issuance of warrants in connection with debt and revenue arrangements— — ——27 — — — 27 
Share-based compensation— — ——13,866 — — — 13,866 
Net income (loss) attributable to noncontrolling interest in subsidiaries— — ——— — — (57)(57)
Currency translation adjustment— — ——— (288)— 6 (282)
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units — — (2,573,225)—(2,784)— — — (2,784)
Net income (loss) attributable to Sharecare, Inc.— — ——— — (35,087)— (35,087)
Balance at March 31, 20245,000,000 $58,205 358,572,273 $36 $1,168,869 $(2,551)$(760,460)$(323)$405,571 

The accompanying notes are an integral part of these consolidated financial statements.
















3


SHARECARE, INC.
CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
(In thousands, except share amounts)

Redeemable Convertible
Preferred Stock
Common Stock
Additional
Paid-In
Capital		Accumulated
Other
Comprehensive
Loss		Accumulated
Deficit		Noncontrolling
Interest		Total
Stockholders’ Equity
(Deficit)
SharesAmountSharesAmount
Balance at December 31, 20225,000,000 $58,205 354,463,620 $35 $1,120,024 $(2,794)$(595,820)$1,155 $522,600 
Stock options exercised— — 281,042—282 — — — 282 
Common stock issued upon vesting of restricted stock units— — 1,759,615—— — — — — 
Issuance of warrants in connection with debt and revenue arrangements— — ——14 — — — 14 
Cumulative effect of adopting ASU 2016-13— — ——— — (1,055)— (1,055)
Share-based compensation— — ——10,406 — — — 10,406 
Net income (loss) attributable to noncontrolling interest in subsidiaries— — ——— — — (346)(346)
Currency translation adjustment— — ——— 250 — 57 307 
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units — — (214,984)—(396)— — — (396)
Net income (loss) attributable to Sharecare, Inc.— — — — — — (34,659)— (34,659)
Other— — — — (131)— — — (131)
Balance at March 31, 20235,000,000 $58,205 356,289,293 $35 $1,130,199 $(2,544)$(631,534)$866 $497,022 

The accompanying notes are an integral part of these consolidated financial statements.



4
SHARECARE, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands, except share and per share amounts)
Three Months Ended
March 31,
20242023
Cash flows from operating activities:
Net loss$(35,144)$(35,005)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense13,331 14,781 
Non-cash interest expense68 254 
Amortization of contract liabilities— (451)
Accretion of contract liabilities— 68 
Lease right-of-use assets expense566 1,138 
Change in fair value of warrant liability and contingent consideration(379)(138)
Share-based compensation13,596 9,969 
Deferred income taxes(36)59 
Other151 2,120 
Changes in operating assets and liabilities:
Accounts receivable, net2,842 (1,387)
Prepaid expenses and other assets(3,747)(5,795)
Accounts payable and accrued expenses(10,422)(10,608)
Operating lease liabilities(635)794 
Deferred revenue218 703 
Net cash used in operating activities(19,591)(23,498)
Cash flows from investing activities:
Purchases of property and equipment(51)(368)
Capitalized internal-use software costs(5,135)(4,806)
Net cash used in investing activities(5,186)(5,174)
Cash flows from financing activities:
Payments for shares repurchased(2,784)(131)
Proceeds from exercise of common stock options24 1,023 
Payments on financing lease obligations(285)(370)
Net cash (used in) provided by financing activities(3,045)522 
Effect of exchange rates on cash and cash equivalents(45)72 
Net decrease in cash and cash equivalents(27,867)(28,078)
Cash and cash equivalents at beginning of period128,187 182,508 
Cash and cash equivalents at end of period$100,320 $154,430 
Supplemental disclosure of cash flow information:
Cash paid for interest$151 $236 
Cash paid for amounts included in the measurement of lease liabilities$626 $1,336 
Assets obtained in exchange for lease obligations$— $1,695 
The accompanying notes are an integral part of these consolidated financial statements.
5
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)

1.Nature of Business and Significant Accounting Policies
Nature of Business
Sharecare, Inc. (“Sharecare” or the “Company”) was founded in 2009 to develop an interactive health and wellness platform and began operations in October 2010. Sharecare’s virtual health platform is designed to help people, patients, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. The platform is designed to connect each stakeholder to the health management tools they need to drive engagement, establish sustained participation, increase satisfaction, reduce costs, and improve outcomes. Sharecare bridges scientifically validated clinical programs with content to deliver a personalized experience for its members, beginning with the RealAge® test, Sharecare’s health risk assessment that shows members the true age of their body, capitalizing on people’s innate curiosity of how “young” they are to draw them into the platform. The Sharecare platform provides members with a personalized action plan to guide and educate them on the habits and behaviors making the biggest impact, both positive and negative, on their RealAge. Sharecare provides the resources members need to manage their health through lifestyle or disease management and coaching programs, such as diabetes management and smoking cessation, well-being solutions, such as financial health and anxiety management; care navigation tools such as find-a-doctor, prescription savings, clinical decision support, medical records, home care, and more. In January 2023, Sharecare launched Sharecare+, a digital-first, comprehensive advocacy solution designed to deliver value through benefits navigation, clinical engagement, virtual care, and chronic case and utilization management. Additionally, Sharecare provides secure, automated release of information, audit and business consulting services to streamline the medical records process for medical facilities. Sharecare delivers value via its provider, enterprise, and life sciences channels.
Basis of Presentation and Consolidation Policy
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Sharecare, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Segment Information
The Company operates as a single operating segment. The Company’s chief operating decision maker is its chief executive officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance and allocating resources for the entire company.
Unaudited Interim Financial Information
The accompanying interim Consolidated Balance Sheet as of March 31, 2024 and the Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit), and Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 are unaudited. These unaudited interim consolidated financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. In management’s opinion, the unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024 and the Company’s consolidated results of operations and cash flows for the three months ended March 31, 2024 and 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any other future interim or annual periods. The information contained within the unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s annual financial statements for the year ended December 31, 2023.
Use of Estimates
The preparation of these unaudited interim consolidated financial statements in conformity with GAAP requires the use of management estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the
6
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)

consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include goodwill, revenue recognition, stock-based compensation, and income taxes. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Concentration of Credit Risk
The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash deposits are held with well-known financial institutions and may exceed federally insured limits. The Company grants credit to its customers in the normal course of business and generally requires no collateral from its customers.
Fair Value Measurements
The carrying value of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.
The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires management to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 — Quoted prices in active markets for identical assets or liabilities
•Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
•Level 3 — Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability
Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis
Assets and liabilities that may be measured at fair value on a non-recurring basis relate primarily to the Company’s tangible fixed assets and other intangible assets. For these assets, the Company does not periodically adjust the carrying value to fair value except in the event of an impairment. When the Company determines that an impairment has occurred, the carrying value of the asset is reduced to its fair value and an impairment charge is recorded within operating loss in the Consolidated Statements of Operations and Comprehensive Loss.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable, net, consists of trade accounts receivable which are due under normal trade terms requiring payment, typically within 45 days from the invoice date. The allowance for doubtful accounts is based on management's estimate for expected credit losses for outstanding trade accounts receivable and is recorded as an offset to accounts receivable. Changes in the allowance for doubtful accounts are classified as general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. The Company determines expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, and adjusts based on expectations of changes in macro-economic conditions and customer-specific information that may impact the collectability of outstanding receivables. The Company reassesses the adequacy of the allowance for doubtful accounts each reporting period.
The changes in the allowance for doubtful accounts are as follows (in thousands):
7
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)

Three Months Ended
March 31,
20242023
Allowance for doubtful accounts – beginning balance$8,544 $7,197 
Provision for doubtful accounts411 1,869 
Amounts written off and other adjustments(607)(640)
Allowance for doubtful accounts – ending balance$8,348 $8,426 
Contract Liabilities
In connection with certain acquisitions, the Company has recognized current and noncurrent contract liabilities, representing off-market values associated with certain wellness program royalty agreements. Amortization of these contract liabilities was $0 and $0.5 million for three months ended March 31, 2024 and 2023, respectively, all of which was included within cost of revenues in the Consolidated Statements of Operations and Comprehensive Loss. Additionally, the Company has recognized certain contract liabilities due to a former related party in the amount of $17.5 million, related to service agreements, which is included in accrued expenses and other current liabilities in the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023.
Deferred Revenue
The Company records contract liabilities, which consist of deferred revenue and contract billings in excess of earned revenue, pursuant to ASC 606.
Deferred revenues arise from contracts that permit upfront billing and the collection of fees covering the entire contractual service period, which is generally six to twelve months and in advance of the satisfaction of the performance obligations identified within the related contract. As of March 31, 2024 and December 31, 2023, such fees were $5.7 million and $5.5 million, respectively. The Company recognized $1.2 million of revenue during the three months ended March 31, 2024 that was included in deferred revenue at December 31, 2023.
Revenue Recognition
Performance-Based Revenue
Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as customer cost savings, and/or clinical outcomes improvements (performance-based). The Company uses the most likely amount method to estimate variable consideration for these performance guarantees. The Company includes in the transaction price some, or all, of a variable consideration amount only to the extent that it is not probable that a significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company utilizes customer data to measure performance. Performance-based fees subject to refund that the Company has not recognized as revenues are generally due to either: (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that it is not probable that the Company will meet the relevant performance target(s). As of March 31, 2024 and December 31, 2023, such fees included within deferred revenue were $4.8 million and $4.9 million, respectively.
In the event that performance measures are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, performance-based fees are reconciled and settled. Approximately $1.5 million and $1.2 million of revenues recognized during the three months ended March 31, 2024 and 2023, respectively, were performance-based. As of March 31, 2024 and 2023, the cumulative amount of performance-based revenues that had met the criteria for recognition and had been recognized but had not yet been settled with customers, totaled $1.9 million and $6.5 million, respectively. During the three months ended March 31, 2024, $0.7 million of revenue was recognized, which related to services provided prior to December 31, 2023.
Remaining Performance Obligations
Remaining performance obligations represent contracted revenues that are non-cancellable and have not yet been recognized due to unsatisfied or partially satisfied performance obligations. This includes deferred revenues and amounts that will be invoiced and recognized as revenues in future periods. As of March 31, 2024, future estimated revenue related to
8
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)

performance obligations with terms of more than one year that are unsatisfied or partially unsatisfied at the end of the reporting period was approximately $61.2 million. As of March 31, 2024, the Company expects to recognize revenue on approximately 91% of these unsatisfied performance obligations over the following 24 months and the remainder thereafter.
Disaggregated Revenue
The following table presents the Company’s revenues disaggregated by revenue source (in thousands):
Three Months Ended
March 31,
20242023
Enterprise$46,960 $70,193 
Provider28,427 28,974 
Life Sciences 15,474 17,128 
Total Revenue$90,861 $116,295 
Other Income
For the three months ended March 31, 2024 and 2023, other income (expense) consisted of the following (in thousands):
Three Months Ended
March 31,
20242023
Re-measurement of contingent consideration$294 $138 
Re-measurement of warrant liabilities85 — 
Other(11)291 
Total other income $368 $429 
Accounting Standards Not Yet Adopted
As an emerging growth company (“EGC”), the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are applicable to private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company has elected to use this extended transition period under the JOBS Act until such time as the Company is no longer considered to be an EGC. The adoption dates discussed below reflect this election.
Income Taxes. In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The new ASU requires public business entities, on an annual basis, to provide a tabular rate reconciliation (using both percentages and reporting currency amounts) of (1) the reported income tax expense (or benefit) from continuing operations, to (2) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal (national) income tax rate of the jurisdiction (country) of domicile using specific categories and separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold. A public business entity is required to provide an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes of the reconciling items and the judgment used in categorizing the reconciling items. For each annual period presented, the ASU requires all reporting entities to disclose the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign. It also requires additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The ASU requires that all reporting entities disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign.
9
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)

The ASU is effective for public entities for annual periods beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures.
Segment Reporting. In November 2023, the FASB issued ASU No. 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments in this update address the requirement for a public entity to disclose its significant segment expense categories and amounts for each reportable segment. A significant segment expense is any significant expense incurred by the segment, including direct expenses, shared expenses, allocated corporate overhead, or interest expense that is regularly reported to the chief operating decision maker and is included in the measure of segment profit or loss. The disclosure of significant segment expenses is in addition to the current specifically-enumerated segment expenses required to be disclosed, such as depreciation and interest expense. If a public entity does not disclose any significant segment expenses for a reportable segment, it is required to disclose narratively the nature of the expenses used by the chief operating decision maker to manage the segment's operations. The ASU is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures as it pertains to the Company’s single reportable segment.
2. Fair Value Measurements
The Company’s financial instruments consist of cash equivalents, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration liabilities. Cash equivalents are comprised of money market funds stated at amortized cost, which approximates fair value at the balance sheet dates, due to the short period of time to maturity. Accounts receivable, accounts payable, and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected settlement date. The warrant liabilities and contingent consideration liabilities are recorded at estimated fair value.
The following tables present the fair value hierarchy for assets and liabilities measured at fair value as of March 31, 2024 (in thousands):
March 31, 2024
Level 1Level 2Level 3Total Fair Value
Cash equivalents
Money market funds$10,470 $— $— $10,470 
Total cash equivalents at fair value$10,470 $— $— $10,470 
Liabilities
  Warrant liabilities $317 $— $— $317 
  Contingent consideration – other liabilities— — 101 101 
Total liabilities at fair value$317 $— $101 $418 
The warrants issued during the initial public offering by Falcon Capital Acquisition Corp. “FCAC” and the warrants issued by FCAC simultaneously with its initial public offering in a private placement, are both classified within Level 1 as they are publicly traded and have an observable market price in an active market. Additionally, the warrant liabilities are exercisable for one share of common stock at an exercise price of $11.50.
Contingent consideration is classified within Level 3 as it is valued using certain unobservable inputs. The fair value of the contingent consideration is estimated based on the Company’s stock price and number of shares expected to be issued related to acquisitions in prior years and are estimated using a Monte Carlo simulation with inputs for the Company’s stock price, expected volatility, risk-free rate, first and second earnout hurdles and expected term.
The following is a schedule of changes to the contingent consideration — other liabilities classified as Level 3 for the periods presented (in thousands):
10
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)
December 31, 2023$395 
Re-measurement of contingent consideration(294)
March 31, 2024$101 
3. Balance Sheet Components
Accrued Expenses and Other Current Liabilities
As of March 31, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following (in thousands):
March 31,
2024		December 31,
2023
Accrued expenses$17,304 $15,546 
Accrued compensation10,506 16,235 
Accrued media costs2,506 5,168 
Accrued taxes1,509 1,837 
Operating lease liabilities, current1,684 1,826 
Contract liability due to the Series A Preferred Stockholder
17,496 17,496 
Accrued expenses due to the Series A Preferred Stockholder
3,255 6,084 
Accrued other1,256 1,514 
Total accrued expenses and other current liabilities$55,516 $65,706 
11
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)
4. Goodwill and Other Intangible Assets
Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):
March 31, 2024
CostAccumulated
Amortization		NetWeighted
Average
Remaining
Life
Definite-lived, intangible assets
Technology – features/content$62,926 $(29,650)$33,276 7.2
Trade name3,549 (2,091)1,458 3.3
Customer relationships77,849 (41,121)36,728 8.2
Internal-use software189,631 (140,630)49,001 1.8
Total definite-lived, intangible assets$333,955 $(213,492)$120,463 
Intangible assets not subject to amortization
Internal-use software projects in process$4,770 $— $4,770 
Indefinite-lived, trade names5,030 — 5,030 
Total intangible assets not subject to amortization9,800 — 9,800 
Total intangible assets$343,755 $(213,492)$130,263 
The following tables set forth the changes in the carrying amount of the Company’s goodwill for the period presented (in thousands):
December 31, 2023$192,037 
Foreign currency translation adjustment(177)
March 31, 2024$191,860 
Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subjected to annual tests of impairment. The Company tests goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter and between annual tests if an event occurs or circumstances change that would indicate that it is more likely than not that the carrying amount may be impaired. The Company initially evaluates qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment is not conclusive, a quantitative assessment of the fair value of a reporting unit is performed to test goodwill for impairment using a combination of income and market approaches. There have been no impairments of goodwill since the Company’s inception.
As a result of the sustained decline in the Company’s stock price and associated market capitalization, the Company performed an impairment test during the first quarter of 2024. The fair value of the reporting units for goodwill impairment testing was determined using both an income approach and market approach. The income approach was based on discounted projected future (debt-free) cash flows for each reporting unit. The discount rates applied to these cash flows were based on the weighted average cost of capital for each reporting unit, which takes market participant assumptions into consideration. For the market approach, we used both the guideline public company and similar transaction methods. The guideline public company method analyzes market multiples of revenue and EBITDA for a group of comparable public companies. Under the similar transactions method, valuation multiples are calculated utilizing actual transaction prices and revenue and EBITDA data from target companies deemed similar to the reporting unit. As a result of the interim test, the fair values of each of our reporting units exceeded their respective book values in excess of approximately 10%, and the Company determined there was no impairment. An increase of 100 basis points in the weighted average cost of capital or a decrease of 100 basis points in annual forecasted revenues would have resulted in a 3% and 9% decline in the fair value, respectively of our reporting units which would not have resulted in impairment.
12
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)

Amortization expense for intangible assets during the three months ended March 31, 2024 and 2023 totaled $12.7 million and $14.0 million, respectively. Amortization expense is included in depreciation and amortization in the Consolidated Statements of Operations and Comprehensive Loss.
The following is a schedule of estimated future amortization expense for intangible assets as of March 31, 2024 (in thousands):
Year ending December 31:
Remainder of 2024$33,671 
202531,239 
202617,572 
202710,104 
20286,932 
Thereafter20,945 
Total$120,463 
5. Income Taxes
As a result of the Company’s history of net operating losses, the Company has provided for a full valuation allowance against its deferred tax assets, with the exception of its German and French operations. For the three months ended March 31, 2024, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income. For the three months ended March 31, 2023, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income.
6. Common Stock and Stockholders’ Equity
Warrants
In connection with debt and equity financings and certain partnership arrangements, the Company may issue warrants. Warrants classified as liabilities generally vest immediately and are exercisable upon issuance and have an expiration of seven years from the date of issuance. Warrants classified as equity generally vest after three years from the date of issuance and have an expiration of seven years from the date of issuance.
As of March 31, 2024, the following warrants to purchase common stock were issued and outstanding:
ClassificationWarrants
Outstanding		Exercise Price
per Share
Equity1,278,746 
$4.21 - $5.61
Liability17,433,334 
$11.50
The Company has also entered into, and may in the future enter into, contractual arrangements with certain customers and other parties and earnout arrangements in connection with acquisitions that, in each case, provide for the issuance of warrants and/or common stock upon the achievement of specified milestones. As of March 31, 2024, these agreements provide for the issuance of up to 3,238,675 shares of common stock and 6,353,577 warrants to purchase shares of common stock. With respect to these arrangements, there were 52,589 warrants earned but not issued as of March 31, 2024.
Share-based Payments
Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):
13
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)




Options OutstandingRestricted Stock Units
Number of Options Weighted-
Average
Exercise Price 		Weighted
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic Value
(in thousands)		Number of Plan shares outstandingWeighted-Average Grant Date Fair Value per share
Outstanding as of December 31, 2023
92,218,339$3.01 5.87$1,256 49,007,766 $1.93 
Granted— — 15,089,859 $1.03 
Exercised/Released(40,278)$0.59 $7 (7,674,699)$2.38 
Cancelled/Forfeited(2,685,153)$2.40 (661,764)$1.85 
Outstanding as of March 31, 2024
89,492,908$3.03 5.58$260 55,761,162 $1.62 
Vested and/or exercisable as of March 31, 2024
73,764,072$1.88 5.24$260 
Vested and/or exercisable as of December 31, 202373,902,493$1.89 5.49$1,256 
The intrinsic value is calculated as the difference between the exercise price of the underlying common stock option award and the estimated fair value of the Company’s common stock. Vested but unissued restricted stock units as of March 31, 2024 and December 31, 2023 were immaterial.
Share-based compensation expense for employee and nonemployee options and restricted stock units included in the Consolidated Statements of Operations and Comprehensive Loss is as follows for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended
March 31,
20242023
Cost of revenues$204 $111 
Sales and marketing1,508 828 
Product and technology1,664 1,068 
General and administrative10,468 7,962 
Total share-based compensation expense$13,844 $9,969 
Additionally, share-based compensation costs, reflected within additional paid-in capital in the Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023, included approximately $0.2 million and $0.4 million related to capitalizable internally developed software activities, respectively.
On May 31, 2023, each of the principal executive officer, principal financial officer, other named executive officers, and certain eligible employees of the Company voluntarily elected to forgo up to 25% of their cash base salary for the next 12 months, and in lieu thereof received restricted stock units (“RSUs”) with a value equal to the cash amount they elected to forego over the 12-month period. In consideration for forgoing guaranteed cash compensation, each individual will receive an additional number of RSUs with a value equal to 25% of the amount of cash salary they have elected to forgo. The RSUs were issued in June 2023 and will vest in four equal quarterly installments over the next 12 months, subject to the individual’s continued employment. The ability of the named executive officers and other eligible employees to make such election to forgo guaranteed cash compensation and receive RSUs in lieu thereof was approved by the Compensation and Human Capital Committee of the Company’s board of directors. The unvested RSUs are classified as a liability. As of March 31, 2024, there was $0.4 million of unvested RSUs classified as a liability and recorded to accrued expenses and other current liabilities in the Consolidated Balance Sheets. As such, share-based compensation costs, reflected within additional paid-in capital in the Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months
14
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)




ended March 31, 2024 does not reflect the cost associated with these awards. Upon vesting of these RSUs, amounts will be reclassified from liability to equity.
7. Commitments and Contingencies
Legal Matters
From time to time, the Company is subject to litigation in the normal course of business. The Company is of the opinion that, based on the information presently available, the resolution of any such legal matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. The Company has accrued for losses that are both probable and estimable.
We are also party to investigations and legal disputes and losses related to certain matters that are reasonably possible, but at this time, we cannot estimate a loss or range of losses.
8. Related-Party Transactions
Sul América Serviços de Saúde S.A. (Sul América), is a customer of and owns a 49% interest in Sharecare Brasil Servicios de Consultoria, Ltda. As of the year ended December 31, 2023, the Company ended the services contract with this related party and ceased operations of Sharecare Brasil Servicios de Consultoria, Ltda. Revenues recognized for the three-month period ended March 31, 2024 and 2023 from Sul América totaled $0.3 million and $1.3 million, respectively. For the three-month period ended March 31, 2024, the revenues recognized represent variable termination fee revenue, which was previously contrained and for which uncertainty about the variable amount to be received was resolved.
The Series A Preferred Stock is held by a customer that also had an employee serving on the Sharecare Board. During the three month period ended June 30, 2023, the board member ceased employment with the customer. Subsequent to the board member’s termination of employment with the customer, this customer was no longer considered a related party. Revenues recognized for this customer for the three months ended March 31, 2023 totaled $6.2 million. As of December 31, 2023, $13.0 million in receivables were outstanding from this related party.
During the third quarter of 2022, we entered into a revenue contract with the Series A Preferred Stockholder to provide patient advocacy services. We also entered into separate agreements to purchase distinct goods and services. These agreements are now subject to a dispute. Separate from the above disclosed amounts for this related party, revenues recognized related to these distinct services for the three months ended March 31, 2023 totaled $10.6 million. Additionally, revenue for the three months ended March 31, 2023, included $0.4 million of amortization of contract assets. For the three months ended March 31, 2023, cost of sales totaled $10.9 million. Amounts paid under the agreements that were not determined to be distinct were recorded as a reduction of revenues.
As of December 31, 2023, there were $34.3 million in receivables and $51.1 million in accounts payable and accrued expenses recorded in connection with these distinct agreements. Additionally, in 2022 the Company acquired certain intellectual property which was determined to be distinct and recorded an intangible asset, which is being amortized over its estimated useful life. The unamortized balance of intangible asset was $3.1 million as of December 31, 2023. As of March 31, 2024, the receivables, accounts payable, and accrued expenses balances recorded in connection with these distinct agreements remained unchanged.
The Company has a customer that was a related party for the year ended December 31, 2023 due to an affiliation with a member of the Sharecare Board. This member was nominated during the first quarter of 2023 and has subsequently ceased employment with the customer. This customer is no longer considered a related party as of December 31, 2023. As of December 31, 2023, $1.0 million in receivables were outstanding from this related party and revenues recognized for the three months ended March 31, 2023 totaled $0.7 million.
15
Sharecare, Inc.
Notes to Unaudited Consolidated Financial Statements
(Unaudited)
9. Net Loss Per Share
Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
Three Months Ended
March 31,
20242023
Numerator
Net loss$(35,144)$(35,005)
Less: Net loss attributable to noncontrolling interests in subsidiaries(57)(346)
Net loss available to common stockholders$(35,087)$(34,659)
Denominator
Weighted-average common shares outstanding, basic and diluted354,208,908 352,923,217 
Net loss per share attributable to common stockholders, basic and diluted$(0.10)$(0.10)
The Company’s potential dilutive securities, which include stock options and restricted stock units, redeemable convertible preferred stock, and contingently issuable shares, have been excluded from the computation of diluted net loss per share for the three-months ended March 31, 2024 and 2023, as they are anti-dilutive and the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common share equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Three Months Ended
March 31,
20242023
Stock options and restricted stock units2,660,077 30,951,366 
Redeemable convertible preferred stock5,000,000 5,000,000 
Total7,660,077 35,951,366 
Additionally, stock options of 89.1 million that have exercise prices in excess of the average market price of common shares for the three months ended March 31, 2024 and restricted stock units of 53.5 million as of March 31, 2024 are not included in the calculation of potentially dilutive securities, but could become dilutive in future periods.
For the prior period, stock options of 73.7 million that have exercise prices in excess of the average market price of common shares for the three months ended March 31, 2023 and restricted stock units of 32.5 million as of March 31, 2023 are not included in the calculation of potentially dilutive securities.
10. Subsequent Events
The Company considers events or transactions that occur after the balance sheet date, but before the consolidated financial statements are issued, to provide additional evidence relative to certain estimates or identify matters that require additional disclosures. The Company evaluated subsequent events through, May 9, 2024, the date on which the consolidated financial statements were available to be issued, noting no such material events.
16
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of the financial condition and results of operations of Sharecare, Inc. (for purposes of this section, “the Company,” “Sharecare,” “we,” “us” and “our”) should be read together with the Company’s audited financial statements as of and for the years ended December 31, 2023, 2022, and 2021, together with the related notes thereto, included in our Annual Report on Form 10-K filed with the SEC on March 29, 2024, and Sharecare’s unaudited interim financial statements as of March 31, 2024 and for the three months ended March 31, 2024 and 2023, together with the related notes thereto, included elsewhere in this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements.
Cautionary Statement Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes forward-looking statements regarding, among other things, the plans, strategies and prospects, both business and financial, of Sharecare. These statements are based on the beliefs and assumptions of our management. Although we believe that our plans, intentions, and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties, and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates,” “possible,” “continue,” “might,” “potential” or “intends” or similar expressions. Forward-looking statements contained in this report include, but are not limited to, statements regarding our expectations as to:
•our business, operations and financial performance, including:
◦expectations with respect to our financial and business performance, including financial projections and business metrics and any underlying assumptions thereunder;
◦future business plans and growth opportunities, including revenue opportunities available from new or existing clients and expectations regarding the enhancement of platform capabilities and addition of new solution offerings;
◦developments and projections relating to our competitors and the digital healthcare industry;
◦the impact of rising inflation, increasing interest rates, public health emergencies, financial institution disruptions and other macroeconomics factors on our business and the actions we may take in response thereto;
◦our expectations regarding anticipated and future partnerships or other relationships with third parties and future acquisitions;
◦our future capital requirements and sources and uses of cash, including potential share repurchases and our ability to obtain additional capital in the future and fully access our Revolving Facility; and
◦our ability to recognize performance-based revenue;
•our status as an EGC and our intention to take advantage of accommodations available to EGCs under the JOBS Act;
•our ability to regain and maintain compliance with Nasdaq listing standards;
•our success in retaining or recruiting, or changes required in, our officers, key employees or directors, and the success of our workplace globalization efforts; and
•the other estimates and matters described in this Quarterly Reports on Form 10-Q under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
These forward-looking statements are based on information available as of the date of this report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements include, but are not limited to, those set forth in this report and in the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 29, 2024. For example, the Company’s expectations regarding future performance assume business currently under contract and satisfaction by our customers of their contractual obligations under those agreements, which is not within the
17
Company’s control. If a customer fails to satisfy its contractual obligations, actual results could be negatively impacted. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may vary in material respects from those expressed or implied by these forward-looking statements. You should not place undue reliance on these forward-looking statements.
Overview
We are a leading digital healthcare company that helps people access, navigate and unify resources to improve their health and well-being in one place, regardless of where they are in their health journey. Our comprehensive and data-driven interoperable ecosystem is designed to help people, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by enabling positive behavior change. Driven by our philosophy that we are “all together better”, at Sharecare, we are committed to supporting each individual through the lens of their personal health and ensuring high-quality care is more accessible and affordable for everyone.
Our digital first ecosystem is centered on the person. We believe everyone’s health and well-being is inherently interconnected. Just as a person’s physical health is inextricably linked to their mental and emotional health, an individual’s health is also connected to a greater collective that includes their employer, providers, insurers, colleagues, family, friends, and local communities. However, these groups have historically remained disconnected with various stakeholders providing potentially hundreds of fragmented point solutions, each addressing only one or two specific health-related objectives. By integrating fragmented point solutions and bringing together disparate stakeholders across the healthcare ecosystem into one connected, interoperable virtual care platform, we believe that we can fulfill the role of a unifier and leverage smartphone technology to foster a frictionless user-friendly experience that engages people across the dynamic continuum of their healthcare needs. We have built our platform into what we believe is the most comprehensive and seamless experience currently available in the digital healthcare space.
Our business combines business-to-business and direct-to-consumer sales models and functions on a more distinctive business-to-business-to-person model. Focusing on the individual, we aim to provide a solution that we believe is more comprehensive than other digital platforms by bringing together scientifically validated clinical programs and engaging content to deliver a personalized experience for our members, whether they come to us by way of the workplace, the exam room, or the living room.
We derive revenue from multiple stakeholders and while we are focused on the individual’s unique experience, our platform is purpose-built to seamlessly connect stakeholders to the health management tools they need to drive engagement, establish sustained participation, increase satisfaction, reduce costs, and improve outcomes. As we expand our offerings and look to further develop our technologies, we continue to consider the distinct needs of each client channel as well as opportunities to better connect and cross-sell while we grow and integrate our solutions into one seamless platform.
Our one platform can be disaggregated into three client channels:
•Enterprise Solutions: Our enterprise channel includes a range of clients — from large employers and healthcare systems to government agencies and health plans — that use our platform to engage with their populations, dynamically measure the impact of that engagement, and efficiently deliver health and wellness services.
•Provider Solutions: Our suite of data and information-driven solutions for healthcare providers is tailored to improve productivity and efficiency and enhance patient care and management while upholding the latest compliance, security, and privacy standards.
•Life Sciences: Our robust platform and suite of digital products and medical expert knowledge provides members with personalized information, programs, and resources to improve their health and well-being, and affords sponsors the opportunity to integrate their brands into Sharecare’s consumer experience in a highly contextual, relevant, and targeted environment.
Key Factors and Trends Affecting our Operating Performance
Our financial condition and results of operations have been, and will continue to be, affected by a number of factors, including our success with respect to the following:
18
•Expanding our Footprint. We believe that our current client base represents a small fraction of potential clients that could benefit from our highly differentiated solutions. We will continue to invest in our sales and marketing efforts and leverage our partner relationships to continue to acquire new clients, including individuals, providers, employers, health plans, government organizations, and communities.
•Expanding our Existing Client Relationships. We also believe that there is significant opportunity to generate growth by maintaining and expanding our relationships with existing clients, including:
•increasing engagement and enrollment of eligible members with our existing enterprise clients through continued sales and marketing efforts, including targeted next-generation digital modeling and marketing, and capitalizing on insights from claims ingestion (the process by which we receive and process information from our clients), population risk stratification and incentives management;
•facilitating intervention with Sharecare+, our high-touch, digital-first advocacy driving high quality experience, care, and value support;
•promoting our marketplace of existing targeted digital therapeutics to close gaps in care in high-cost areas, which we believe represents a $1 billion revenue opportunity within our currently contracted clients; and
•expanding our relationships with our top 25 provider clients with an opportunity to extend our provider products and services to more than 8,500 additional healthcare sites.
•Offering Additional Solutions. We believe there is significant opportunity to cross-sell our provider solutions to existing accounts, including deploying our value-based care solution to approximately 6,000 health system clients.
•Growing our Platform. We are constantly evaluating the marketplace for ways to broaden and enhance our client and member experience, improve clinical results, and increase revenue through product innovation, partnerships, and acquisitions. We intend to continue to leverage our expertise through adding digital therapeutics partnerships as well as the acquisition of products and services that are directly relevant to our existing clients. Additionally, we believe our strong and embedded client relationships provide us with unique perspectives into their evolving needs and the needs of their populations. For example, in January 2023, we launched Sharecare+, our digital-first, comprehensive advocacy solution designed to deliver value through benefits navigation, clinical engagement, virtual care, and chronic case and utilization management.
•Evolving our Products to Cater to an Evolving Industry. As the digital healthcare industry grows, we closely monitor evolving consumer trends and organizations’ needs so that we may adapt our platform to better suit our clients’ demands. Since March 2020, the COVID-19 pandemic greatly accelerated the demand for virtual care solutions and resulted in rapid growth and increased adoption of digital health technologies, which Sharecare was in a unique position to undertake. By building on our deep expertise in handling and managing mass health data, we launched a suite of distinct but complementary digital tools and programs to address the evolving emotional, educational, clinical, and operational challenges introduced by the pandemic. We intend to continue to look for opportunities to leverage our platform and expertise to provide first-mover solutions to evolving and future demands in the digital healthcare industry.
•Acquisitions. We believe that our proven track record of successful acquisitions coupled with the flexibility and capabilities of our platform positions us to continue opportunistically pursuing attractive M&A opportunities. We believe this potential is further accentuated by our multiple client channels and constantly expanding member base. Future acquisitions could drive value and growth in a host of ways, including access to new customers and potential cross-sell opportunities; unlocking new customer channels or geographies; adding new solutions to serve our existing client base; and adding new capabilities to enhance our existing solution offering or the efficiency of our platform. In addition, we believe our acquisition track record demonstrates our ability to realize synergies and optimize performance of potential M&A partners.
•Globalization Efforts and Cost Savings. Through our globalization efforts, we believe there is opportunity to achieve approximately $30 million in annualized cost savings, which will include both operating and capitalized expense reductions. These efforts across our Provider and Enterprise channels have begun to yield cost savings, which began in the first quarter of 2023 and continue to increase as we expect the global shared service center to become fully operational during the first half of 2024.
•Contract Dispute. We are currently in a contract dispute with a customer over an attempted termination by that party of a contract we believe is non-terminable, with remaining fees owed to the Company totaling $50 million over the life of the contract. The counterparty has withheld payment of outstanding invoices and has indicated it
19
does not intend to make any additional payments to the Company under the contract. We believe the contract unambiguously prohibits termination by the counterparty or the withholding of any fees payable to the Company and counterparty’s failure to remit payments and repudiation of future payment obligations constitutes a clear and material breach of the contract. Therefore, we have disputed the purported termination and are vigorously pursuing recovery of the amounts owed under the contract plus damages from the counterparty. We also have other commercial contracts related to advocacy services with certain subsidiaries of the same party that we believe have been breached by such subsidiaries, and we are in the process of taking action to enforce our rights and remedies under the applicable contracts. That contract dispute relates to pricing, amounts owed under the contracts and related matters and is not related to issues regarding the delivery of services by Sharecare. However, it became unfeasible for us to continue to deliver contracted services during the fourth quarter of 2023, which has had a negative impact on our financial results. These disputes are expected to continue to impact our financial results, and we are unable to estimate the probability of a favorable or unfavorable outcome with respect to the disputes at this time. We also expect to incur additional costs as we pursue our legal rights and remedies.
Components of Our Results of Operations
Revenue
The enterprise channel provides employers and health plans with health management programs for large populations, including digital engagement, telephonic coaching, incentives, biometrics, digital therapeutics, home health offerings, advocacy solutions, and subscriptions to the Sharecare platform. Revenue is recognized on a per member per month (“PMPM”) basis or as services are provided. Provider revenue is primarily based on health document requests filled in the health data services business line, as well as subscription fees for various technology related services that assist providers with performance and maximizing reimbursement. Life sciences revenue is generated mostly through ad sponsorships to Sharecare’s extensive member database.
Costs of Revenue
Costs of revenue consist of costs incurred in connection with delivering our various revenue generating activities. Costs are primarily driven by volumes related to requests, engagement, and incentive fulfillment. The major components that make up our cost of revenue are personnel costs to support program delivery as well as customer service along with share-based compensation for employees engaged in delivering products and services to customers, data management fees related to file processing, and variable fees to deliver specific services that may require third party vendors, direct marketing, fulfillment, transaction fees, costs associated with exiting a contract, settlement of contractual obligations, or other costs that can be reduced to offset a decline in revenue. Because our growth strategy includes substantial opportunity to scale low-personnel cost products, we would anticipate future revenue to grow at a faster rate than cost of revenue as those low-personnel cost products mature. Costs of revenue do not include depreciation or amortization, which are accounted for separately.
Sales and Marketing Expenses
Sales and marketing expenses consist primarily of employee-related expenses, including salaries, benefits, commissions, employment taxes, travel, globalization efforts, and share-based compensation costs for our employees engaged in sales, account management, marketing, public relations and related support. In addition, these expenses include marketing sponsorships and engagement marketing spend. These expenses exclude any allocation of occupancy expense and depreciation and amortization.
We expect our sales and marketing expenses to fluctuate as we strategically invest to expand our business while also cutting back on marketing sponsorships. As we scale our sales and marketing personnel in the medium- to long-term, we expect these expenses to fluctuate in both absolute dollars and as a percentage of revenue.
Product and Technology Expenses
Product and technology expenses include personnel and related expenses for software engineering, information technology infrastructure, business intelligence, technical account management, project management, security, product development, globalization efforts, and share-based compensation. Product and technology expenses also include indirect hosting and related costs to support our technology, outsourced software, and engineering services. Our technology and development expenses exclude any allocation of occupancy expense and depreciation and amortization.
We continue to invest in the development of our technology platform with a more focused effort on the globalization of our technology teams, which has helped to reduce overall spend. This effort has resulted in significant decreases in both operating expenses and capital expenditures. Our technology and development expenses may fluctuate as a percentage of our total revenue from period to period partially due to the timing and extent of our technology and development expenses.
20
General and Administrative Expenses
General and administrative expenses include personnel and related expenses for our executive, finance, legal, and human resources departments plus all indirect staff in the divisions not attributable to service delivery, sales and marketing, product and technology and our globalization efforts. They also include professional fees, share-based compensation, settlement of legal obligations, lease termination expense, enterprise resource planning implementation costs, acquisition related costs, rent, utilities and maintenance-related costs. Our general and administrative expenses exclude any allocation of depreciation and amortization. Our general and administrative expenses may fluctuate as a percentage of our total revenue from period to period partially due to the timing and extent of our general and administrative expenses.
Depreciation and Amortization
Depreciation and amortization consists primarily of depreciation of fixed assets, amortization of software, amortization of capitalized software development costs and amortization of acquisition-related intangible assets.
Interest Income
Interest income primarily relates to interest recognized on our money market and overnight interest-bearing accounts.
Interest Expense
Interest expense primarily relates to interest and fees incurred on our line of credit and the amortization of debt issuance costs.
Other Income
Other income primarily relates to the guarantee expense of a standby letter of credit for a third party non-profit organization and changes in the fair value of contingent consideration and warrant liabilities.
21
Results of Operations
Comparison of the Three Months Ended March 31, 2024 and 2023
The following table presents our unaudited Consolidated Statement of Operations for the three months ended March 31, 2024 and 2023, and the percentage change between the two periods:
Three Months Ended March 31,
(in thousands)20242023$ Change% Change
Revenue$90,861 $116,295 $(25,434)(22)%
Costs and operating expenses:
Costs of revenue (exclusive of amortization and depreciation below)51,121 67,890 (16,769)(25)%
Sales and marketing13,558 15,348 (1,790)(12)%
Product and technology14,544 20,808 (6,264)(30)%
General and administrative34,907 34,121 786 2 %
Depreciation and amortization13,331 14,781 (1,450)(10)%
Total costs and operating expenses127,461 152,948 (25,487)(17)%
Loss from operations(36,600)(36,653)53 — %
Other income (expense)
Interest income1,274 1,680 (406)(24)%
Interest expense(217)(430)(213)(50)%
Other income368 429 (61)14 %
Total other income (expense) 1,425 1,679 (254)15 %
Net loss before taxes(35,175)(34,974)(201)(1)%
Income tax benefit31 (31)62 (200)%
Net loss(35,144)(35,005)(139)— %
Net loss attributable to noncontrolling interest in subsidiaries(57)(346)289 (84)%
Net loss attributable to Sharecare, Inc.$(35,087)$(34,659)$(428)(1)%
____________
n.m. — Percentage change not meaningful
Revenue
Revenue decreased $25.4 million, or 22%, from $116.3 million for the three months ended March 31, 2023 to $90.9 million for the three months ended March 31, 2024. Overall, the revenue decrease was attributable mostly to our Enterprise channel, including a contractual dispute with a large advocacy customer as outlined in the footnotes of the Company’s financial statements and as discussed above under Key Factors and Trends Affecting our Operating Performance - Contract Dispute. Additionally, revenue decreased due to reduced supplemental hours in our home health business, the ceasing of our Brazil operations, and the expiration of two payor customers in the population health line of business.
The channel revenue changed as follows: enterprise channel decreased by $23.2 million (from $70.2 million for 2023 to $47.0 million for 2024), the provider channel decreased by $0.6 million (from $29.0 million for 2023 to $28.4 million for 2024) and the life sciences channel decreased by $1.6 million (from $17.1 million for 2023 to $15.5 million for 2024). The decrease in the enterprise channel of 33% was attributable to a contractual dispute with a large advocacy customer, expiration of two payor customers and reduced supplemental staffing hours in home health. The provider channel decrease of 2% was primarily attributable to seasonal timing of audit volumes that were delivered earlier in the prior year. The life sciences channel decreased 9% due to an expiring patent for a large brand and the expected decrease of Smart Omix deliverables.
22
Costs of Revenue
Costs of revenue decreased $16.8 million, or 25%, from $67.9 million for the three months ended March 31, 2023 to $51.1 million for the three months ended March 31, 2024. The decrease was primarily associated with lower revenue due to the aforementioned advocacy contract dispute along with cost optimization in the Provider channel.
Sales and Marketing
Sales and marketing expense decreased $1.8 million, or 12%, from $15.3 million for the three months ended March 31, 2023 to $13.6 million for the three months ended March 31, 2024. The decrease was primarily due to reduced marketing sponsorship fees, along with reduced third party application and consulting expense, and lower travel and sales event expenses.
Product and Technology
Product and technology expenses decreased $6.3 million, or 30%, from $20.8 million for the three months ended March 31, 2023 to $14.5 million for the three months ended March 31, 2024. The decrease was attributable to globalization of technology operations, reduced severance costs, the wind down of our Brazil joint venture, and the discontinuation of up front research and development amortization as recognized in prior periods.
General and Administrative
General and administrative expense increased $0.8 million, or 2%, from $34.1 million for the three months ended March 31, 2023 to $34.9 million for the three months ended March 31, 2024. General and administrative expense increased due to an increase in share-based compensation of $2.5 million, which was offset by cost reduction efforts of our facility lease footprint, lower business insurance, and lower content/video production.
Depreciation and Amortization
Depreciation and amortization decreased $1.5 million, or 10%, from $14.8 million for the three months ended March 31, 2023 to $13.3 million for the three months ended March 31, 2024. The decrease was primarily related to the lower capitalization rates of internal use software development as compared to the prior year.
Non-GAAP Financial Measures
In addition to our financial results determined in accordance with U.S. GAAP, we believe the non-GAAP measures adjusted EBITDA, adjusted net loss, and adjusted loss per share, are useful in evaluating our operating performance. We use adjusted EBITDA, adjusted net loss, and adjusted loss per share to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. In particular, we believe that the use of adjusted EBITDA, adjusted net loss, and adjusted loss per share is helpful to our investors as they are metrics used by management in assessing the health of our business and our operating performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as a tool for comparison. The reconciliations of adjusted EBITDA, adjusted net loss, and adjusted loss per share to net loss, the most directly comparable financial measure stated in accordance with GAAP, are provided below. Investors are encouraged to review the reconciliations and not to rely on any single financial measure to evaluate our business.
Adjusted EBITDA
Adjusted EBITDA is a key performance measure that management uses to assess our operating performance. Because adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes.
We calculate adjusted EBITDA as net loss adjusted to exclude (i) depreciation and amortization, (ii) interest income, (iii) interest expense, (iv) income tax (benefit) expense, (v) other income (non-operating), (vi) share-based compensation, (vii) warrants issued with revenue contracts, (viii) amortization of non-cash payment for research and development, (ix) non-operating, non-recurring costs, (x) reorganizational and severance costs, and (xi) acquisition-related costs. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate our lines of business and services.
23
Non-operating, non-recurring costs for the three months ended March 31, 2024 include costs related to legal matters involving prior acquisitions and in connection with the contractual obligation with a financially distressed vendor and are recorded in general and administrative operating expense.
Non-operating, non-recurring costs for the three months ended March 31, 2023 include costs of our enterprise resource planning (“ERP”) system implementation, costs of contractual obligations associated with a financially distressed vendor, and costs related to legal matters. The ERP and legal matter costs are recorded in general and administrative operating expense and the financially distressed vendor costs are recorded in cost of revenue in the Consolidated Statement of Operations and Comprehensive Loss for each respective period presented.
Legal matter costs include attorney fees associated with a dispute that arose from a prior acquisition, attorney fees associated with the submission of an unsolicited acquisition offer as filed in the Schedule 13D with the SEC on October 11, 2023, and attorney fees related to contractual obligations associated with a financially distressed vendor. These matters have unique facts and circumstance that are not directly related to our operations. We do not consider these costs to be normal, recurring, cash operating expenses necessary to operate our business.
The ERP implementation is viewed as a transformational undertaking due to the extensive scope and inherent change management involved to transition to a new single-solution ERP system from the disparate legacy systems. These costs consist of internal and third-party costs of the ERP implementation and do not include capitalized costs, depreciation and/or amortization, or costs to support or maintain software applications or systems once they are in productive use. The ERP system was fully implemented as planned in 2023, and such costs are not expected to recur in the foreseeable future. We do not consider these costs to be normal, recurring, cash operating expenses necessary to operate our business.
Financially distressed vendor costs include financial support from us to a vendor in response to the vendor’s financial difficulties, which absent such support would have resulted in an interruption of our service to our customers. Because we are committed to providing uninterrupted service to our customers, and to minimizing the risk of such a disruption, we made additional, advance payments to the vendor beyond those that were due to the vendor in association with services procured from the vendor. We ceased procuring services from the vendor in Q2 2023 and subsequent to that period no further amounts were paid. Because the costs of the additional payments made to the vendor were incremental to the costs incurred by us to deliver service to our customers, we do not consider them to be normal, recurring, cash operating expenses necessary to operate our business.
Reorganizational and severance costs are a component of our Globalization Efforts and Cost Savings as described in Key Factors and Trends Affecting our Operating Performance. These costs are due to efforts to globalize and centralize our workforce through the creation of the global shared service center which is expected to be fully operational during the first half of 2024. We have never had a global shared service center and view this undertaking as outside the scope of normal operations. Costs include salary, benefits, equity and bonus compensation, and other employee costs for those who were identified to be terminated. These costs were recorded in sales and marketing, product and technology, and general and administrative operating expenses in the Consolidated Statement of Operations and Comprehensive Loss for the periods presented, based on the employee’s respective job function. Because these costs are part of a specific and unprecedented initiative, we do not consider these expenses to be normal, recurring, cash operating expenses necessary to operate our business.
Certain prior period adjusted EBITDA add-back amounts have been reclassified to new add-back line items in order to conform to the current period presentation and to more accurately describe the nature of the amounts year-over-year.
The following table presents a reconciliation of adjusted EBITDA from the most comparable GAAP measure, net loss, for the three months ended March 31, 2024 and 2023 (in thousands):
24
Three Months Ended
March 31,
20242023
Net loss$(35,144)$(35,005)
Add:
Depreciation and amortization13,331 14,781 
Interest income(1,274)(1,680)
Interest expense217 430 
Income tax (benefit) expense(31)31 
Other income (non-operating)(368)(429)
Share-based compensation13,596 9,969 
Warrants issued with revenue contracts28 14 
Amortization of non-cash payment for research and development — 1,190 
Non-operating, non-recurring costs(a)
2,162 1,716 
Reorganizational and severance costs(b)
3,345 9,030 
Acquisition-related costs1,413 558 
Adjusted EBITDA(c)(d)
$(2,725)$605 
____________
(a)For the three months ended March 31, 2024, primarily represents costs related to legal matters involving prior acquisitions for $1.7 million and in connection with the contractual obligation with a financially distressed vendor of $0.4 million. For the three months ended March 31, 2023, primarily represents costs related to the ERP implementation of $0.4 million, contractual obligations with a financially distressed vendor of $0.4 million, and legal matters of $0.2 million.
(b)For the three months ended March 31, 2024, primarily represents costs related to globalizing the Company's workforce of $2.9 million and severance of $0.4 million. For the three months ended March 31, 2023, primarily represents costs related to globalizing the Company's workforce of $8.3 million and severance of $0.8 million.
(c)Includes non-cash amortization associated with contract liabilities recorded in connection with acquired businesses.
(d)Effective September 30, 2023, we no longer exclude costs associated with exiting a contract and lease terminations from our computation of adjusted EBITDA. For the three months ended March 31, 2023 these costs totaled $0.7 and $0.8 million, respectively.
Adjusted Net Loss
Adjusted net loss is a key performance measure that management uses to assess our operating performance. Because adjusted net loss facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and to evaluate our performance.
We calculate adjusted net loss as net loss attributable to Sharecare, Inc. adjusted to exclude (i) amortization of acquired intangibles, (ii) amortization of deferred financing fees, (iii) change in fair value of warrant liability and contingent consideration, (iv) share-based compensation, (v) warrants issued with revenue contracts, (vi) amortization of non-cash payment for research and development, (vii) non-operating, non-recurring costs, (viii) reorganizational and severance costs, and (ix) acquisition-related costs. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate our lines of business and services.
See Adjusted EBITDA above for the discussion of the nature of costs underlying the categories of net costs associated with exiting a contract, non-operating, non-recurring costs, and reorganizational and severance costs.
Certain prior period adjusted net loss add-back amounts have been reclassified to new add-back line items in order to conform to the current period presentation and to more accurately describe the nature of the amounts year-over-year.
Adjusted Loss Per Share
25
Adjusted loss per share is a key performance measure that management uses to assess our operating performance. Because adjusted loss per share facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes and to evaluate our performance.
We calculate adjusted loss per share as adjusted net loss, as defined above, divided by the number of weighted average common shares outstanding - basic and diluted. We do not view the items excluded as representative of normal, recurring, cash operating expenses necessary to operate our lines of business and services.
The following table presents a reconciliation of adjusted net loss and adjusted loss per share from the most comparable GAAP measure, net loss, for the three months ended March 31, 2024 and 2023 (in thousands, except share numbers and per share amounts):
Three Months Ended
March 31,
20242023
Net loss attributable to Sharecare, Inc.$(35,087)$(34,659)
Add:
Amortization of acquired intangibles(a)
1,599 1,632 
Amortization of deferred financing fees— 31 
Change in fair value of warrant liability and contingent consideration(379)(138)
Share-based compensation13,596 9,969 
Warrants issued with revenue contracts28 14 
Amortization of non-cash payment for research and development — 1,190 
Non-operating, non-recurring costs(b)
2,162 1,716 
Reorganizational and severance costs(c)
3,345 9,030 
Acquisition-related costs1,413 558 
Adjusted net loss(d)(e)
$(13,323)$(10,657)
Weighted-average common shares outstanding, basic and diluted354,208,908 352,923,217 
Loss per share$(0.10)$(0.10)
Adjusted loss per share$(0.04)$(0.03)
____________
(a)Represents non-cash expenses related to the amortization of intangibles in connection with acquired businesses.
(b)For the three months ended March 31, 2024, primarily represents costs related to legal matters involving prior acquisitions for $1.7 million and in connection with the contractual obligation with a financially distressed vendor of $0.4 million. For the three months ended March 31, 2023, primarily represents costs related to the ERP implementation of $0.4 million, contractual obligations with a financially distressed vendor of $0.4 million, and legal matters of $0.2 million.
(c)For the three months ended March 31, 2024, primarily represents costs related to globalizing the Company's workforce of $2.9 million and severance of $0.4 million. For the three months ended March 31, 2023, primarily represents costs related to globalizing the Company's workforce of $8.3 million and severance of $0.8 million.
(d)The income tax effect of the Company’s non-GAAP reconciling items are offset by valuation allowance adjustments of the same amount given the Company is in a full valuation allowance position.
(e)Effective September 30, 2023, we no longer exclude costs associated with exiting a contract and lease terminations from our computation of adjusted EBITDA. For the three months ended March 31, 2023 these costs totaled $0.7 and $0.8 million, respectively.
26
Liquidity and Capital Resources
We measure liquidity in terms of our ability to fund the cash requirements of our business operations, including working capital and capital expenditure needs, share repurchases, contractual obligations and other commitments, with cash flows from operations and other sources of funding. Our ability to expand and grow our business will depend on many factors, including our working capital needs and the evolution of our operating cash flows.
We had $100.3 million in cash and cash equivalents as of March 31, 2024. Our principal commitments as of March 31, 2024 consist of operating leases and purchase commitments. The Company maintains its Senior Secured Credit Agreement. As of March 31, 2024, there was $53.9 million available for borrowing under the Revolving Facility.
We believe our cash on hand will be sufficient to meet our operating cash flow, working capital, capital expenditure requirements, and fund share repurchases in the short-term (i.e., the 12 months from the date of this Quarterly Report on Form 10-Q). Our long-term liquidity (i.e., more than 12 months from the date of this Quarterly Report on Form 10-Q) needs include cash necessary to support our business growth and contractual commitments. We believe that the potential financing capital available to us in the future is sufficient to fund our long-term liquidity needs, however, we are continually reviewing our capital resources to determine whether we can meet our short- and long-term goals and we may require additional capital to do so. We may also need additional cash resources due to potential changes in business conditions or other developments, including unanticipated regulatory developments, significant acquisitions, and competitive pressures. We expect our capital expenditures and working capital requirements to continue to increase in the immediate future as we seek to expand our solution offerings. To the extent that our current resources are insufficient to satisfy our cash requirements, we may need to seek additional equity or debt financing. If the needed financing is not available, or if the terms of financing are less desirable than we expect, we may be forced to decrease our level of investment in new product offerings and related marketing initiatives or to scale back our existing operations, which could have an adverse impact on our business and financial prospects.
The following table summarizes our cash flow activities for the periods presented:
Three Months Ended March 31,
(in thousands)20242023
Net cash used in operating activities$(19,591)$(23,498)
Net cash used in investing activities$(5,186)$(5,174)
Net cash (used in) provided by financing activities$(3,045)$522 
Operating Activities
Net cash used in operating activities for the three months ended March 31, 2024 was $19.6 million, a decrease of $3.9 million from $23.5 million of net cash used in operating activities for the three months ended March 31, 2023. Cash used during this period included the $35.1 million net loss for the three months ended March 31, 2024, offset by non-cash items of $27.3 million, which were primarily attributable to depreciation and amortization expense, and share-based compensation. In addition, changes in operating assets and liabilities of $11.7 million resulted in net cash used, attributable to accounts receivable, net, prepaid expense and other assets, and accounts payable and accrued expenses.
Investing Activities
Net cash used in investing activities for the three months ended March 31, 2024 was $5.2 million compared to $5.2 million of net cash used in investing activities for the three months ended March 31, 2023. Cash outflows increased for capitalized internal-use software costs offset by a reduction in cash outflows for purchases of property and equipment.
Financing Activities
Net cash used in financing activities for the three months ended March 31, 2024 was $3.0 million, primarily due to payments for shares repurchased of $2.8 million related to taxes paid in association with vesting restricted stock units.
Net cash provided by financing activities for the three months ended March 31, 2023 was $0.5 million, primarily due to cash received from the proceeds from exercised common stock options of $1.0 million and offset by payments on financing lease obligations of $0.4 million.
Contractual Obligations
There were no material changes to contractual obligations since our Annual Report on Form 10-K filed with the SEC on March 29, 2024.
27
Financing Arrangements
Senior Secured Credit Agreement
The Company’s senior secured revolving credit facility (the “Revolving Facility”) is governed by a Credit Agreement, dated as of March 9, 2017 (as amended, the “Senior Secured Credit Agreement”), among the Company, certain subsidiaries of the Company, as borrowers (the “Borrowers”), the lenders named therein and Wells Fargo Bank, National Association, as administrative agent. On February 10, 2023, the company renewed its Senior Secured Credit Agreement. The Senior Secured Credit Agreement was due to mature on February 10, 2023 and the Company entered into the Ninth Amendment to the Senior Secured Credit Agreement which extends the maturity date of the Senior Secured Credit Agreement to February 10, 2026. The total commitments under the Revolving Facility remain unchanged at $60.0 million as a result of the Ninth Amendment but the sub-limit for letters of credit has increased from $10.0 million to $15.0 million. Availability under the Revolving Facility is generally subject to a borrowing base based on a percentage of applicable eligible receivables. Borrowings under the Revolving Facility bear interest at a rate equal to, at the applicable Borrower’s option, either (a) a base rate plus a margin of 0.75%, or (b) the 1, 3, or 6-month Secured Overnight Financing Rate (SOFR) plus 1.75%. The Ninth Amendment amends other terms of the existing Senior Secured Credit Agreement, including eliminating minimum liquidity and minimum EBITDA covenants, increased thresholds for certain permitted transactions, modifications to reporting and other changes.
The Senior Secured Credit Agreement contains a number of customary affirmative and negative covenants and we were in compliance with those covenants as of March 31, 2024. As of March 31, 2024, there were $0.6 million borrowings outstanding under the Revolving Facility.
Critical Accounting Estimates
Our financial statements are prepared in accordance with GAAP. The preparation of the consolidated financial statements in conformity with GAAP requires management to make a number of estimates and assumptions relating to the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We evaluate our significant estimates on an ongoing basis, including, but not limited to, goodwill, revenue recognition, share-based compensation, and income taxes. We base our estimates on historical experience, known trends, and other market-specific or relevant factors that we believe to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
We believe that the accounting policies described below involve a significant degree of judgment and complexity. Accordingly, we believe these are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations. For further information, see Note 1 to Sharecare’s consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Revenue Recognition
Revenue is recognized when control of the promised good or service is transferred to the client, in an amount that reflects the consideration we expect to be entitled to in exchange for that good or service. Sales and usage-based taxes are excluded from revenue. We serve a diverse group of clients. We are the principal in all outstanding revenue arrangements except for CareLinx. CareLinx has B2C and B2B2C service lines for which CareLinx is generally the agent and we recognize the commission revenue based on the amount billed using the “as-invoiced” practical expedient.
Enterprise Revenue
The enterprise channel provides employers and health plans with health management programs for large populations, including digital engagement, telephonic coaching, incentives, biometrics, digital therapeutics, home care health offerings, advocacy solutions, and subscriptions to the Sharecare platform. Revenue is recognized on a PMPM basis or as services are provided. Member participation fees are generally determined by multiplying the contractually negotiated member rate by the number of members eligible for services during the month. Member participation rates are established during contract negotiations with clients, often based on a portion of the value the programs are expected to create. Contracts with health plans, health care systems and government organizations generally range from three to five years with several comprehensive strategic agreements extending for longer periods. Contracts with larger employer clients typically have two-to-four-year terms.
Health management program contracts often include a fee for the subscription of the Sharecare digital platform and various other platforms under doc.ai, which may also be sold on a stand-alone basis. These services allow members to access Sharecare’s proprietary mobile application with a comprehensive suite of health and wellness management programs, content, and tools. Revenue is recognized on a per member or a fixed fee basis as the services are provided.
28
Sharecare’s Blue Zones Project is a community well-being improvement initiative designed to change the way people experience the world around them by encouraging and promoting better lifestyle choices, such as commuting, eating, and social habits. Because healthier environments naturally nudge people toward healthier choices, Blue Zones Project focuses on influencing the Life Radius®, the area close to home in which people spend 90% of their lives. Blue Zones Project best practices use people, places, and policy as levers to transform those surroundings. These contracts normally include two performance obligations, the discovery period and the subsequent content delivery, for each year of engagement. The revenue is recognized based on the relative standalone selling price of the performance obligations evenly over time. These contracts do not include termination clauses and often have two-to-four-year terms.
Sharecare’s doc.ai offering unlocks the value of health data through licensing artificial intelligence modules and through the creation of products for a portfolio of clients including payors, pharma, and providers. These contracts generally include two performance obligations. The software license and maintenance/support are considered one series of distinct performance obligations and professional services is considered a separate distinct performance obligation. Revenue is recognized for all identified performance obligations as services are delivered.
Sharecare’s CareLinx offerings are focused on connecting caregivers with facilities or individuals that are in need of additional support. These services are generally considered a series of distinct performance obligations. Revenue is recognized for all identified performance obligations as billed using the “as-invoiced” practical expedient.
Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as cost savings, and/or clinical outcomes improvements (performance-based). We use the most likely amount method to estimate variable consideration for these performance guarantees. We include in the transaction price some, or all, of an amount of a variable consideration amount only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. We utilize customer data to measure performance.
In the event that performance levels are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, performance-based fees are reconciled and settled.
Clients are generally billed monthly for the entire amount of the fees contractually due for the prior month’s enrollment, which typically includes the amount, if any, that is performance-based and may be subject to refund should performance targets not be met. Fees for participation are typically billed in the month after the services are provided. Deferred revenues arise from contracts that permit upfront billing and collection of fees covering the entire contractual service period, generally six months to a year. A limited number of contracts provide for certain performance-based fees that cannot be billed until after they are reconciled with the client.
Provider Revenue
Our provider channel revenue is primarily based on the volume of health document requests fulfilled and recognized upon satisfactory delivery to the client. In addition, provider revenue is derived from subscription fees for various technology-related services that assist providers with efficiency and productivity and enhanced patient care. Subscription fees are recognized ratably over the contractual period.
Life Sciences Revenue
Our life sciences channel generates revenue mostly through ad sponsorships and content delivery. Content delivery revenue is recognized when the content is delivered to the client. Ad sponsorship revenue is recognized when the contractual page views or impressions are delivered and the transaction has met the criteria for revenue recognition.
Certain customer transactions may contain multiple performance obligations that may include delivery of content, page views, and ad sponsorship over time. To account for each of these elements separately, the delivered elements must be capable of being distinct and must be distinct in the context of the contract.
Goodwill
Goodwill represents the excess of the purchase price over the fair value of net assets acquired in a business combination. Goodwill is tested for impairment at the reporting unit level, which is the same or one level below the operating segment. We have one operating segment and two reporting units. We identify our reporting units by assessing whether there are components of our operating segment which constitute businesses for which discrete financial information is available and reviewed regularly by the segment managers and consider whether such components should be aggregated into a single reporting unit. We test goodwill for impairment at least annually during the fourth fiscal quarter, or more frequently if indicators of
29
impairment exist during the fiscal year. Events or circumstances which could trigger an impairment review include a significant decline in market capitalization, adverse change in legal factors or in the business climate, loss of key customers, an adverse action or assessment by a regulator, unanticipated competition, a loss of key personnel, significant changes in the manner of our use of the acquired assets or the strategy for our overall business, significant negative industry or economic trends or significant underperformance relative to expected historical or projected future results of operations. When testing goodwill for impairment, we first perform a qualitative assessment. If we determine it is not more likely than not that a reporting unit’s fair value is less than its carrying amount, then no further analysis is necessary. If we determine it is more likely than not that a reporting unit’s fair value is less than its carrying amount, then we compare the estimated fair value of the reporting unit with its carrying amount, including goodwill. If the estimated fair value of the reporting unit exceeds its carrying amount, goodwill is not considered to be impaired. If, however, the fair value of the reporting unit is less than its carrying amount, the difference between the carrying value and the fair value would be recorded as an impairment loss. Any impairment loss is limited to the carrying amount of goodwill allocated to the reporting unit.
We estimate the fair value of our reporting units using a weighted approach that considers a discounted cash flow method, a market multiple method, and a similar transactions method. Under the discounted cash flow approach, we project future cash flows which are discounted using a weighted-average cost of capital analysis that reflects current market conditions, adjusted for specific reporting unit risks (primarily the uncertainty of achieving projected operating cash flows), in arriving at the fair value of the reporting unit. Under the market multiple approach, we estimate a fair value based on comparable companies’ market multiples of revenues and under the similar transactions method we estimate a fair value using market multiples of revenue for comparable companies, for which information is available about recent market transactions.
Management’s judgment utilized in the goodwill impairment evaluation is critical. The computations require management to make estimates and assumptions and actual results may differ significantly, particularly if there are significant adverse changes in the operating environment. Critical assumptions that are used as part of a quantitative goodwill evaluation include:
•The potential future revenue, EBITDA and cash flows of the reporting unit. The projections use management’s assumptions about economic and market conditions over the projected period as well as our estimates of future performance and reporting unit revenue, gross margin, expenses and other factors. The resulting revenue, EBITDA and cash flow estimates are based on our most recent business operating plans, and various growth rates are assumed for years beyond the current business plan period. These operating plans include plans to grow our sales, plans to globalize the Company’s workforce, plans to reduce operating costs, and plans for enhancements to our technology and platform infrastructure. Variations in the assumptions, estimates and rates could result in significantly different estimates of fair value.
•Selection of an appropriate discount rate. Calculating the present value of future cash flows requires the selection of an appropriate discount rate, which is based on a weighted-average cost of capital analysis. The discount rate is affected by changes in short-term interest rates and long-term yield as well as variances in the typical capital structure of marketplace participants. Given current economic conditions, it is possible that the discount rate will fluctuate in the near term. We engaged third party experts to assist in the determination of the weighted-average cost of capital used to discount the cash flows for the goodwill impairment tests.
New Accounting Pronouncements
See Note 1 to Sharecare’s consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.
Emerging Growth Company Accounting Election
Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can choose not to take advantage of the extended transition period and comply with the requirements that apply to non-emerging growth companies, and any such election to not take advantage of the extended transition period is irrevocable. We expect to remain an emerging growth company at least through the end of the 2024 fiscal year and expect to continue to take advantage of the benefits of the extended transition period. This may make it difficult or impossible to compare our financial results with the financial results of another public company that is either not an emerging growth company or is an emerging growth company that has chosen not to take advantage of the extended transition period exemptions for emerging growth companies because of the potential differences in accounting standards used.
30
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We have in the past and may in the future be exposed to certain market risks, including interest rate, foreign currency exchange, and financial instrument risks, in the ordinary course of our business. Currently, these risks are not material to our financial condition or results of operations, but they may be in the future.
31
ITEM 4. CONTROLS AND PROCEDURES
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer (who serves as our Principal Executive Officer) and Chief Financial Officer (who serves as our Principal Financial Officer), as appropriate, to allow timely decisions regarding required disclosure.
Evaluation of Disclosure Controls and Procedures
As required by Rules 13a-15 and 15d-15 under the Exchange Act, our Chief Executive Officer and Chief Financial Officer carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2024. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of March 31, 2024, due solely to the material weakness in our internal control over financial reporting described below. Notwithstanding this material weakness described further below, management believes that the financial statements included in this Quarterly Report on Form 10-Q present fairly in all material respects our financial position, results of operations and cash flows for the periods presented.
Previously Reported Material Weakness
As previously reported in Part II, Item 9A, “Controls and Procedures” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, management identified a material weakness in the Company’s internal control over financial reporting as of December 31, 2023 due to the Company not maintaining adequate internal controls with respect to its revenue recognition evaluation resulting from a change in services provided to a customer, due to untimely communication between cross-functional teams. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.
Remediation Measures
Management is implementing remediation steps to address the material weakness described above. Specifically, during the first quarter of 2024, we began implementing specific remediation actions to address the material weakness, which include the following:
•Conducting training and coaching sessions with cross-functional teams to educate appropriate parties on matters of contractual and operational significance that may have an impact on accounting conclusions and financial reporting;
•Establishing and maintaining periodic meetings between cross-functional teams specific to complex customer contracts to evaluate for potential changes in relationships and services provided to customers that could impact accounting decisions.
Limitations on Effectiveness of Controls and Procedures
Our management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Due to inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.
Changes in Internal Control over Financial Reporting
Except as described above, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 of the SEC that occurred during our last quarter ended
32
March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
33
Part II - Other Information
ITEM 1. LEGAL PROCEEDINGS
From time-to-time, we may be subject to various legal proceedings and claims that arise in the normal course of our business activities. Although the results of these legal proceedings, claims, and investigations cannot be predicted with certainty, we do not believe that the final outcome of any matters that we, or any of our subsidiaries, are currently involved in are reasonably likely to have a material adverse effect on our business, financial condition or results of operations. Regardless of final outcomes, however, any such proceedings, claims and investigations may nonetheless impose a significant burden on management and employees and be costly to defend, with unfavorable preliminary or interim rulings.
The section entitled “Legal Matters” in Note 7 to Sharecare’s consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q is incorporated by reference herein.
ITEM 1A.     RISK FACTORS
Factors that could cause our actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K filed with the SEC on March 29, 2024. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.
As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the SEC on March 29, 2024. However, we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following table provides information about the purchases of shares of our common stock during the three months ended March 31, 2024:
PeriodTotal number of shares purchasedAverage price paid per share
Total number of shares purchased as part of publicly announced program(1)
Approximate dollar value of shares that may yet be purchased under the program
January 1, 2024 through January 31, 2024— $— — $40,774,500 
February 1, 2023 through February 29, 2024— $— — $40,774,500 
March 1, 2024 through March 31, 2024 — $— — $40,774,500 
Totals— $— — $40,774,500 
(1) On May 31, 2023, the Board of Directors announced that it had re-authorized a $50 million stock repurchase program. The stock repurchase program has a 12-month term from May 31, 2023 to May 31, 2024. As of March 31, 2024, a dollar value of approximately $40.8 million in shares authorized remain available to be repurchased. There were no other repurchase programs announced as of March 31, 2024.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
During the quarter ended March 31, 2024, none of our directors or executive officers adopted, modified, or terminated any contract, instruction, or written plan for the purchase or sale of our common stock that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

34
ITEM 6. EXHIBITS
Exhibit
Description
3.1
10.1#†
31.1*
31.2*
32.1**
32.2**
101.INS*
Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH*
Inline XBRL Taxonomy Extension Schema Document
101.CAL*
Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*        
Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*
Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*
Inline XBRL Taxonomy Extension Presentation Linkbase Document
104
The cover page for the Company’s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101
____________
*
Filed herewith
**
Furnished herewith
#
Indicates a management contract or compensatory plan or arrangement
†
Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request.

35
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: May 9, 2024
SHARECARE, INC.
By: /s/ Brent Layton
Name:
Brent Layton
Title:
Chief Executive Officer (Principal Executive Officer)
By: /s/ Justin Ferrero
Name:
Justin Ferrero
Title:
President and Chief Financial Officer (Principal Financial Officer)
36
 EX-31.1 2 sharecareincq12024x311xsec.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a) AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Brent Layton, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Sharecare, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: May 9, 2024
/s/ Brent Layton
Brent Layton
Chief Executive Officer
(Principal Executive Officer)


 EX-31.2 3 sharecareincq12024x312xsec.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULE 13a-14(a) AS
ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Justin Ferrero, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Sharecare, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Dated: May 9, 2024
/s/ Justin Ferrero
Justin Ferrero
President and Chief Financial Officer
(Principal Financial Officer)


 EX-32.1 4 sharecareincq12024x321xsec.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Sharecare, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Brent Layton, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.
Date: May 9, 2024
By:/s/ Brent Layton
Brent Layton
Chief Executive Officer
(Principal Executive Officer)


 EX-32.2 5 sharecareincq12024x322xsec.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Sharecare, Inc. (the “Company”) on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Justin Ferrero, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.
Date: May 9, 2024
By:/s/ Justin Ferrero
Justin Ferrero
President and Chief Financial Officer
(Principal Financial Officer)


 EX-101.SCH 6 shcr-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Nature of Business and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Common Stock and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Common Stock and Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Nature of Business and Significant Accounting Policies - Contract Liabilities and Deferred Revenue (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Nature of Business and Significant Accounting Policies - Performance-Based Revenue (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Nature of Business and Significant Accounting Policies - Remaining Performance Obligations (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Nature of Business and Significant Accounting Policies - Remaining Performance Obligations (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Other Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Fair Value Measurements - Schedule of Changes to the Warrant Liability and Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Balance Sheet Components (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Common Stock and Stockholders' Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Warrants Issued and Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Share-Based Compensation Expense for Employee and Nonemployee Options (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Net Loss Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 shcr-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 shcr-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 shcr-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Re-measurement of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Net loss attributable to noncontrolling interest in subsidiaries Net income (loss) attributable to noncontrolling interest in subsidiaries Less: Net loss attributable to noncontrolling interests in subsidiaries Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Schedule of Accrued Expense and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] Product and technology Product And Technology Expense Product And Technology Expense Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Unsatisfied performance obligations expected recognition period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Performance-based revenue recognized but not yet settled with customers Deferred Revenue, Performance Based Revenue Recognized, Not Yet Settled With Customers Deferred Revenue, Performance Based Revenue Recognized, Not Yet Settled With Customers Statement of Stockholders' Equity [Abstract] Effect of exchange rates on cash and cash equivalents Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Life Sciences Life Sciences [Member] Life Sciences Accounts payable Accounts Payable, Current Restatement Determination Date: Restatement Determination Date [Axis] Total other income Nonoperating Income (Expense) Commitments and contingencies (Note 7) Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Income Taxes Income Tax Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Ownership [Axis] Ownership [Axis] Common stock issued upon vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Units Stock Issued During Period, Value, Restricted Stock Units Current liabilities: Liabilities, Current [Abstract] Restricted Stock Units - Weighted-Average Grant Date Fair Value per share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cancelled/forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Net loss per share attributable to common stockholders, diluted (in USD per share) Earnings Per Share, Diluted Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable, net (net of allowance for doubtful accounts of $8,348 and $8,544, respectively) Accounts Receivable, after Allowance for Credit Loss, Current Goodwill [Roll Forward] Goodwill [Roll Forward] Accounting standards update, extensible enumeration Accounting Standards Update [Extensible Enumeration] Board of Directors Related Customer Customer, Board Of Directors Related [Member] Customer, Board Of Directors Related Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units (in shares) Stock Repurchased During Period Related To Exercise Of Stock Options And Vesting Of Restricted Stock Units, Shares Stock Repurchased During Period Related To Exercise Of Stock Options And Vesting Of Restricted Stock Units, Shares Customer Customer [Member] Customer Outstanding, beginning (in shares) Outstanding, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Warrants vesting period (in years) Warrants And Rights Outstanding, Vesting Period Warrants And Rights Outstanding, Vesting Period Stock options exercised Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Non-cash interest expense Interest Expense, Noncash Interest Expense, Noncash Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Net loss attributable to Sharecare, Inc. Net income (loss) attributable to Sharecare, Inc. Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Total intangible assets, cost Intangible Assets, Gross (Excluding Goodwill) Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity Liabilities and Equity [Abstract] Entity Ex Transition Period Entity Ex Transition Period Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Stock options exercised (in shares) Exercised/released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Accounts receivable, net Increase (Decrease) in Receivables Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Common stock issued upon vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Units Stock Issued During Period, Shares, Restricted Stock Units Derivative liability, statement of financial position Derivative Liability, Statement of Financial Position [Extensible Enumeration] Executive Category: Executive Category [Axis] Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Liabilities Financial Liabilities Fair Value Disclosure [Abstract] Exercised/released (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Level 1 Fair Value, Inputs, Level 1 [Member] Payments on financing lease obligations Repayments Of Capital Lease Obligations Repayments Of Capital Lease Obligations Name Measure Name Name Forgone Recovery, Individual Name Issuance of warrants in connection with debt and revenue arrangements Adjustments to Additional Paid in Capital, Warrant Issued Goodwill Beginning balance Ending balance Goodwill Equity Components [Axis] Equity Components [Axis] Exercise price per share (in USD per share) Exercise price per share (in USD per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Warrant liabilities Warrant Liability Warrant Liability Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Warrants outstanding (in shares) Warrant Liability, Outstanding Warrant Liability, Outstanding Local Phone Number Local Phone Number Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Measurement Frequency [Axis] Measurement Frequency [Axis] Thereafter Finite-Lived Intangible Asset, Expected Amortization, After Year Four Finite-Lived Intangible Asset, Expected Amortization, After Year Four Provider Provider [Member] Provider Nature of Business and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] RSUs Restricted Stock Units Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Class of Warrant or Right [Table] Class of Warrant or Right [Table] Cumulative effect of adopting ASU 2016-13 Cumulative Effect, Period of Adoption, Adjustment [Member] Basis point decrease in annual forecasted revenues Reporting Unit, Basis Decrease Threshold In Annual Forecasted Revenues Reporting Unit, Basis Decrease Threshold In Annual Forecasted Revenues Changes in liability Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Income Statement Location [Axis] Income Statement Location [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Product and Service [Domain] Product and Service [Domain] Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Series A redeemable convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of $50,000 as of March 31, 2024 and December 31, 2023 Redeemable convertible preferred stock, beginning balance Redeemable convertible preferred stock, ending balance Temporary Equity, Carrying Amount, Attributable to Parent Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Accrued expenses Accrued Expenses, Current Accrued Expenses, Current Series A Preferred Stock Redeemable Convertible Preferred Stock, Series A [Member] Redeemable Convertible Preferred Stock, Series A Potential common stock equivalents (in shares) Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Document Quarterly Report Document Quarterly Report Interest expense Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] General and administrative General and Administrative Expense [Member] Outstanding, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets obtained in exchange for lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Remainder of 2024 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Allowance for Doubtful Accounts Accounts Receivable, Allowance for Credit Loss [Roll Forward] Trading Arrangement: Trading Arrangement [Axis] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Revenue recognized related to services provided in prior period Contract with Customer, Performance Obligation Satisfied in Previous Period Contractual Arrangements [Axis] Contractual Arrangements [Axis] Contractual Arrangements Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Percentage of fair value in excess of book value Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Operating lease liabilities, current Operating Lease, Liability, Current Schedule of Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Prepaid expenses Prepaid Expense, Current Internal-use software Computer Software, Intangible Asset [Member] Amortization expense for intangible assets Amortization of Intangible Assets Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Entity Shell Company Entity Shell Company Net Finite-Lived Intangible Assets, Net Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Other Other Miscellaneous Income (Expense) Other Miscellaneous Income (Expense) Performance-based fees not recognized as revenue Deferred Revenue, Performance Based Fees Not Recognized As Revenue Deferred Revenue, Performance Based Fees Not Recognized As Revenue Temporary Equity [Line Items] Temporary Equity [Line Items] Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Accumulated Amortization Total intangible assets, accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Denominator Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares, issued (in shares) Common Stock, Shares, Issued Costs and operating expenses: Operating Costs and Expenses [Abstract] Deferred revenue Contract with Customer, Liability, Current Redeemable convertible preferred stock, par value (in USD per share) Temporary Equity, Par or Stated Value Per Share Security Exchange Name Security Exchange Name Settlement process term Revenue, Settlement Process Term Revenue, Settlement Process Term Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Cancelled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations Stock options Employee Stock Option [Member] Contingent Consideration Contingent Consideration Liability [Member] Contingent Consideration Liability Basis point increase in weighted average cost of capital Reporting Unit, Basis Increase Threshold In Weighted Average Cost Of Capital Reporting Unit, Basis Increase Threshold In Weighted Average Cost Of Capital Common Stock, par value $0.0001 per share Common Class A [Member] Total costs and operating expenses Costs and Expenses Maximum Maximum [Member] Comprehensive loss attributable to Sharecare, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Outstanding, beginning (in shares) Outstanding, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Accrued expenses and other current liabilities (Note 3) Accrued liabilities and other liabilities Total accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities Cumulative Effect, Period of Adoption [Domain] Cumulative Effect, Period of Adoption [Domain] Costs of revenue (exclusive of depreciation and amortization) Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Basis of Presentation and Unaudited Interim Financial Information Basis of Accounting, Policy [Policy Text Block] Other Other Noncash Income (Expense) Options Outstanding - Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Accrued taxes Taxes Payable, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Remaining performance obligations percentage to be recognized Revenue, Remaining Performance Obligation, Percentage Accretion of contract liabilities Contract Liabilities, Accretion Contract Liabilities, Accretion Accounts receivable, allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Total cash equivalents at fair value Cash and Cash Equivalents, Fair Value Disclosure Related Party [Domain] Related Party, Type [Domain] Number of securities called by each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Warrant liabilities Derivative Liability Intangible assets not subject to amortization Indefinite-Lived Intangible Assets (Excluding Goodwill) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Noncontrolling interest Subsidiary, Ownership Percentage, Noncontrolling Owner Product and technology Product And Technology Expense [Member] Product And Technology Expense Contract Liabilities Contract Liabilities, Off Market Value Instruments, Policy [Policy Text Block] Contract Liabilities, Off Market Value Instruments, Policy Outstanding, beginning (in USD per share) Outstanding, ending (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Other current assets Other Assets, Current Class of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Percentage of decline in fair value, in event increase in weighted average capital Reporting Unit, Percentage Of Decline In Fair Value, In Event Of Increase In Weighted Average Capital Reporting Unit, Percentage Of Decline In Fair Value, In Event Of Increase In Weighted Average Capital Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Allowance for Doubtful Accounts Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Tax Identification Number Entity Tax Identification Number Foreign currency translation adjustment Goodwill, Foreign Currency Translation Gain (Loss) Share-based compensation Capitalized Contract Cost, Amortization Statistical Measurement [Axis] Statistical Measurement [Axis] Cumulative Effect, Period of Adoption [Axis] Cumulative Effect, Period of Adoption [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Total Shareholder Return Amount Total Shareholder Return Amount Payments for shares repurchased Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Schedule of Other Income Schedule of Other Nonoperating Income (Expense) [Table Text Block] Accumulated deficit Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Deferred Revenue and Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Number of quarterly installments Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Vesting Installments Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Vesting Installments Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Contract liability due to the Series A Preferred Stockholder Contract Liabilities Due To A Related Party Current Contract Liabilities Due To A Related Party Current Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Common stock, shares, outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other Stockholders' Equity, Other Compensation costs related to share-based payment awards reflected within additional paid-in capital related to capitalizable internally developed software activities APIC, Share-Based Payment Arrangement, Other, Increase for Cost Recognition Series A Preferred Stock Holder Series A Preferred Stock Holder [Member] Series A Preferred Stock Holder Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Net loss available to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Equity Warrants Equity Warrant, Equity [Member] Warrant, Equity Options Outstanding - Number of Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Vested and/or exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Common Stock and Stockholders' Equity Shareholders' Equity and Share-Based Payments [Text Block] Vested and/or exercisable (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Internal-use software projects in process Computer Software, Projects In Process, Intangible Asset [Member] Computer Software, Projects In Process, Intangible Asset Net Loss per Share Earnings Per Share [Abstract] Restricted Stock Units - Number of Plan shares outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Sales and marketing Selling and Marketing Expense Common stock $0.0001 par value; 600,000,000 and 600,000,000 shares authorized; 358,572,273 and 353,430,357 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Temporary Equity, by Class of Stock [Table] Temporary Equity, by Class of Stock [Table] General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade name Indefinite-lived, trade names Trade Names [Member] Lease right-of-use assets expense Operating Lease, Right-of-Use Asset, Periodic Reduction Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Contingent consideration – other liabilities Business Combination, Contingent Consideration, Liability All Individuals All Individuals [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Intangible asset recognized Contract With Customer, Intangible Asset Contract With Customer, Intangible Asset Other income Total other income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Depreciation and amortization Cost, Depreciation and Amortization Percentage of decline in fair value, in event of decrease in annual forecasted revenue Reporting Unit, Percentage Of Decline In Fair Value, In Event Of Decrease In Annual Forecasted Revenue Reporting Unit, Percentage Of Decline In Fair Value, In Event Of Decrease In Annual Forecasted Revenue Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Stock Option Activity Schedule of Stock Options Roll Forward [Table Text Block] Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] PEO Name PEO Name Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Performance-based revenue recognized Deferred Revenue, Performance Based Revenue Recognized Deferred Revenue, Performance Based Revenue Recognized Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Accounts Receivable and Allowance for Doubtful Accounts Accounts Receivable [Policy Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Schedule of Estimated Future Amortization Expense for Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Class of Stock [Axis] Class of Stock [Axis] Entities [Table] Entities [Table] Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Change in fair value of warrant liability and contingent consideration Increase (Decrease) in Fair Value Of Warrant Liabilities And Contingent Consideration Increase (Decrease) in Fair Value Of Warrant Liabilities And Contingent Consideration Accrued other Other Accrued Liabilities, Current Re-measurement of warrant liabilities Fair Value Adjustment of Warrants Warrants Warrant, Private [Member] Warrant, Private Depreciation and amortization expense Depreciation, Depletion and Amortization Capitalized internal-use software costs Payments to Develop Software Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Entity Information [Line Items] Entity Information [Line Items] Total Sharecare, Inc. stockholders’ equity Equity, Attributable to Parent Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revenue recognized that was previously in deferred revenue Contract with Customer, Liability, Revenue Recognized Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Foreign currency translation Currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Subsequent Events [Abstract] Loss before income tax benefit (expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Level 2 Fair Value, Inputs, Level 2 [Member] Sul América Sul América Serviços de Saúde S.A. (Sul América) [Member] Sul América Serviços de Saúde S.A. (Sul América) Entity Emerging Growth Company Entity Emerging Growth Company Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Contractual Arrangements [Domain] Contractual Arrangements [Domain] Contractual Arrangements [Domain] Intangible assets, net Total intangible assets, net Intangible Assets, Net (Excluding Goodwill) Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Stock options and restricted stock units Share-Based Payment Arrangement [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted Title Trading Arrangement, Individual Title Outstanding, beginning (in USD per share) Outstanding, ending (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation Share-Based Payment Arrangement, Noncash Expense Warrants reserved for future issuance (in shares) Warrants Reserved For Future Issuance Warrants Reserved For Future Issuance Common Stock Common Stock [Member] Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Net Loss Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Schedule of Changes to the Warrant Liability and Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Total stockholders’ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Accrued media costs Accrued Marketing Costs, Current Enterprise Enterprise [Member] Enterprise Director Affiliated Customer Director Affiliated Customer [Member] Director Affiliated Customer Minimum Minimum [Member] Exercise Price Award Exercise Price Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accrued Expenses and Other Current Liabilities Accrued Liabilities and Other Liabilities [Abstract] Schedule of Warrants Issued and Outstanding Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Total liabilities at fair value Liabilities, Fair Value Disclosure Operating lease liabilities Increase (Decrease) in Operating Lease Liability Net loss Net loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Schedule of Share-Based Compensation Expense for Employee and Nonemployee Options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities, redeemable convertible preferred stock and stockholders’ equity Liabilities and Equity Other long-term assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Ownership [Domain] Ownership [Domain] Weighted Average Remaining Life Finite-Lived Intangible Assets, Remaining Amortization Period Net loss per share attributable to common stockholders, basic (in USD per share) Earnings Per Share, Basic Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Warrants expiration period (in years) Warrants and Rights Outstanding, Term Indefinite-lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Exercised, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Net loss available to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Vested and/or exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Consolidation Policy Consolidation, Policy [Policy Text Block] Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Technology – features/content Technology-Based Intangible Assets [Member] Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Exercised/released (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Redeemable convertible preferred stock, aggregate liquidation preference Temporary Equity, Liquidation Preference Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Liability Class [Axis] Liability Class [Axis] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Comprehensive loss (income) attributable to noncontrolling interest in subsidiaries Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Provision for doubtful accounts Accounts Receivable, Credit Loss Expense (Reversal) Additional paid-in capital Additional Paid in Capital Share-based compensation arrangement by share-based payment award, voluntarily elected to forgo, cash base salary Share-Based Compensation Arrangement By Share-Based Payment Award, Voluntarily Elected To Forgo, Cash Base Salary, Period Share-Based Compensation Arrangement By Share-Based Payment Award, Voluntarily Elected To Forgo, Cash Base Salary, Period Cancelled/forfeited (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Deferred income taxes Deferred Income Tax Expense (Benefit) Proceeds from exercise of common stock options Proceeds from Stock Options Exercised Sharecare Brasil Servicios de Consultoria, Ltda Sharecare Brasil Servicios de Consultoria, Ltda [Member] Sharecare Brasil Servicios de Consultoria, Ltda Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Insider Trading Arrangements [Line Items] Allowance for doubtful accounts – beginning balance Allowance for doubtful accounts – ending balance Accounts Receivable, Allowance for Credit Loss Related Party, Type [Axis] Related Party, Type [Axis] Outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Intangible assets not subject to amortization Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract] Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of revenues Cost of Sales [Member] Re-measurement of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Noncontrolling interest in subsidiaries Equity, Attributable to Noncontrolling Interest Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other income: Interest and Debt Expense [Abstract] Entity Central Index Key Entity Central Index Key Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Numerator Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Cost Finite-Lived Intangible Assets, Gross Income tax benefit (expense) Income tax benefit (less than) Income Tax Expense (Benefit) Redeemable convertible preferred stock, shares authorized (in shares) Temporary Equity, Shares Authorized Accrued compensation Employee-related Liabilities, Current Fair Value Measurements Fair Value Disclosures [Text Block] Name Trading Arrangement, Individual Name Schedule of Revenues Disaggregated by Revenue Source Disaggregation of Revenue [Table Text Block] Equity [Abstract] Revenue Total Revenue Revenue Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other Receivables, Net, Current Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Redeemable convertible preferred stock, shares outstanding (in shares) Temporary Equity, Shares Outstanding Legal Entity [Axis] Legal Entity [Axis] Definite-lived, intangible assets Finite-Lived Intangible Assets, Net [Abstract] Money market funds Money Market Funds [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Amortization of contract liabilities Amortization of contract liabilities Contract Liabilities, Amortization Contract Liabilities, Amortization Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Redeemable Convertible Preferred Stock Temporary Equity, Other Disclosure [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Cash equivalents Assets, Fair Value Disclosure [Abstract] Redeemable convertible preferred stock, shares issued (in shares) Redeemable convertible preferred stock, beginning balance (in shares) Redeemable convertible preferred stock, ending balance (in shares) Temporary Equity, Shares Issued Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Long-term debt Long-Term Debt, Excluding Current Maturities Sales and marketing Selling and Marketing Expense [Member] Weighted-average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Share-based compensation arrangement by share-based payment award, voluntarily elected to forgo, cash base salary, percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Voluntarily Elected To Forgo, Cash Base Salary, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Voluntarily Elected To Forgo, Cash Base Salary, Percentage Total intangible assets Intangible Assets, Net (Excluding Goodwill) [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional Paid-In Capital Additional Paid-in Capital [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units Stock Repurchased During Period Related To Exercise Of Stock Options And Vesting Of Restricted Stock Units, Value Stock Repurchased During Period Related To Exercise Of Stock Options And Vesting Of Restricted Stock Units, Value Cover [Abstract] Vested and/or exercisable, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Subsequent Events Subsequent Events [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Recurring Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Exercised/released (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share Redeemable Warrants [Member] Redeemable Warrants Non-NEOs Non-NEOs [Member] Cancelled/forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Remaining performance obligations Revenue, Remaining Performance Obligation, Amount Accrued expenses due to the Series A Preferred Stockholder Accrued Expenses Related To A Related Party Accrued Expenses Related To A Related Party Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Adjustment to Compensation: Adjustment to Compensation [Axis] Unvested liability Share-Based Compensation Arrangement By Share-Based Payment Award, Unvested Liability Share-Based Compensation Arrangement By Share-Based Payment Award, Unvested Liability Measurement period Revenue, Performance Measurement Period Revenue, Performance Measurement Period Liability Warrants Liability Warrant, Liability [Member] Warrant, Liability Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-average common shares outstanding, basic (in shares) Weighted-average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Warrants earned but not issued (in shares) Warrants, Earned But Unisssued Warrants, Earned But Unisssued Loss from operations Operating Income (Loss) Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Estimated future amortization expense: Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Comprehensive loss attributable to Sharecare, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Contractual and Earnout Arrangements Contractual And Earnout Arrangements [Member] Contractual And Earnout Arrangements Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Contractual service period (in months) Deferred Revenue, Contractual Service Period Deferred Revenue, Contractual Service Period Statement [Line Items] Statement [Line Items] Amounts written off and other adjustments Accounts Receivable, Allowance For Credit Loss, Writeoff And Other Adjustments Accounts Receivable, Allowance For Credit Loss, Writeoff And Other Adjustments Options, Additional Disclosures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Customer relationships Customer Relationships [Member] Redeemable Convertible Preferred Stock Redeemable convertible preferred stock Redeemable Convertible Preferred Stock [Member] Stockholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Noncontrolling Interest Noncontrolling Interest [Member] Accounting Standards Update 2016-13 [Member] EX-101.PRE 10 shcr-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
May 06, 2024
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 001-39535  
Entity Registrant Name SHARECARE, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-1365053  
Entity Address, Address Line One 255 East Paces Ferry Road NE,  
Entity Address, Address Line Two Suite 700  
Entity Address, City or Town Atlanta  
Entity Address, State or Province GA  
Entity Address, Postal Zip Code 30305  
City Area Code 404  
Local Phone Number 671-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   362,409,958
Entity Central Index Key 0001816233  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
Common Stock, par value $0.0001 per share    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol SHCR  
Security Exchange Name NASDAQ  
Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share    
Entity Information [Line Items]    
Title of 12(b) Security Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share  
Trading Symbol SHCRW  
Security Exchange Name NASDAQ  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 100,320 $ 128,187
Accounts receivable, net (net of allowance for doubtful accounts of $8,348 and $8,544, respectively) 124,936 128,173
Other receivables 2,213 2,262
Prepaid expenses 9,875 6,007
Other current assets 2,814 3,178
Total current assets 240,158 267,807
Property and equipment, net 2,751 3,375
Other long-term assets 13,599 13,863
Intangible assets, net 130,263 136,552
Goodwill 191,860 192,037
Total assets 578,631 613,634
Current liabilities:    
Accounts payable 45,530 45,388
Accrued expenses and other current liabilities (Note 3) 55,516 65,706
Deferred revenue 5,735 5,517
Total current liabilities 106,781 116,611
Warrant liabilities 317 403
Long-term debt 586 519
Other long-term liabilities 7,171 8,032
Total liabilities 114,855 125,565
Commitments and contingencies (Note 7)
Series A redeemable convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of $50,000 as of March 31, 2024 and December 31, 2023 58,205 58,205
Stockholders’ equity:    
Common stock $0.0001 par value; 600,000,000 and 600,000,000 shares authorized; 358,572,273 and 353,430,357 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively 36 35
Additional paid-in capital 1,168,869 1,157,737
Accumulated other comprehensive loss (2,551) (2,263)
Accumulated deficit (760,460) (725,373)
Total Sharecare, Inc. stockholders’ equity 405,894 430,136
Noncontrolling interest in subsidiaries (323) (272)
Total stockholders’ equity 405,571 429,864
Total liabilities, redeemable convertible preferred stock and stockholders’ equity $ 578,631 $ 613,634
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Accounts receivable, allowance for doubtful accounts $ 8,348 $ 8,544
Stockholders’ equity:    
Common stock, par value (in USD per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 600,000,000 600,000,000
Common stock, shares, issued (in shares) 358,572,273 353,430,357
Common stock, shares, outstanding (in shares) 358,572,273 353,430,357
Series A Preferred Stock    
Temporary Equity [Line Items]    
Redeemable convertible preferred stock, par value (in USD per share) $ 0.0001 $ 0.0001
Redeemable convertible preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Redeemable convertible preferred stock, shares issued (in shares) 5,000,000 5,000,000
Redeemable convertible preferred stock, shares outstanding (in shares) 5,000,000 5,000,000
Redeemable convertible preferred stock, aggregate liquidation preference $ 50,000 $ 50,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Revenue $ 90,861 $ 116,295
Costs and operating expenses:    
Costs of revenue (exclusive of depreciation and amortization) 51,121 67,890
Sales and marketing 13,558 15,348
Product and technology 14,544 20,808
General and administrative 34,907 34,121
Depreciation and amortization 13,331 14,781
Total costs and operating expenses 127,461 152,948
Loss from operations (36,600) (36,653)
Other income:    
Interest income 1,274 1,680
Interest expense (217) (430)
Other income 368 429
Total other income 1,425 1,679
Loss before income tax benefit (expense) (35,175) (34,974)
Income tax benefit (expense) 31 (31)
Net loss (35,144) (35,005)
Net loss attributable to noncontrolling interest in subsidiaries (57) (346)
Net loss attributable to Sharecare, Inc. $ (35,087) $ (34,659)
Net Loss per Share    
Net loss per share attributable to common stockholders, basic (in USD per share) $ (0.10) $ (0.10)
Net loss per share attributable to common stockholders, diluted (in USD per share) $ (0.10) $ (0.10)
Weighted-average common shares outstanding, basic (in shares) 354,208,908 352,923,217
Weighted-average common shares outstanding, diluted (in shares) 354,208,908 352,923,217
Comprehensive loss attributable to Sharecare, Inc.    
Net loss $ (35,144) $ (35,005)
Foreign currency translation (282) 307
Comprehensive loss (35,426) (34,698)
Comprehensive loss (income) attributable to noncontrolling interest in subsidiaries (51) (289)
Comprehensive loss attributable to Sharecare, Inc. $ (35,375) $ (34,409)
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Cumulative effect of adopting ASU 2016-13
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Accumulated Deficit
Cumulative effect of adopting ASU 2016-13
Noncontrolling Interest
Redeemable Convertible Preferred Stock
Redeemable convertible preferred stock, beginning balance (in shares) at Dec. 31, 2022                 5,000,000
Redeemable convertible preferred stock, beginning balance at Dec. 31, 2022                 $ 58,205
Redeemable convertible preferred stock, ending balance (in shares) at Mar. 31, 2023                 5,000,000
Redeemable convertible preferred stock, ending balance at Mar. 31, 2023                 $ 58,205
Beginning balance (in shares) at Dec. 31, 2022     354,463,620            
Beginning balance at Dec. 31, 2022 $ 522,600 $ (1,055) $ 35 $ 1,120,024 $ (2,794) $ (595,820) $ (1,055) $ 1,155  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock options exercised (in shares)     281,042            
Stock options exercised 282     282          
Common stock issued upon vesting of restricted stock units (in shares)     1,759,615            
Issuance of warrants in connection with debt and revenue arrangements 14     14          
Share-based compensation 10,406     10,406          
Net income (loss) attributable to noncontrolling interest in subsidiaries (346)             (346)  
Currency translation adjustment 307       250     57  
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units (in shares)     (214,984)            
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units (396)     (396)          
Net income (loss) attributable to Sharecare, Inc. (34,659)         (34,659)      
Other (131)     (131)          
Ending balance (in shares) at Mar. 31, 2023     356,289,293            
Ending balance at Mar. 31, 2023 497,022   $ 35 1,130,199 (2,544) (631,534)   866  
Redeemable convertible preferred stock, beginning balance (in shares) at Dec. 31, 2023                 5,000,000
Redeemable convertible preferred stock, beginning balance at Dec. 31, 2023 58,205               $ 58,205
Redeemable convertible preferred stock, ending balance (in shares) at Mar. 31, 2024                 5,000,000
Redeemable convertible preferred stock, ending balance at Mar. 31, 2024 $ 58,205               $ 58,205
Beginning balance (in shares) at Dec. 31, 2023 353,430,357   353,430,357            
Beginning balance at Dec. 31, 2023 $ 429,864   $ 35 1,157,737 (2,263) (725,373)   (272)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock options exercised (in shares) 40,278   40,278            
Stock options exercised $ 24     24          
Common stock issued upon vesting of restricted stock units (in shares)     7,674,863            
Common stock issued upon vesting of restricted stock units 0   $ 1 (1)          
Issuance of warrants in connection with debt and revenue arrangements 27     27          
Share-based compensation 13,866     13,866          
Net income (loss) attributable to noncontrolling interest in subsidiaries (57)             (57)  
Currency translation adjustment (282)       (288)     6  
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units (in shares)     (2,573,225)            
Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units (2,784)     (2,784)          
Net income (loss) attributable to Sharecare, Inc. $ (35,087)         (35,087)      
Ending balance (in shares) at Mar. 31, 2024 358,572,273   358,572,273            
Ending balance at Mar. 31, 2024 $ 405,571   $ 36 $ 1,168,869 $ (2,551) $ (760,460)   $ (323)  
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net loss $ (35,144) $ (35,005)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 13,331 14,781
Non-cash interest expense 68 254
Amortization of contract liabilities 0 (451)
Accretion of contract liabilities 0 68
Lease right-of-use assets expense 566 1,138
Change in fair value of warrant liability and contingent consideration (379) (138)
Share-based compensation 13,596 9,969
Deferred income taxes (36) 59
Other 151 2,120
Changes in operating assets and liabilities:    
Accounts receivable, net 2,842 (1,387)
Prepaid expenses and other assets (3,747) (5,795)
Accounts payable and accrued expenses (10,422) (10,608)
Operating lease liabilities (635) 794
Deferred revenue 218 703
Net cash used in operating activities (19,591) (23,498)
Cash flows from investing activities:    
Purchases of property and equipment (51) (368)
Capitalized internal-use software costs (5,135) (4,806)
Net cash used in investing activities (5,186) (5,174)
Cash flows from financing activities:    
Payments for shares repurchased (2,784) (131)
Proceeds from exercise of common stock options 24 1,023
Payments on financing lease obligations (285) (370)
Net cash (used in) provided by financing activities (3,045) 522
Effect of exchange rates on cash and cash equivalents (45) 72
Net decrease in cash and cash equivalents (27,867) (28,078)
Cash and cash equivalents at beginning of period 128,187 182,508
Cash and cash equivalents at end of period 100,320 154,430
Supplemental disclosure of cash flow information:    
Cash paid for interest 151 236
Cash paid for amounts included in the measurement of lease liabilities 626 1,336
Assets obtained in exchange for lease obligations $ 0 $ 1,695
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Nature of Business and Significant Accounting Policies Nature of Business and Significant Accounting Policies
Nature of Business
Sharecare, Inc. (“Sharecare” or the “Company”) was founded in 2009 to develop an interactive health and wellness platform and began operations in October 2010. Sharecare’s virtual health platform is designed to help people, patients, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. The platform is designed to connect each stakeholder to the health management tools they need to drive engagement, establish sustained participation, increase satisfaction, reduce costs, and improve outcomes. Sharecare bridges scientifically validated clinical programs with content to deliver a personalized experience for its members, beginning with the RealAge® test, Sharecare’s health risk assessment that shows members the true age of their body, capitalizing on people’s innate curiosity of how “young” they are to draw them into the platform. The Sharecare platform provides members with a personalized action plan to guide and educate them on the habits and behaviors making the biggest impact, both positive and negative, on their RealAge. Sharecare provides the resources members need to manage their health through lifestyle or disease management and coaching programs, such as diabetes management and smoking cessation, well-being solutions, such as financial health and anxiety management; care navigation tools such as find-a-doctor, prescription savings, clinical decision support, medical records, home care, and more. In January 2023, Sharecare launched Sharecare+, a digital-first, comprehensive advocacy solution designed to deliver value through benefits navigation, clinical engagement, virtual care, and chronic case and utilization management. Additionally, Sharecare provides secure, automated release of information, audit and business consulting services to streamline the medical records process for medical facilities. Sharecare delivers value via its provider, enterprise, and life sciences channels.
Basis of Presentation and Consolidation Policy
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Sharecare, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Segment Information
The Company operates as a single operating segment. The Company’s chief operating decision maker is its chief executive officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance and allocating resources for the entire company.
Unaudited Interim Financial Information
The accompanying interim Consolidated Balance Sheet as of March 31, 2024 and the Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit), and Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 are unaudited. These unaudited interim consolidated financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. In management’s opinion, the unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024 and the Company’s consolidated results of operations and cash flows for the three months ended March 31, 2024 and 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any other future interim or annual periods. The information contained within the unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s annual financial statements for the year ended December 31, 2023.
Use of Estimates
The preparation of these unaudited interim consolidated financial statements in conformity with GAAP requires the use of management estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include goodwill, revenue recognition, stock-based compensation, and income taxes. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Concentration of Credit Risk
The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash deposits are held with well-known financial institutions and may exceed federally insured limits. The Company grants credit to its customers in the normal course of business and generally requires no collateral from its customers.
Fair Value Measurements
The carrying value of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.
The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires management to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 — Quoted prices in active markets for identical assets or liabilities
•Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
•Level 3 — Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability
Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis
Assets and liabilities that may be measured at fair value on a non-recurring basis relate primarily to the Company’s tangible fixed assets and other intangible assets. For these assets, the Company does not periodically adjust the carrying value to fair value except in the event of an impairment. When the Company determines that an impairment has occurred, the carrying value of the asset is reduced to its fair value and an impairment charge is recorded within operating loss in the Consolidated Statements of Operations and Comprehensive Loss.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable, net, consists of trade accounts receivable which are due under normal trade terms requiring payment, typically within 45 days from the invoice date. The allowance for doubtful accounts is based on management's estimate for expected credit losses for outstanding trade accounts receivable and is recorded as an offset to accounts receivable. Changes in the allowance for doubtful accounts are classified as general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. The Company determines expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, and adjusts based on expectations of changes in macro-economic conditions and customer-specific information that may impact the collectability of outstanding receivables. The Company reassesses the adequacy of the allowance for doubtful accounts each reporting period.
The changes in the allowance for doubtful accounts are as follows (in thousands):
Three Months Ended
March 31,
20242023
Allowance for doubtful accounts – beginning balance$8,544 $7,197 
Provision for doubtful accounts411 1,869 
Amounts written off and other adjustments(607)(640)
Allowance for doubtful accounts – ending balance$8,348 $8,426 
Contract Liabilities
In connection with certain acquisitions, the Company has recognized current and noncurrent contract liabilities, representing off-market values associated with certain wellness program royalty agreements. Amortization of these contract liabilities was $0 and $0.5 million for three months ended March 31, 2024 and 2023, respectively, all of which was included within cost of revenues in the Consolidated Statements of Operations and Comprehensive Loss. Additionally, the Company has recognized certain contract liabilities due to a former related party in the amount of $17.5 million, related to service agreements, which is included in accrued expenses and other current liabilities in the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023.
Deferred Revenue
The Company records contract liabilities, which consist of deferred revenue and contract billings in excess of earned revenue, pursuant to ASC 606.
Deferred revenues arise from contracts that permit upfront billing and the collection of fees covering the entire contractual service period, which is generally six to twelve months and in advance of the satisfaction of the performance obligations identified within the related contract. As of March 31, 2024 and December 31, 2023, such fees were $5.7 million and $5.5 million, respectively. The Company recognized $1.2 million of revenue during the three months ended March 31, 2024 that was included in deferred revenue at December 31, 2023.
Revenue Recognition
Performance-Based Revenue
Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as customer cost savings, and/or clinical outcomes improvements (performance-based). The Company uses the most likely amount method to estimate variable consideration for these performance guarantees. The Company includes in the transaction price some, or all, of a variable consideration amount only to the extent that it is not probable that a significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company utilizes customer data to measure performance. Performance-based fees subject to refund that the Company has not recognized as revenues are generally due to either: (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that it is not probable that the Company will meet the relevant performance target(s). As of March 31, 2024 and December 31, 2023, such fees included within deferred revenue were $4.8 million and $4.9 million, respectively.
In the event that performance measures are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, performance-based fees are reconciled and settled. Approximately $1.5 million and $1.2 million of revenues recognized during the three months ended March 31, 2024 and 2023, respectively, were performance-based. As of March 31, 2024 and 2023, the cumulative amount of performance-based revenues that had met the criteria for recognition and had been recognized but had not yet been settled with customers, totaled $1.9 million and $6.5 million, respectively. During the three months ended March 31, 2024, $0.7 million of revenue was recognized, which related to services provided prior to December 31, 2023.
Remaining Performance Obligations
Remaining performance obligations represent contracted revenues that are non-cancellable and have not yet been recognized due to unsatisfied or partially satisfied performance obligations. This includes deferred revenues and amounts that will be invoiced and recognized as revenues in future periods. As of March 31, 2024, future estimated revenue related to
performance obligations with terms of more than one year that are unsatisfied or partially unsatisfied at the end of the reporting period was approximately $61.2 million. As of March 31, 2024, the Company expects to recognize revenue on approximately 91% of these unsatisfied performance obligations over the following 24 months and the remainder thereafter.
Disaggregated Revenue
The following table presents the Company’s revenues disaggregated by revenue source (in thousands):
Three Months Ended
March 31,
20242023
Enterprise$46,960 $70,193 
Provider28,427 28,974 
Life Sciences 15,474 17,128 
Total Revenue$90,861 $116,295 
Other Income
For the three months ended March 31, 2024 and 2023, other income (expense) consisted of the following (in thousands):
Three Months Ended
March 31,
20242023
Re-measurement of contingent consideration$294 $138 
Re-measurement of warrant liabilities85 — 
Other(11)291 
Total other income $368 $429 
Accounting Standards Not Yet Adopted
As an emerging growth company (“EGC”), the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are applicable to private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company has elected to use this extended transition period under the JOBS Act until such time as the Company is no longer considered to be an EGC. The adoption dates discussed below reflect this election.
Income Taxes. In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The new ASU requires public business entities, on an annual basis, to provide a tabular rate reconciliation (using both percentages and reporting currency amounts) of (1) the reported income tax expense (or benefit) from continuing operations, to (2) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal (national) income tax rate of the jurisdiction (country) of domicile using specific categories and separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold. A public business entity is required to provide an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes of the reconciling items and the judgment used in categorizing the reconciling items. For each annual period presented, the ASU requires all reporting entities to disclose the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign. It also requires additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The ASU requires that all reporting entities disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign.
The ASU is effective for public entities for annual periods beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures.
Segment Reporting. In November 2023, the FASB issued ASU No. 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments in this update address the requirement for a public entity to disclose its significant segment expense categories and amounts for each reportable segment. A significant segment expense is any significant expense incurred by the segment, including direct expenses, shared expenses, allocated corporate overhead, or interest expense that is regularly reported to the chief operating decision maker and is included in the measure of segment profit or loss. The disclosure of significant segment expenses is in addition to the current specifically-enumerated segment expenses required to be disclosed, such as depreciation and interest expense. If a public entity does not disclose any significant segment expenses for a reportable segment, it is required to disclose narratively the nature of the expenses used by the chief operating decision maker to manage the segment's operations. The ASU is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures as it pertains to the Company’s single reportable segment.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company’s financial instruments consist of cash equivalents, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration liabilities. Cash equivalents are comprised of money market funds stated at amortized cost, which approximates fair value at the balance sheet dates, due to the short period of time to maturity. Accounts receivable, accounts payable, and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected settlement date. The warrant liabilities and contingent consideration liabilities are recorded at estimated fair value.
The following tables present the fair value hierarchy for assets and liabilities measured at fair value as of March 31, 2024 (in thousands):
March 31, 2024
Level 1Level 2Level 3Total Fair Value
Cash equivalents
Money market funds$10,470 $— $— $10,470 
Total cash equivalents at fair value$10,470 $— $— $10,470 
Liabilities
  Warrant liabilities $317 $— $— $317 
  Contingent consideration – other liabilities— — 101 101 
Total liabilities at fair value$317 $— $101 $418 
The warrants issued during the initial public offering by Falcon Capital Acquisition Corp. “FCAC” and the warrants issued by FCAC simultaneously with its initial public offering in a private placement, are both classified within Level 1 as they are publicly traded and have an observable market price in an active market. Additionally, the warrant liabilities are exercisable for one share of common stock at an exercise price of $11.50.
Contingent consideration is classified within Level 3 as it is valued using certain unobservable inputs. The fair value of the contingent consideration is estimated based on the Company’s stock price and number of shares expected to be issued related to acquisitions in prior years and are estimated using a Monte Carlo simulation with inputs for the Company’s stock price, expected volatility, risk-free rate, first and second earnout hurdles and expected term.
The following is a schedule of changes to the contingent consideration — other liabilities classified as Level 3 for the periods presented (in thousands):
December 31, 2023$395 
Re-measurement of contingent consideration(294)
March 31, 2024$101 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Balance Sheet Components
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Balance Sheet Components Balance Sheet Components
Accrued Expenses and Other Current Liabilities
As of March 31, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following (in thousands):
March 31,
2024		December 31,
2023
Accrued expenses$17,304 $15,546 
Accrued compensation10,506 16,235 
Accrued media costs2,506 5,168 
Accrued taxes1,509 1,837 
Operating lease liabilities, current1,684 1,826 
Contract liability due to the Series A Preferred Stockholder
17,496 17,496 
Accrued expenses due to the Series A Preferred Stockholder
3,255 6,084 
Accrued other1,256 1,514 
Total accrued expenses and other current liabilities$55,516 $65,706 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets Goodwill and Other Intangible Assets
Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):
March 31, 2024
CostAccumulated
Amortization		NetWeighted
Average
Remaining
Life
Definite-lived, intangible assets
Technology – features/content$62,926 $(29,650)$33,276 7.2
Trade name3,549 (2,091)1,458 3.3
Customer relationships77,849 (41,121)36,728 8.2
Internal-use software189,631 (140,630)49,001 1.8
Total definite-lived, intangible assets$333,955 $(213,492)$120,463 
Intangible assets not subject to amortization
Internal-use software projects in process$4,770 $— $4,770 
Indefinite-lived, trade names5,030 — 5,030 
Total intangible assets not subject to amortization9,800 — 9,800 
Total intangible assets$343,755 $(213,492)$130,263 
The following tables set forth the changes in the carrying amount of the Company’s goodwill for the period presented (in thousands):
December 31, 2023$192,037 
Foreign currency translation adjustment(177)
March 31, 2024$191,860 
Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subjected to annual tests of impairment. The Company tests goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter and between annual tests if an event occurs or circumstances change that would indicate that it is more likely than not that the carrying amount may be impaired. The Company initially evaluates qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment is not conclusive, a quantitative assessment of the fair value of a reporting unit is performed to test goodwill for impairment using a combination of income and market approaches. There have been no impairments of goodwill since the Company’s inception.
As a result of the sustained decline in the Company’s stock price and associated market capitalization, the Company performed an impairment test during the first quarter of 2024. The fair value of the reporting units for goodwill impairment testing was determined using both an income approach and market approach. The income approach was based on discounted projected future (debt-free) cash flows for each reporting unit. The discount rates applied to these cash flows were based on the weighted average cost of capital for each reporting unit, which takes market participant assumptions into consideration. For the market approach, we used both the guideline public company and similar transaction methods. The guideline public company method analyzes market multiples of revenue and EBITDA for a group of comparable public companies. Under the similar transactions method, valuation multiples are calculated utilizing actual transaction prices and revenue and EBITDA data from target companies deemed similar to the reporting unit. As a result of the interim test, the fair values of each of our reporting units exceeded their respective book values in excess of approximately 10%, and the Company determined there was no impairment. An increase of 100 basis points in the weighted average cost of capital or a decrease of 100 basis points in annual forecasted revenues would have resulted in a 3% and 9% decline in the fair value, respectively of our reporting units which would not have resulted in impairment.
Amortization expense for intangible assets during the three months ended March 31, 2024 and 2023 totaled $12.7 million and $14.0 million, respectively. Amortization expense is included in depreciation and amortization in the Consolidated Statements of Operations and Comprehensive Loss.
The following is a schedule of estimated future amortization expense for intangible assets as of March 31, 2024 (in thousands):
Year ending December 31:
Remainder of 2024$33,671 
202531,239 
202617,572 
202710,104 
20286,932 
Thereafter20,945 
Total$120,463 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income TaxesAs a result of the Company’s history of net operating losses, the Company has provided for a full valuation allowance against its deferred tax assets, with the exception of its German and French operations. For the three months ended March 31, 2024, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income. For the three months ended March 31, 2023, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock and Stockholders' Equity
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Common Stock and Stockholders' Equity Common Stock and Stockholders’ Equity
Warrants
In connection with debt and equity financings and certain partnership arrangements, the Company may issue warrants. Warrants classified as liabilities generally vest immediately and are exercisable upon issuance and have an expiration of seven years from the date of issuance. Warrants classified as equity generally vest after three years from the date of issuance and have an expiration of seven years from the date of issuance.
As of March 31, 2024, the following warrants to purchase common stock were issued and outstanding:
ClassificationWarrants
Outstanding		Exercise Price
per Share
Equity1,278,746 
$4.21 - $5.61
Liability17,433,334 
$11.50
The Company has also entered into, and may in the future enter into, contractual arrangements with certain customers and other parties and earnout arrangements in connection with acquisitions that, in each case, provide for the issuance of warrants and/or common stock upon the achievement of specified milestones. As of March 31, 2024, these agreements provide for the issuance of up to 3,238,675 shares of common stock and 6,353,577 warrants to purchase shares of common stock. With respect to these arrangements, there were 52,589 warrants earned but not issued as of March 31, 2024.
Share-based Payments
Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):
Options OutstandingRestricted Stock Units
Number of Options Weighted-
Average
Exercise Price 		Weighted
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic Value
(in thousands)		Number of Plan shares outstandingWeighted-Average Grant Date Fair Value per share
Outstanding as of December 31, 2023
92,218,339$3.01 5.87$1,256 49,007,766 $1.93 
Granted— — 15,089,859 $1.03 
Exercised/Released(40,278)$0.59 $7 (7,674,699)$2.38 
Cancelled/Forfeited(2,685,153)$2.40 (661,764)$1.85 
Outstanding as of March 31, 2024
89,492,908$3.03 5.58$260 55,761,162 $1.62 
Vested and/or exercisable as of March 31, 2024
73,764,072$1.88 5.24$260 
Vested and/or exercisable as of December 31, 202373,902,493$1.89 5.49$1,256 
The intrinsic value is calculated as the difference between the exercise price of the underlying common stock option award and the estimated fair value of the Company’s common stock. Vested but unissued restricted stock units as of March 31, 2024 and December 31, 2023 were immaterial.
Share-based compensation expense for employee and nonemployee options and restricted stock units included in the Consolidated Statements of Operations and Comprehensive Loss is as follows for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended
March 31,
20242023
Cost of revenues$204 $111 
Sales and marketing1,508 828 
Product and technology1,664 1,068 
General and administrative10,468 7,962 
Total share-based compensation expense$13,844 $9,969 
Additionally, share-based compensation costs, reflected within additional paid-in capital in the Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023, included approximately $0.2 million and $0.4 million related to capitalizable internally developed software activities, respectively.
On May 31, 2023, each of the principal executive officer, principal financial officer, other named executive officers, and certain eligible employees of the Company voluntarily elected to forgo up to 25% of their cash base salary for the next 12 months, and in lieu thereof received restricted stock units (“RSUs”) with a value equal to the cash amount they elected to forego over the 12-month period. In consideration for forgoing guaranteed cash compensation, each individual will receive an additional number of RSUs with a value equal to 25% of the amount of cash salary they have elected to forgo. The RSUs were issued in June 2023 and will vest in four equal quarterly installments over the next 12 months, subject to the individual’s continued employment. The ability of the named executive officers and other eligible employees to make such election to forgo guaranteed cash compensation and receive RSUs in lieu thereof was approved by the Compensation and Human Capital Committee of the Company’s board of directors. The unvested RSUs are classified as a liability. As of March 31, 2024, there was $0.4 million of unvested RSUs classified as a liability and recorded to accrued expenses and other current liabilities in the Consolidated Balance Sheets. As such, share-based compensation costs, reflected within additional paid-in capital in the Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months
ended March 31, 2024 does not reflect the cost associated with these awards. Upon vesting of these RSUs, amounts will be reclassified from liability to equity.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Matters
From time to time, the Company is subject to litigation in the normal course of business. The Company is of the opinion that, based on the information presently available, the resolution of any such legal matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. The Company has accrued for losses that are both probable and estimable.
We are also party to investigations and legal disputes and losses related to certain matters that are reasonably possible, but at this time, we cannot estimate a loss or range of losses.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related-Party Transactions
 3 Months Ended
Mar. 31, 2024
Related Party Transactions [Abstract]  
Related-Party Transactions Related-Party Transactions
Sul América Serviços de Saúde S.A. (Sul América), is a customer of and owns a 49% interest in Sharecare Brasil Servicios de Consultoria, Ltda. As of the year ended December 31, 2023, the Company ended the services contract with this related party and ceased operations of Sharecare Brasil Servicios de Consultoria, Ltda. Revenues recognized for the three-month period ended March 31, 2024 and 2023 from Sul América totaled $0.3 million and $1.3 million, respectively. For the three-month period ended March 31, 2024, the revenues recognized represent variable termination fee revenue, which was previously contrained and for which uncertainty about the variable amount to be received was resolved.
The Series A Preferred Stock is held by a customer that also had an employee serving on the Sharecare Board. During the three month period ended June 30, 2023, the board member ceased employment with the customer. Subsequent to the board member’s termination of employment with the customer, this customer was no longer considered a related party. Revenues recognized for this customer for the three months ended March 31, 2023 totaled $6.2 million. As of December 31, 2023, $13.0 million in receivables were outstanding from this related party.
During the third quarter of 2022, we entered into a revenue contract with the Series A Preferred Stockholder to provide patient advocacy services. We also entered into separate agreements to purchase distinct goods and services. These agreements are now subject to a dispute. Separate from the above disclosed amounts for this related party, revenues recognized related to these distinct services for the three months ended March 31, 2023 totaled $10.6 million. Additionally, revenue for the three months ended March 31, 2023, included $0.4 million of amortization of contract assets. For the three months ended March 31, 2023, cost of sales totaled $10.9 million. Amounts paid under the agreements that were not determined to be distinct were recorded as a reduction of revenues.
As of December 31, 2023, there were $34.3 million in receivables and $51.1 million in accounts payable and accrued expenses recorded in connection with these distinct agreements. Additionally, in 2022 the Company acquired certain intellectual property which was determined to be distinct and recorded an intangible asset, which is being amortized over its estimated useful life. The unamortized balance of intangible asset was $3.1 million as of December 31, 2023. As of March 31, 2024, the receivables, accounts payable, and accrued expenses balances recorded in connection with these distinct agreements remained unchanged.
The Company has a customer that was a related party for the year ended December 31, 2023 due to an affiliation with a member of the Sharecare Board. This member was nominated during the first quarter of 2023 and has subsequently ceased employment with the customer. This customer is no longer considered a related party as of December 31, 2023. As of December 31, 2023, $1.0 million in receivables were outstanding from this related party and revenues recognized for the three months ended March 31, 2023 totaled $0.7 million.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
Three Months Ended
March 31,
20242023
Numerator
Net loss$(35,144)$(35,005)
Less: Net loss attributable to noncontrolling interests in subsidiaries(57)(346)
Net loss available to common stockholders$(35,087)$(34,659)
Denominator
Weighted-average common shares outstanding, basic and diluted354,208,908 352,923,217 
Net loss per share attributable to common stockholders, basic and diluted$(0.10)$(0.10)
The Company’s potential dilutive securities, which include stock options and restricted stock units, redeemable convertible preferred stock, and contingently issuable shares, have been excluded from the computation of diluted net loss per share for the three-months ended March 31, 2024 and 2023, as they are anti-dilutive and the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common share equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Three Months Ended
March 31,
20242023
Stock options and restricted stock units2,660,077 30,951,366 
Redeemable convertible preferred stock5,000,000 5,000,000 
Total7,660,077 35,951,366 
Additionally, stock options of 89.1 million that have exercise prices in excess of the average market price of common shares for the three months ended March 31, 2024 and restricted stock units of 53.5 million as of March 31, 2024 are not included in the calculation of potentially dilutive securities, but could become dilutive in future periods.
For the prior period, stock options of 73.7 million that have exercise prices in excess of the average market price of common shares for the three months ended March 31, 2023 and restricted stock units of 32.5 million as of March 31, 2023 are not included in the calculation of potentially dilutive securities.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
The Company considers events or transactions that occur after the balance sheet date, but before the consolidated financial statements are issued, to provide additional evidence relative to certain estimates or identify matters that require additional disclosures. The Company evaluated subsequent events through, May 9, 2024, the date on which the consolidated financial statements were available to be issued, noting no such material events.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net income (loss) attributable to Sharecare, Inc. $ (35,087) $ (34,659)
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Unaudited Interim Financial Information
Basis of Presentation and Consolidation Policy
The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”).
Unaudited Interim Financial Information
The accompanying interim Consolidated Balance Sheet as of March 31, 2024 and the Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit), and Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 are unaudited. These unaudited interim consolidated financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. In management’s opinion, the unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of March 31, 2024 and the Company’s consolidated results of operations and cash flows for the three months ended March 31, 2024 and 2023. The results of operations for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for the full fiscal year or any other future interim or annual periods. The information contained within the unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s annual financial statements for the year ended December 31, 2023.
Consolidation Policy The consolidated financial statements include the accounts of Sharecare, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Segment Information
Segment Information
The Company operates as a single operating segment. The Company’s chief operating decision maker is its chief executive officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance and allocating resources for the entire company.
Use of Estimates
Use of Estimates
The preparation of these unaudited interim consolidated financial statements in conformity with GAAP requires the use of management estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the
consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include goodwill, revenue recognition, stock-based compensation, and income taxes. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Concentration of Credit Risk
Concentration of Credit Risk
The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash deposits are held with well-known financial institutions and may exceed federally insured limits. The Company grants credit to its customers in the normal course of business and generally requires no collateral from its customers.
Fair Value Measurements
Fair Value Measurements
The carrying value of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.
The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires management to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:
•Level 1 — Quoted prices in active markets for identical assets or liabilities
•Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities
•Level 3 — Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability
Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis
Assets and liabilities that may be measured at fair value on a non-recurring basis relate primarily to the Company’s tangible fixed assets and other intangible assets. For these assets, the Company does not periodically adjust the carrying value to fair value except in the event of an impairment. When the Company determines that an impairment has occurred, the carrying value of the asset is reduced to its fair value and an impairment charge is recorded within operating loss in the Consolidated Statements of Operations and Comprehensive Loss.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts Receivable and Allowance for Doubtful Accounts
Accounts receivable, net, consists of trade accounts receivable which are due under normal trade terms requiring payment, typically within 45 days from the invoice date. The allowance for doubtful accounts is based on management's estimate for expected credit losses for outstanding trade accounts receivable and is recorded as an offset to accounts receivable. Changes in the allowance for doubtful accounts are classified as general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. The Company determines expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, and adjusts based on expectations of changes in macro-economic conditions and customer-specific information that may impact the collectability of outstanding receivables. The Company reassesses the adequacy of the allowance for doubtful accounts each reporting period.
Contract Liabilities
Contract Liabilities
In connection with certain acquisitions, the Company has recognized current and noncurrent contract liabilities, representing off-market values associated with certain wellness program royalty agreements. Amortization of these contract liabilities was $0 and $0.5 million for three months ended March 31, 2024 and 2023, respectively, all of which was included within cost of revenues in the Consolidated Statements of Operations and Comprehensive Loss. Additionally, the Company has recognized certain contract liabilities due to a former related party in the amount of $17.5 million, related to service agreements, which is included in accrued expenses and other current liabilities in the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023.
Deferred Revenue and Revenue Recognition
Deferred Revenue
The Company records contract liabilities, which consist of deferred revenue and contract billings in excess of earned revenue, pursuant to ASC 606.
Deferred revenues arise from contracts that permit upfront billing and the collection of fees covering the entire contractual service period, which is generally six to twelve months and in advance of the satisfaction of the performance obligations identified within the related contract. As of March 31, 2024 and December 31, 2023, such fees were $5.7 million and $5.5 million, respectively. The Company recognized $1.2 million of revenue during the three months ended March 31, 2024 that was included in deferred revenue at December 31, 2023.
Revenue Recognition
Performance-Based Revenue
Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as customer cost savings, and/or clinical outcomes improvements (performance-based). The Company uses the most likely amount method to estimate variable consideration for these performance guarantees. The Company includes in the transaction price some, or all, of a variable consideration amount only to the extent that it is not probable that a significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company utilizes customer data to measure performance. Performance-based fees subject to refund that the Company has not recognized as revenues are generally due to either: (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that it is not probable that the Company will meet the relevant performance target(s). As of March 31, 2024 and December 31, 2023, such fees included within deferred revenue were $4.8 million and $4.9 million, respectively.
In the event that performance measures are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs six to eight months after the end of a contract year, performance-based fees are reconciled and settled. Approximately $1.5 million and $1.2 million of revenues recognized during the three months ended March 31, 2024 and 2023, respectively, were performance-based. As of March 31, 2024 and 2023, the cumulative amount of performance-based revenues that had met the criteria for recognition and had been recognized but had not yet been settled with customers, totaled $1.9 million and $6.5 million, respectively. During the three months ended March 31, 2024, $0.7 million of revenue was recognized, which related to services provided prior to December 31, 2023.
Remaining Performance Obligations
Remaining performance obligations represent contracted revenues that are non-cancellable and have not yet been recognized due to unsatisfied or partially satisfied performance obligations. This includes deferred revenues and amounts that will be invoiced and recognized as revenues in future periods. As of March 31, 2024, future estimated revenue related to
performance obligations with terms of more than one year that are unsatisfied or partially unsatisfied at the end of the reporting period was approximately $61.2 million. As of March 31, 2024, the Company expects to recognize revenue on approximately 91% of these unsatisfied performance obligations over the following 24 months and the remainder thereafter.
Accounting Standards Not Yet Adopted
Accounting Standards Not Yet Adopted
As an emerging growth company (“EGC”), the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are applicable to private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company has elected to use this extended transition period under the JOBS Act until such time as the Company is no longer considered to be an EGC. The adoption dates discussed below reflect this election.
Income Taxes. In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The new ASU requires public business entities, on an annual basis, to provide a tabular rate reconciliation (using both percentages and reporting currency amounts) of (1) the reported income tax expense (or benefit) from continuing operations, to (2) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal (national) income tax rate of the jurisdiction (country) of domicile using specific categories and separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold. A public business entity is required to provide an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes of the reconciling items and the judgment used in categorizing the reconciling items. For each annual period presented, the ASU requires all reporting entities to disclose the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign. It also requires additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The ASU requires that all reporting entities disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign.
The ASU is effective for public entities for annual periods beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures.
Segment Reporting. In November 2023, the FASB issued ASU No. 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments in this update address the requirement for a public entity to disclose its significant segment expense categories and amounts for each reportable segment. A significant segment expense is any significant expense incurred by the segment, including direct expenses, shared expenses, allocated corporate overhead, or interest expense that is regularly reported to the chief operating decision maker and is included in the measure of segment profit or loss. The disclosure of significant segment expenses is in addition to the current specifically-enumerated segment expenses required to be disclosed, such as depreciation and interest expense. If a public entity does not disclose any significant segment expenses for a reportable segment, it is required to disclose narratively the nature of the expenses used by the chief operating decision maker to manage the segment's operations. The ASU is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures as it pertains to the Company’s single reportable segment.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule of Allowance for Doubtful Accounts
The changes in the allowance for doubtful accounts are as follows (in thousands):
Three Months Ended
March 31,
20242023
Allowance for doubtful accounts – beginning balance$8,544 $7,197 
Provision for doubtful accounts411 1,869 
Amounts written off and other adjustments(607)(640)
Allowance for doubtful accounts – ending balance$8,348 $8,426 
Schedule of Revenues Disaggregated by Revenue Source
The following table presents the Company’s revenues disaggregated by revenue source (in thousands):
Three Months Ended
March 31,
20242023
Enterprise$46,960 $70,193 
Provider28,427 28,974 
Life Sciences 15,474 17,128 
Total Revenue$90,861 $116,295 
Schedule of Other Income
For the three months ended March 31, 2024 and 2023, other income (expense) consisted of the following (in thousands):
Three Months Ended
March 31,
20242023
Re-measurement of contingent consideration$294 $138 
Re-measurement of warrant liabilities85 — 
Other(11)291 
Total other income $368 $429 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value
The following tables present the fair value hierarchy for assets and liabilities measured at fair value as of March 31, 2024 (in thousands):
March 31, 2024
Level 1Level 2Level 3Total Fair Value
Cash equivalents
Money market funds$10,470 $— $— $10,470 
Total cash equivalents at fair value$10,470 $— $— $10,470 
Liabilities
  Warrant liabilities $317 $— $— $317 
  Contingent consideration – other liabilities— — 101 101 
Total liabilities at fair value$317 $— $101 $418 
Schedule of Changes to the Warrant Liability and Contingent Consideration
The following is a schedule of changes to the contingent consideration — other liabilities classified as Level 3 for the periods presented (in thousands):
December 31, 2023$395 
Re-measurement of contingent consideration(294)
March 31, 2024$101 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Balance Sheet Components (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Accrued Expense and Other Current Liabilities As of March 31, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following (in thousands):
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets (Tables)
 3 Months Ended
Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):
March 31, 2024
CostAccumulated
Amortization		NetWeighted
Average
Remaining
Life
Definite-lived, intangible assets
Technology – features/content$62,926 $(29,650)$33,276 7.2
Trade name3,549 (2,091)1,458 3.3
Customer relationships77,849 (41,121)36,728 8.2
Internal-use software189,631 (140,630)49,001 1.8
Total definite-lived, intangible assets$333,955 $(213,492)$120,463 
Intangible assets not subject to amortization
Internal-use software projects in process$4,770 $— $4,770 
Indefinite-lived, trade names5,030 — 5,030 
Total intangible assets not subject to amortization9,800 — 9,800 
Total intangible assets$343,755 $(213,492)$130,263 
Schedule of Indefinite-Lived Intangible Assets
Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):
March 31, 2024
CostAccumulated
Amortization		NetWeighted
Average
Remaining
Life
Definite-lived, intangible assets
Technology – features/content$62,926 $(29,650)$33,276 7.2
Trade name3,549 (2,091)1,458 3.3
Customer relationships77,849 (41,121)36,728 8.2
Internal-use software189,631 (140,630)49,001 1.8
Total definite-lived, intangible assets$333,955 $(213,492)$120,463 
Intangible assets not subject to amortization
Internal-use software projects in process$4,770 $— $4,770 
Indefinite-lived, trade names5,030 — 5,030 
Total intangible assets not subject to amortization9,800 — 9,800 
Total intangible assets$343,755 $(213,492)$130,263 
Schedule of Carrying Amount of Goodwill
The following tables set forth the changes in the carrying amount of the Company’s goodwill for the period presented (in thousands):
December 31, 2023$192,037 
Foreign currency translation adjustment(177)
March 31, 2024$191,860 
Schedule of Estimated Future Amortization Expense for Intangible Assets
The following is a schedule of estimated future amortization expense for intangible assets as of March 31, 2024 (in thousands):
Year ending December 31:
Remainder of 2024$33,671 
202531,239 
202617,572 
202710,104 
20286,932 
Thereafter20,945 
Total$120,463 
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock and Stockholders' Equity (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Warrants Issued and Outstanding
As of March 31, 2024, the following warrants to purchase common stock were issued and outstanding:
ClassificationWarrants
Outstanding		Exercise Price
per Share
Equity1,278,746 
$4.21 - $5.61
Liability17,433,334 
$11.50
Schedule of Stock Option Activity
Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):
Options OutstandingRestricted Stock Units
Number of Options Weighted-
Average
Exercise Price 		Weighted
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic Value
(in thousands)		Number of Plan shares outstandingWeighted-Average Grant Date Fair Value per share
Outstanding as of December 31, 2023
92,218,339$3.01 5.87$1,256 49,007,766 $1.93 
Granted— — 15,089,859 $1.03 
Exercised/Released(40,278)$0.59 $7 (7,674,699)$2.38 
Cancelled/Forfeited(2,685,153)$2.40 (661,764)$1.85 
Outstanding as of March 31, 2024
89,492,908$3.03 5.58$260 55,761,162 $1.62 
Vested and/or exercisable as of March 31, 2024
73,764,072$1.88 5.24$260 
Vested and/or exercisable as of December 31, 202373,902,493$1.89 5.49$1,256 
Schedule of Restricted Stock Unit Activity
Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):
Options OutstandingRestricted Stock Units
Number of Options Weighted-
Average
Exercise Price 		Weighted
Average
Remaining
Contractual
Term (Years)		Aggregate
Intrinsic Value
(in thousands)		Number of Plan shares outstandingWeighted-Average Grant Date Fair Value per share
Outstanding as of December 31, 2023
92,218,339$3.01 5.87$1,256 49,007,766 $1.93 
Granted— — 15,089,859 $1.03 
Exercised/Released(40,278)$0.59 $7 (7,674,699)$2.38 
Cancelled/Forfeited(2,685,153)$2.40 (661,764)$1.85 
Outstanding as of March 31, 2024
89,492,908$3.03 5.58$260 55,761,162 $1.62 
Vested and/or exercisable as of March 31, 2024
73,764,072$1.88 5.24$260 
Vested and/or exercisable as of December 31, 202373,902,493$1.89 5.49$1,256 
Schedule of Share-Based Compensation Expense for Employee and Nonemployee Options
Share-based compensation expense for employee and nonemployee options and restricted stock units included in the Consolidated Statements of Operations and Comprehensive Loss is as follows for the three months ended March 31, 2024 and 2023 (in thousands):
Three Months Ended
March 31,
20242023
Cost of revenues$204 $111 
Sales and marketing1,508 828 
Product and technology1,664 1,068 
General and administrative10,468 7,962 
Total share-based compensation expense$13,844 $9,969 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders
Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
Three Months Ended
March 31,
20242023
Numerator
Net loss$(35,144)$(35,005)
Less: Net loss attributable to noncontrolling interests in subsidiaries(57)(346)
Net loss available to common stockholders$(35,087)$(34,659)
Denominator
Weighted-average common shares outstanding, basic and diluted354,208,908 352,923,217 
Net loss per share attributable to common stockholders, basic and diluted$(0.10)$(0.10)
Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share The Company excluded the following potential common share equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
Three Months Ended
March 31,
20242023
Stock options and restricted stock units2,660,077 30,951,366 
Redeemable convertible preferred stock5,000,000 5,000,000 
Total7,660,077 35,951,366 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Allowance for Doubtful Accounts    
Allowance for doubtful accounts – beginning balance $ 8,544 $ 7,197
Provision for doubtful accounts 411 1,869
Amounts written off and other adjustments (607) (640)
Allowance for doubtful accounts – ending balance $ 8,348 $ 8,426
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies - Contract Liabilities and Deferred Revenue (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Disaggregation of Revenue [Line Items]      
Amortization of contract liabilities $ 0 $ 451  
Accrued liabilities and other liabilities 55,516   $ 65,706
Deferred revenue 5,735   5,517
Revenue recognized that was previously in deferred revenue $ 1,200    
Minimum      
Disaggregation of Revenue [Line Items]      
Contractual service period (in months) 6 months    
Maximum      
Disaggregation of Revenue [Line Items]      
Contractual service period (in months) 12 months    
Related Party      
Disaggregation of Revenue [Line Items]      
Accrued liabilities and other liabilities $ 17,500   $ 17,500
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies - Performance-Based Revenue (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Disaggregation of Revenue [Line Items]      
Performance-based fees not recognized as revenue $ 4.8   $ 4.9
Performance-based revenue recognized 1.5 $ 1.2  
Performance-based revenue recognized but not yet settled with customers 1.9 $ 6.5  
Revenue recognized related to services provided in prior period $ 0.7    
Enterprise      
Disaggregation of Revenue [Line Items]      
Measurement period 1 year    
Enterprise | Minimum      
Disaggregation of Revenue [Line Items]      
Settlement process term 6 months    
Enterprise | Maximum      
Disaggregation of Revenue [Line Items]      
Settlement process term 8 months    
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies - Remaining Performance Obligations (Narrative) (Details)
$ in Millions
Mar. 31, 2024
USD ($)
Accounting Policies [Abstract]  
Remaining performance obligations $ 61.2
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-04-01  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]  
Remaining performance obligations percentage to be recognized 91.00%
Unsatisfied performance obligations expected recognition period 24 months
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Total Revenue $ 90,861 $ 116,295
Enterprise    
Disaggregation of Revenue [Line Items]    
Total Revenue 46,960 70,193
Provider    
Disaggregation of Revenue [Line Items]    
Total Revenue 28,427 28,974
Life Sciences    
Disaggregation of Revenue [Line Items]    
Total Revenue $ 15,474 $ 17,128
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Nature of Business and Significant Accounting Policies - Schedule of Other Income (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Accounting Policies [Abstract]    
Re-measurement of contingent consideration $ 294 $ 138
Re-measurement of warrant liabilities 85 0
Other (11) 291
Total other income $ 368 $ 429
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Liabilities  
Derivative liability, statement of financial position Warrant liabilities
Recurring  
Cash equivalents  
Total cash equivalents at fair value $ 10,470
Liabilities  
Warrant liabilities 317
Contingent consideration – other liabilities 101
Total liabilities at fair value 418
Recurring | Money market funds  
Cash equivalents  
Total cash equivalents at fair value 10,470
Recurring | Level 1  
Cash equivalents  
Total cash equivalents at fair value 10,470
Liabilities  
Warrant liabilities 317
Contingent consideration – other liabilities 0
Total liabilities at fair value 317
Recurring | Level 1 | Money market funds  
Cash equivalents  
Total cash equivalents at fair value 10,470
Recurring | Level 2  
Cash equivalents  
Total cash equivalents at fair value 0
Liabilities  
Warrant liabilities 0
Contingent consideration – other liabilities 0
Total liabilities at fair value 0
Recurring | Level 2 | Money market funds  
Cash equivalents  
Total cash equivalents at fair value 0
Recurring | Level 3  
Cash equivalents  
Total cash equivalents at fair value 0
Liabilities  
Warrant liabilities 0
Contingent consideration – other liabilities 101
Total liabilities at fair value 101
Recurring | Level 3 | Money market funds  
Cash equivalents  
Total cash equivalents at fair value $ 0
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Narrative (Details) - Warrants
Mar. 31, 2024
$ / shares
shares
Class of Warrant or Right [Line Items]  
Number of securities called by each warrant (in shares) | shares 1
Exercise price per share (in USD per share) | $ / shares $ 11.50
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Schedule of Changes to the Warrant Liability and Contingent Consideration (Details) - Contingent Consideration
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Changes in liability  
Beginning balance $ 395
Re-measurement of contingent consideration (294)
Ending balance $ 101
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Balance Sheet Components (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Accrued Expenses and Other Current Liabilities    
Accrued expenses $ 17,304 $ 15,546
Accrued compensation 10,506 16,235
Accrued media costs 2,506 5,168
Accrued taxes 1,509 1,837
Operating lease liabilities, current 1,684 1,826
Contract liability due to the Series A Preferred Stockholder 17,496 17,496
Accrued expenses due to the Series A Preferred Stockholder 3,255 6,084
Accrued other 1,256 1,514
Total accrued expenses and other current liabilities $ 55,516 $ 65,706
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Definite-lived, intangible assets    
Cost $ 333,955  
Accumulated Amortization (213,492)  
Net 120,463  
Intangible assets not subject to amortization    
Intangible assets not subject to amortization 9,800  
Total intangible assets    
Total intangible assets, cost 343,755  
Total intangible assets, accumulated amortization (213,492)  
Total intangible assets, net 130,263 $ 136,552
Internal-use software projects in process    
Intangible assets not subject to amortization    
Intangible assets not subject to amortization 4,770  
Indefinite-lived, trade names    
Intangible assets not subject to amortization    
Intangible assets not subject to amortization 5,030  
Technology – features/content    
Definite-lived, intangible assets    
Cost 62,926  
Accumulated Amortization (29,650)  
Net $ 33,276  
Weighted Average Remaining Life 7 years 2 months 12 days  
Total intangible assets    
Total intangible assets, accumulated amortization $ (29,650)  
Indefinite-lived, trade names    
Definite-lived, intangible assets    
Cost 3,549  
Accumulated Amortization (2,091)  
Net $ 1,458  
Weighted Average Remaining Life 3 years 3 months 18 days  
Total intangible assets    
Total intangible assets, accumulated amortization $ (2,091)  
Customer relationships    
Definite-lived, intangible assets    
Cost 77,849  
Accumulated Amortization (41,121)  
Net $ 36,728  
Weighted Average Remaining Life 8 years 2 months 12 days  
Total intangible assets    
Total intangible assets, accumulated amortization $ (41,121)  
Internal-use software    
Definite-lived, intangible assets    
Cost 189,631  
Accumulated Amortization (140,630)  
Net $ 49,001  
Weighted Average Remaining Life 1 year 9 months 18 days  
Total intangible assets    
Total intangible assets, accumulated amortization $ (140,630)  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets - Schedule of Carrying Amount of Goodwill (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
USD ($)
Goodwill [Roll Forward]  
Beginning balance $ 192,037
Foreign currency translation adjustment (177)
Ending balance $ 191,860
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
Percentage of fair value in excess of book value 10.00%  
Basis point increase in weighted average cost of capital 10000.00%  
Basis point decrease in annual forecasted revenues 10000.00%  
Percentage of decline in fair value, in event increase in weighted average capital 3.00%  
Percentage of decline in fair value, in event of decrease in annual forecasted revenue 9.00%  
Amortization expense for intangible assets $ 12.7 $ 14.0
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Goodwill and Other Intangible Assets - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)
$ in Thousands
Mar. 31, 2024
USD ($)
Estimated future amortization expense:  
Remainder of 2024 $ 33,671
2025 31,239
2026 17,572
2027 10,104
2028 6,932
Thereafter 20,945
Net $ 120,463
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Tax Disclosure [Abstract]    
Income tax benefit (less than) $ 31 $ (31)
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock and Stockholders' Equity - Narrative (Details)
$ in Millions
 3 Months Ended
May 31, 2023
installment
Mar. 31, 2024
USD ($)
shares
Mar. 31, 2023
USD ($)
Class of Stock [Line Items]      
Compensation costs related to share-based payment awards reflected within additional paid-in capital related to capitalizable internally developed software activities | $   $ 0.2 $ 0.4
RSUs      
Class of Stock [Line Items]      
Share-based compensation arrangement by share-based payment award, voluntarily elected to forgo, cash base salary, percentage 0.25    
Share-based compensation arrangement by share-based payment award, voluntarily elected to forgo, cash base salary 12 months    
Number of quarterly installments | installment 4    
Unvested liability | $   $ 0.4  
Contractual and Earnout Arrangements      
Class of Stock [Line Items]      
Common stock reserved for future issuance (in shares)   3,238,675  
Warrants reserved for future issuance (in shares)   6,353,577  
Warrants earned but not issued (in shares)   52,589  
Liability Warrants      
Class of Stock [Line Items]      
Warrants expiration period (in years)   7 years  
Equity Warrants      
Class of Stock [Line Items]      
Warrants expiration period (in years)   7 years  
Warrants vesting period (in years)   3 years  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock and Stockholders' Equity - Schedule of Warrants Issued and Outstanding (Details)
Mar. 31, 2024
$ / shares
shares
Equity  
Class of Warrant or Right [Line Items]  
Warrants outstanding (in shares) | shares 1,278,746
Equity | Minimum  
Class of Warrant or Right [Line Items]  
Exercise price per share (in USD per share) $ 4.21
Equity | Maximum  
Class of Warrant or Right [Line Items]  
Exercise price per share (in USD per share) $ 5.61
Liability  
Class of Warrant or Right [Line Items]  
Warrants outstanding (in shares) | shares 17,433,334
Exercise price per share (in USD per share) $ 11.50
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock and Stockholders' Equity - Schedule of Stock Options (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Options Outstanding - Number of Options    
Outstanding, beginning (in shares) 92,218,339  
Granted (in shares) 0  
Exercised/released (in shares) (40,278)  
Cancelled/forfeited (in shares) (2,685,153)  
Outstanding, ending (in shares) 89,492,908 92,218,339
Vested and/or exercisable (in shares) 73,764,072 73,902,493
Options Outstanding - Weighted Average Exercise Price    
Outstanding, beginning (in USD per share) $ 3.01  
Granted (in USD per share) 0  
Exercised/released (in USD per share) 0.59  
Cancelled/forfeited (in USD per share) 2.40  
Outstanding, ending (in USD per share) 3.03 $ 3.01
Vested and/or exercisable (in USD per share) $ 1.88 $ 1.89
Options, Additional Disclosures    
Outstanding, weighted average remaining contractual term 5 years 6 months 29 days 5 years 10 months 13 days
Vested and/or exercisable, weighted average remaining contractual term 5 years 2 months 26 days 5 years 5 months 26 days
Outstanding, aggregate intrinsic value $ 260 $ 1,256
Exercised, aggregate intrinsic value 7  
Vested and/or exercisable, aggregate intrinsic value $ 260 $ 1,256
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock and Stockholders' Equity - Schedule of Restricted Stock Units (Details) - Restricted Stock Units
 3 Months Ended
Mar. 31, 2024
$ / shares
shares
Restricted Stock Units - Number of Plan shares outstanding  
Outstanding, beginning (in shares) | shares 49,007,766
Granted (in shares) | shares 15,089,859
Exercised/released (in shares) | shares (7,674,699)
Cancelled/forfeited (in shares) | shares (661,764)
Outstanding, ending (in shares) | shares 55,761,162
Restricted Stock Units - Weighted-Average Grant Date Fair Value per share  
Outstanding, beginning (in USD per share) | $ / shares $ 1.93
Granted (in USD per share) | $ / shares 1.03
Exercised/released (in USD per share) | $ / shares 2.38
Cancelled/forfeited (in USD per share) | $ / shares 1.85
Outstanding, ending (in USD per share) | $ / shares $ 1.62
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Common Stock and Stockholders' Equity - Schedule of Share-Based Compensation Expense for Employee and Nonemployee Options (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense $ 13,844 $ 9,969
Cost of revenues    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense 204 111
Sales and marketing    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense 1,508 828
Product and technology    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense 1,664 1,068
General and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total share-based compensation expense $ 10,468 $ 7,962
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Related-Party Transactions (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Related Party Transaction [Line Items]      
Revenue $ 90,861 $ 116,295  
Other receivables 2,213   $ 2,262
Costs of revenue (exclusive of depreciation and amortization) 51,121 67,890  
Accrued liabilities and other liabilities 55,516   65,706
Board of Directors Related Customer      
Related Party Transaction [Line Items]      
Revenue   6,200  
Other receivables     13,000
Series A Preferred Stock Holder      
Related Party Transaction [Line Items]      
Revenue   10,600  
Other receivables     34,300
Share-based compensation   400  
Costs of revenue (exclusive of depreciation and amortization)   10,900  
Accrued liabilities and other liabilities     51,100
Intangible asset recognized     3,100
Director Affiliated Customer      
Related Party Transaction [Line Items]      
Revenue   700  
Other receivables     $ 1,000
Sul América | Customer      
Related Party Transaction [Line Items]      
Revenue $ 300 $ 1,300  
Sharecare Brasil Servicios de Consultoria, Ltda | Sul América      
Related Party Transaction [Line Items]      
Noncontrolling interest 49.00%    
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Numerator    
Net loss $ (35,144) $ (35,005)
Less: Net loss attributable to noncontrolling interests in subsidiaries (57) (346)
Net loss available to common stockholders, basic (35,087) (34,659)
Net loss available to common stockholders, diluted $ (35,087) $ (34,659)
Denominator    
Weighted-average common shares outstanding, basic (in shares) 354,208,908 352,923,217
Weighted-average common shares outstanding, diluted (in shares) 354,208,908 352,923,217
Net loss per share attributable to common stockholders, basic (in USD per share) $ (0.10) $ (0.10)
Net loss per share attributable to common stockholders, diluted (in USD per share) $ (0.10) $ (0.10)
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share - Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common stock equivalents (in shares) 7,660,077 35,951,366
Stock options and restricted stock units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common stock equivalents (in shares) 2,660,077 30,951,366
Redeemable convertible preferred stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common stock equivalents (in shares) 5,000,000 5,000,000
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Net Loss Per Share - Narrative (Details) - shares
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities (in shares) 7,660,077 35,951,366
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities (in shares) 89,100,000 73,700,000
Restricted Stock Units    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities (in shares) 53,500,000 32,500,000
XML 61 R9999.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Label Element Value
Accounting Standards Update [Extensible Enumeration] us-gaap_AccountingStandardsUpdateExtensibleList Accounting Standards Update 2016-13 [Member]
EXCEL 62 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 116 267 1 false 49 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://www.sharecare.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 0000005 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT) Sheet http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS??? EQUITY (DEFICIT) Statements 5 false false R6.htm 0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Disclosure - Nature of Business and Significant Accounting Policies Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPolicies Nature of Business and Significant Accounting Policies Notes 7 false false R8.htm 0000008 - Disclosure - Fair Value Measurements Sheet http://www.sharecare.com/role/FairValueMeasurements Fair Value Measurements Notes 8 false false R9.htm 0000009 - Disclosure - Balance Sheet Components Sheet http://www.sharecare.com/role/BalanceSheetComponents Balance Sheet Components Notes 9 false false R10.htm 0000010 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.sharecare.com/role/GoodwillandOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 10 false false R11.htm 0000011 - Disclosure - Income Taxes Sheet http://www.sharecare.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 0000012 - Disclosure - Common Stock and Stockholders' Equity Sheet http://www.sharecare.com/role/CommonStockandStockholdersEquity Common Stock and Stockholders' Equity Notes 12 false false R13.htm 0000013 - Disclosure - Commitments and Contingencies Sheet http://www.sharecare.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 13 false false R14.htm 0000014 - Disclosure - Related-Party Transactions Sheet http://www.sharecare.com/role/RelatedPartyTransactions Related-Party Transactions Notes 14 false false R15.htm 0000015 - Disclosure - Net Loss Per Share Sheet http://www.sharecare.com/role/NetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 0000016 - Disclosure - Subsequent Events Sheet http://www.sharecare.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 17 false false R18.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 9954471 - Disclosure - Nature of Business and Significant Accounting Policies (Policies) Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies Nature of Business and Significant Accounting Policies (Policies) Policies http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPolicies 19 false false R20.htm 9954472 - Disclosure - Nature of Business and Significant Accounting Policies (Tables) Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesTables Nature of Business and Significant Accounting Policies (Tables) Tables http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPolicies 20 false false R21.htm 9954473 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.sharecare.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.sharecare.com/role/FairValueMeasurements 21 false false R22.htm 9954474 - Disclosure - Balance Sheet Components (Tables) Sheet http://www.sharecare.com/role/BalanceSheetComponentsTables Balance Sheet Components (Tables) Tables http://www.sharecare.com/role/BalanceSheetComponents 22 false false R23.htm 9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables) Sheet http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsTables Goodwill and Other Intangible Assets (Tables) Tables http://www.sharecare.com/role/GoodwillandOtherIntangibleAssets 23 false false R24.htm 9954476 - Disclosure - Common Stock and Stockholders' Equity (Tables) Sheet http://www.sharecare.com/role/CommonStockandStockholdersEquityTables Common Stock and Stockholders' Equity (Tables) Tables http://www.sharecare.com/role/CommonStockandStockholdersEquity 24 false false R25.htm 9954477 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.sharecare.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.sharecare.com/role/NetLossPerShare 25 false false R26.htm 9954478 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details) Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofAllowanceforDoubtfulAccountsDetails Nature of Business and Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details) Details 26 false false R27.htm 9954479 - Disclosure - Nature of Business and Significant Accounting Policies - Contract Liabilities and Deferred Revenue (Narrative) (Details) Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails Nature of Business and Significant Accounting Policies - Contract Liabilities and Deferred Revenue (Narrative) (Details) Details 27 false false R28.htm 9954480 - Disclosure - Nature of Business and Significant Accounting Policies - Performance-Based Revenue (Narrative) (Details) Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails Nature of Business and Significant Accounting Policies - Performance-Based Revenue (Narrative) (Details) Details 28 false false R29.htm 9954481 - Disclosure - Nature of Business and Significant Accounting Policies - Remaining Performance Obligations (Narrative) (Details) Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesRemainingPerformanceObligationsNarrativeDetails Nature of Business and Significant Accounting Policies - Remaining Performance Obligations (Narrative) (Details) Details 29 false false R30.htm 9954482 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails Nature of Business and Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details) Details 30 false false R31.htm 9954483 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Other Income (Details) Sheet http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails Nature of Business and Significant Accounting Policies - Schedule of Other Income (Details) Details 31 false false R32.htm 9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value (Details) Details 32 false false R33.htm 9954485 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 33 false false R34.htm 9954486 - Disclosure - Fair Value Measurements - Schedule of Changes to the Warrant Liability and Contingent Consideration (Details) Sheet http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails Fair Value Measurements - Schedule of Changes to the Warrant Liability and Contingent Consideration (Details) Details 34 false false R35.htm 9954487 - Disclosure - Balance Sheet Components (Details) Sheet http://www.sharecare.com/role/BalanceSheetComponentsDetails Balance Sheet Components (Details) Details http://www.sharecare.com/role/BalanceSheetComponentsTables 35 false false R36.htm 9954488 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) Sheet http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails Goodwill and Other Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details) Details 36 false false R37.htm 9954489 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Carrying Amount of Goodwill (Details) Sheet http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails Goodwill and Other Intangible Assets - Schedule of Carrying Amount of Goodwill (Details) Details 37 false false R38.htm 9954490 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) Sheet http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails Goodwill and Other Intangible Assets - Narrative (Details) Details 38 false false R39.htm 9954491 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details) Sheet http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails Goodwill and Other Intangible Assets - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details) Details 39 false false R40.htm 9954492 - Disclosure - Income Taxes (Details) Sheet http://www.sharecare.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.sharecare.com/role/IncomeTaxes 40 false false R41.htm 9954493 - Disclosure - Common Stock and Stockholders' Equity - Narrative (Details) Sheet http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails Common Stock and Stockholders' Equity - Narrative (Details) Details 41 false false R42.htm 9954494 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Warrants Issued and Outstanding (Details) Sheet http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails Common Stock and Stockholders' Equity - Schedule of Warrants Issued and Outstanding (Details) Details 42 false false R43.htm 9954495 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Stock Options (Details) Sheet http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails Common Stock and Stockholders' Equity - Schedule of Stock Options (Details) Details 43 false false R44.htm 9954496 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Restricted Stock Units (Details) Sheet http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails Common Stock and Stockholders' Equity - Schedule of Restricted Stock Units (Details) Details 44 false false R45.htm 9954497 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Share-Based??Compensation Expense for Employee and Nonemployee Options (Details) Sheet http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails Common Stock and Stockholders' Equity - Schedule of Share-Based??Compensation Expense for Employee and Nonemployee Options (Details) Details 45 false false R46.htm 9954498 - Disclosure - Related-Party Transactions (Details) Sheet http://www.sharecare.com/role/RelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://www.sharecare.com/role/RelatedPartyTransactions 46 false false R47.htm 9954499 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Sheet http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Details 47 false false R48.htm 9954500 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details) Sheet http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails Net Loss Per Share - Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details) Details 48 false false R49.htm 9954501 - Disclosure - Net Loss Per Share - Narrative (Details) Sheet http://www.sharecare.com/role/NetLossPerShareNarrativeDetails Net Loss Per Share - Narrative (Details) Details 49 false false R9999.htm Uncategorized Items - shcr-20240331.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - shcr-20240331.htm Cover 50 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: shcr:DeferredRevenueContractualServicePeriod, shcr:RevenueSettlementProcessTerm - shcr-20240331.htm 4 shcr-20240331.htm shcr-20240331.xsd shcr-20240331_cal.xml shcr-20240331_def.xml shcr-20240331_lab.xml shcr-20240331_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "shcr-20240331.htm": { "nsprefix": "shcr", "nsuri": "http://www.sharecare.com/20240331", "dts": { "inline": { "local": [ "shcr-20240331.htm" ] }, "schema": { "local": [ "shcr-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "shcr-20240331_cal.xml" ] }, "definitionLink": { "local": [ "shcr-20240331_def.xml" ] }, "labelLink": { "local": [ "shcr-20240331_lab.xml" ] }, "presentationLink": { "local": [ "shcr-20240331_pre.xml" ] } }, "keyStandard": 230, "keyCustom": 37, "axisStandard": 20, "axisCustom": 1, "memberStandard": 27, "memberCustom": 18, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2023": 5, "http://fasb.org/us-gaap/2023": 2, "http://www.sharecare.com/20240331": 2 }, "contextCount": 116, "entityCount": 1, "segmentCount": 49, "elementCount": 516, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 477, "http://xbrl.sec.gov/dei/2023": 34, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://www.sharecare.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SellingAndMarketingExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R5": { "role": "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "shortName": "CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS\u2019 EQUITY (DEFICIT)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:TemporaryEquitySharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:TemporaryEquitySharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R7": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPolicies", "longName": "0000007 - Disclosure - Nature of Business and Significant Accounting Policies", "shortName": "Nature of Business and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.sharecare.com/role/FairValueMeasurements", "longName": "0000008 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.sharecare.com/role/BalanceSheetComponents", "longName": "0000009 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssets", "longName": "0000010 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.sharecare.com/role/IncomeTaxes", "longName": "0000011 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.sharecare.com/role/CommonStockandStockholdersEquity", "longName": "0000012 - Disclosure - Common Stock and Stockholders' Equity", "shortName": "Common Stock and Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.sharecare.com/role/CommitmentsandContingencies", "longName": "0000013 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.sharecare.com/role/RelatedPartyTransactions", "longName": "0000014 - Disclosure - Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.sharecare.com/role/NetLossPerShare", "longName": "0000015 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.sharecare.com/role/SubsequentEvents", "longName": "0000016 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Nature of Business and Significant Accounting Policies (Policies)", "shortName": "Nature of Business and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Nature of Business and Significant Accounting Policies (Tables)", "shortName": "Nature of Business and Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.sharecare.com/role/FairValueMeasurementsTables", "longName": "9954473 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.sharecare.com/role/BalanceSheetComponentsTables", "longName": "9954474 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsTables", "longName": "9954475 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.sharecare.com/role/CommonStockandStockholdersEquityTables", "longName": "9954476 - Disclosure - Common Stock and Stockholders' Equity (Tables)", "shortName": "Common Stock and Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.sharecare.com/role/NetLossPerShareTables", "longName": "9954477 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofAllowanceforDoubtfulAccountsDetails", "longName": "9954478 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details)", "shortName": "Nature of Business and Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "longName": "9954479 - Disclosure - Nature of Business and Significant Accounting Policies - Contract Liabilities and Deferred Revenue (Narrative) (Details)", "shortName": "Nature of Business and Significant Accounting Policies - Contract Liabilities and Deferred Revenue (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "shcr:ContractLiabilitiesAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R28": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails", "longName": "9954480 - Disclosure - Nature of Business and Significant Accounting Policies - Performance-Based Revenue (Narrative) (Details)", "shortName": "Nature of Business and Significant Accounting Policies - Performance-Based Revenue (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-5", "name": "shcr:DeferredRevenuePerformanceBasedFeesNotRecognizedAsRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "shcr:DeferredRevenuePerformanceBasedFeesNotRecognizedAsRevenue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesRemainingPerformanceObligationsNarrativeDetails", "longName": "9954481 - Disclosure - Nature of Business and Significant Accounting Policies - Remaining Performance Obligations (Narrative) (Details)", "shortName": "Nature of Business and Significant Accounting Policies - Remaining Performance Obligations (Narrative) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails", "longName": "9954482 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "shortName": "Nature of Business and Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-53", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R31": { "role": "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails", "longName": "9954483 - Disclosure - Nature of Business and Significant Accounting Policies - Schedule of Other Income (Details)", "shortName": "Nature of Business and Significant Accounting Policies - Schedule of Other Income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails", "longName": "9954484 - Disclosure - Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-69", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-69", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails", "longName": "9954485 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails", "longName": "9954486 - Disclosure - Fair Value Measurements - Schedule of Changes to the Warrant Liability and Contingent Consideration (Details)", "shortName": "Fair Value Measurements - Schedule of Changes to the Warrant Liability and Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-71", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-71", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.sharecare.com/role/BalanceSheetComponentsDetails", "longName": "9954487 - Disclosure - Balance Sheet Components (Details)", "shortName": "Balance Sheet Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-5", "name": "shcr:AccruedExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "shcr:AccruedExpensesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails", "longName": "9954488 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets - Schedule of Finite-Lived and Indefinite-Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails", "longName": "9954489 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Carrying Amount of Goodwill (Details)", "shortName": "Goodwill and Other Intangible Assets - Schedule of Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R38": { "role": "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "longName": "9954490 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails", "longName": "9954491 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets - Schedule of Estimated Future Amortization Expense for Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.sharecare.com/role/IncomeTaxesDetails", "longName": "9954492 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails", "longName": "9954493 - Disclosure - Common Stock and Stockholders' Equity - Narrative (Details)", "shortName": "Common Stock and Stockholders' Equity - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "longName": "9954494 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Warrants Issued and Outstanding (Details)", "shortName": "Common Stock and Stockholders' Equity - Schedule of Warrants Issued and Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-82", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-82", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails", "longName": "9954495 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Stock Options (Details)", "shortName": "Common Stock and Stockholders' Equity - Schedule of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R44": { "role": "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails", "longName": "9954496 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Restricted Stock Units (Details)", "shortName": "Common Stock and Stockholders' Equity - Schedule of Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-87", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-87", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails", "longName": "9954497 - Disclosure - Common Stock and Stockholders' Equity - Schedule of Share-Based\u00a0Compensation Expense for Employee and Nonemployee Options (Details)", "shortName": "Common Stock and Stockholders' Equity - Schedule of Share-Based\u00a0Compensation Expense for Employee and Nonemployee Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.sharecare.com/role/RelatedPartyTransactionsDetails", "longName": "9954498 - Disclosure - Related-Party Transactions (Details)", "shortName": "Related-Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-103", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R47": { "role": "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails", "longName": "9954499 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R48": { "role": "http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails", "longName": "9954500 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details)", "shortName": "Net Loss Per Share - Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-109", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R49": { "role": "http://www.sharecare.com/role/NetLossPerShareNarrativeDetails", "longName": "9954501 - Disclosure - Net Loss Per Share - Narrative (Details)", "shortName": "Net Loss Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "shcr-20240331.htm", "unique": true } }, "R9999": { "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "longName": "Uncategorized Items - shcr-20240331.htm", "shortName": "Uncategorized Items - shcr-20240331.htm", "isDefault": "false", "groupType": "", "subGroupType": "", "menuCat": "Cover", "order": "50", "firstAnchor": null, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdateExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingStandardsUpdateExtensibleList", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting standards update, extensible enumeration", "label": "Accounting Standards Update [Extensible Enumeration]", "documentation": "Indicates amendment to accounting standards." } } }, "auth_ref": [ "r145", "r146", "r147", "r148", "r149", "r199", "r200", "r201", "r263", "r264", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r292", "r374", "r375", "r376", "r384", "r385", "r393", "r394", "r395", "r406", "r407", "r408", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r436", "r437", "r440", "r441", "r442", "r443", "r451", "r452", "r454", "r455", "r456", "r461", "r462", "r463", "r464", "r465", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r794" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r683" ] }, "shcr_AccountsReceivableAllowanceForCreditLossWriteoffAndOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "AccountsReceivableAllowanceForCreditLossWriteoffAndOtherAdjustments", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts written off and other adjustments", "label": "Accounts Receivable, Allowance For Credit Loss, Writeoff And Other Adjustments", "documentation": "Accounts Receivable, Allowance For Credit Loss, Writeoff And Other Adjustments" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net (net of allowance for doubtful accounts of $8,348 and $8,544, respectively)", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r257", "r258" ] }, "shcr_AccruedExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "AccruedExpensesCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Expenses, Current", "documentation": "Accrued Expenses, Current" } } }, "auth_ref": [] }, "shcr_AccruedExpensesRelatedToARelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "AccruedExpensesRelatedToARelatedParty", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses due to the Series A Preferred Stockholder", "label": "Accrued Expenses Related To A Related Party", "documentation": "Accrued Expenses Related To A Related Party" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails", "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities (Note 3)", "verboseLabel": "Accrued liabilities and other liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses and Other Current Liabilities", "label": "Accrued Liabilities and Other Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued media costs", "label": "Accrued Marketing Costs, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r34", "r35", "r91", "r162", "r507", "r534", "r538" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r10", "r35", "r410", "r413", "r465", "r529", "r530", "r782", "r783", "r784", "r791", "r792", "r793" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r734" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r86", "r683", "r839" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r374", "r375", "r376", "r551", "r791", "r792", "r793", "r823", "r841" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r740" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r740" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r740" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r740" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation costs related to share-based payment awards reflected within additional paid-in capital related to capitalizable internally developed software activities", "label": "APIC, Share-Based Payment Arrangement, Other, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement, classified as other." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r63", "r64", "r345" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of warrants in connection with debt and revenue arrangements", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r11", "r50", "r115" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r705", "r716", "r726", "r751" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r708", "r719", "r729", "r754" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r740" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r747" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r712", "r720", "r730", "r747", "r755", "r759", "r767" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r765" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r373", "r378" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Allowance for doubtful accounts \u2013 beginning balance", "periodEndLabel": "Allowance for doubtful accounts \u2013 ending balance", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r163", "r261", "r276", "r277", "r279", "r835" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, allowance for doubtful accounts", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r163", "r261", "r276" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for Doubtful Accounts", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense for intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r44", "r49" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareNarrativeDetails", "http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential common stock equivalents (in shares)", "verboseLabel": "Potentially dilutive securities (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r226" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareNarrativeDetails", "http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r39" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareNarrativeDetails", "http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareNarrativeDetails", "http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r39" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r124", "r157", "r189", "r233", "r248", "r252", "r265", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r399", "r403", "r439", "r503", "r592", "r683", "r696", "r817", "r818", "r827" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r151", "r166", "r189", "r265", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r399", "r403", "r439", "r683", "r817", "r818", "r827" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r762" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r763" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r758" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r758" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails", "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r761" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r760" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r759" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r759" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Unaudited Interim Financial Information", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Re-measurement of contingent consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r397", "r786" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration\u00a0\u2013 other liabilities", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r2", "r67", "r396" ] }, "us-gaap_CapitalizedContractCostAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostAmortization", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Capitalized Contract Cost, Amortization", "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r282" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r38", "r153", "r654" ] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAxis", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": [ "r153" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash equivalents at fair value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r38", "r101", "r188" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r101" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r144", "r159", "r160", "r161", "r189", "r215", "r216", "r223", "r225", "r231", "r232", "r265", "r300", "r302", "r303", "r304", "r307", "r308", "r311", "r312", "r314", "r315", "r317", "r439", "r540", "r541", "r542", "r543", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r580", "r601", "r624", "r642", "r643", "r644", "r645", "r646", "r774", "r788", "r795" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r159", "r160", "r161", "r231", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r540", "r541", "r542", "r543", "r668", "r774", "r788" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails", "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails", "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercise price per share (in USD per share)", "terseLabel": "Exercise price per share (in USD per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities called by each warrant (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants outstanding (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r59" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r739" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r739" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 7)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r29", "r80", "r504", "r579" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.sharecare.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r111", "r294", "r295", "r648", "r814" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock, par value $0.0001 per share", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r841" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r30" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r791", "r792", "r823", "r837", "r841" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in USD per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r85" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r85", "r580" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r85" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r85", "r580", "r598", "r841", "r842" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock $0.0001 par value; 600,000,000 and 600,000,000 shares authorized; 358,572,273 and 353,430,357 shares issued and outstanding as of March\u00a031, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r85", "r505", "r683" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r744" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r743" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r745" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r742" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss attributable to Sharecare, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r36", "r170", "r172", "r179", "r500", "r517" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss attributable to Sharecare, Inc.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss (income) attributable to noncontrolling interest in subsidiaries", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r7", "r70", "r74", "r170", "r172", "r178", "r499", "r516" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r74", "r120", "r170", "r172", "r177", "r498", "r515" ] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal-use software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r653", "r810", "r811" ] }, "shcr_ComputerSoftwareProjectsInProcessIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ComputerSoftwareProjectsInProcessIntangibleAssetMember", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal-use software projects in process", "label": "Computer Software, Projects In Process, Intangible Asset [Member]", "documentation": "Computer Software, Projects In Process, Intangible Asset" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r81", "r136" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Policy", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r71", "r659" ] }, "shcr_ContingentConsiderationLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContingentConsiderationLiabilityMember", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration", "label": "Contingent Consideration Liability [Member]", "documentation": "Contingent Consideration Liability" } } }, "auth_ref": [] }, "shcr_ContractLiabilitiesAccretion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContractLiabilitiesAccretion", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accretion of contract liabilities", "label": "Contract Liabilities, Accretion", "documentation": "Contract Liabilities, Accretion" } } }, "auth_ref": [] }, "shcr_ContractLiabilitiesAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContractLiabilitiesAmortization", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization of contract liabilities", "terseLabel": "Amortization of contract liabilities", "label": "Contract Liabilities, Amortization", "documentation": "Contract Liabilities, Amortization" } } }, "auth_ref": [] }, "shcr_ContractLiabilitiesDueToARelatedPartyCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContractLiabilitiesDueToARelatedPartyCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract liability due to the Series A Preferred Stockholder", "label": "Contract Liabilities Due To A Related Party Current", "documentation": "Contract Liabilities Due To A Related Party Current" } } }, "auth_ref": [] }, "shcr_ContractLiabilitiesOffMarketValueInstrumentsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContractLiabilitiesOffMarketValueInstrumentsPolicyPolicyTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liabilities", "label": "Contract Liabilities, Off Market Value Instruments, Policy [Policy Text Block]", "documentation": "Contract Liabilities, Off Market Value Instruments, Policy" } } }, "auth_ref": [] }, "shcr_ContractWithCustomerIntangibleAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContractWithCustomerIntangibleAsset", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset recognized", "label": "Contract With Customer, Intangible Asset", "documentation": "Contract With Customer, Intangible Asset" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r320", "r321", "r333" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized that was previously in deferred revenue", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r334" ] }, "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized related to services provided in prior period", "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period", "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price." } } }, "auth_ref": [ "r322" ] }, "shcr_ContractualAndEarnoutArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContractualAndEarnoutArrangementsMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual and Earnout Arrangements", "label": "Contractual And Earnout Arrangements [Member]", "documentation": "Contractual And Earnout Arrangements" } } }, "auth_ref": [] }, "shcr_ContractualArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContractualArrangementsAxis", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Arrangements [Axis]", "label": "Contractual Arrangements [Axis]", "documentation": "Contractual Arrangements" } } }, "auth_ref": [] }, "shcr_ContractualArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ContractualArrangementsDomain", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual Arrangements [Domain]", "label": "Contractual Arrangements [Domain]", "documentation": "Contractual Arrangements [Domain]" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Costs of revenue (exclusive of depreciation and amortization)", "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization", "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization." } } }, "auth_ref": [ "r779", "r780" ] }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Cost, Depreciation and Amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service." } } }, "auth_ref": [ "r785" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenues", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r95" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r193", "r194", "r309", "r313", "r472", "r656", "r658" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative effect of adopting ASU 2016-13", "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]" } } }, "auth_ref": [ "r147", "r198", "r204", "r210", "r269", "r275", "r374", "r375", "r376", "r384", "r385", "r409", "r410", "r411", "r413", "r414", "r415", "r419", "r422", "r424", "r425", "r463" ] }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionAxis", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Axis]", "label": "Cumulative Effect, Period of Adoption [Axis]" } } }, "auth_ref": [ "r147", "r198", "r204", "r210", "r269", "r275", "r374", "r375", "r376", "r384", "r385", "r409", "r410", "r411", "r413", "r414", "r415", "r419", "r422", "r424", "r425", "r463" ] }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CumulativeEffectPeriodOfAdoptionDomain", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative Effect, Period of Adoption [Domain]", "label": "Cumulative Effect, Period of Adoption [Domain]" } } }, "auth_ref": [ "r147", "r198", "r204", "r210", "r269", "r275", "r374", "r375", "r376", "r384", "r385", "r409", "r410", "r411", "r413", "r414", "r415", "r419", "r422", "r424", "r425", "r463" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "shcr_CustomerBoardOfDirectorsRelatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "CustomerBoardOfDirectorsRelatedMember", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors Related Customer", "label": "Customer, Board Of Directors Related [Member]", "documentation": "Customer, Board Of Directors Related" } } }, "auth_ref": [] }, "shcr_CustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "CustomerMember", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer [Member]", "documentation": "Customer" } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerRelationshipsMember", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": [ "r66" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r118", "r141", "r388", "r389", "r790" ] }, "shcr_DeferredRevenueContractualServicePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "DeferredRevenueContractualServicePeriod", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contractual service period (in months)", "label": "Deferred Revenue, Contractual Service Period", "documentation": "Deferred Revenue, Contractual Service Period" } } }, "auth_ref": [] }, "shcr_DeferredRevenuePerformanceBasedFeesNotRecognizedAsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "DeferredRevenuePerformanceBasedFeesNotRecognizedAsRevenue", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-based fees not recognized as revenue", "label": "Deferred Revenue, Performance Based Fees Not Recognized As Revenue", "documentation": "Deferred Revenue, Performance Based Fees Not Recognized As Revenue" } } }, "auth_ref": [] }, "shcr_DeferredRevenuePerformanceBasedRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "DeferredRevenuePerformanceBasedRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-based revenue recognized", "label": "Deferred Revenue, Performance Based Revenue Recognized", "documentation": "Deferred Revenue, Performance Based Revenue Recognized" } } }, "auth_ref": [] }, "shcr_DeferredRevenuePerformanceBasedRevenueRecognizedNotYetSettledWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "DeferredRevenuePerformanceBasedRevenueRecognizedNotYetSettledWithCustomers", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance-based revenue recognized but not yet settled with customers", "label": "Deferred Revenue, Performance Based Revenue Recognized, Not Yet Settled With Customers", "documentation": "Deferred Revenue, Performance Based Revenue Recognized, Not Yet Settled With Customers" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r238" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r167", "r168", "r438", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r593", "r595", "r596", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r658", "r838" ] }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative liability, statement of financial position", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative liability." } } }, "auth_ref": [ "r405" ] }, "shcr_DirectorAffiliatedCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "DirectorAffiliatedCustomerMember", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director Affiliated Customer", "label": "Director Affiliated Customer [Member]", "documentation": "Director Affiliated Customer" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r332", "r669", "r670", "r671", "r672", "r673", "r674", "r675" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r332", "r669", "r670", "r671", "r672", "r673", "r674", "r675" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues Disaggregated by Revenue Source", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r820" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r700" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r733" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share attributable to common stockholders, basic (in USD per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r180", "r202", "r203", "r204", "r205", "r206", "r212", "r215", "r223", "r224", "r225", "r229", "r425", "r426", "r501", "r518", "r660" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common stockholders, diluted (in USD per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r180", "r202", "r203", "r204", "r205", "r206", "r215", "r223", "r224", "r225", "r229", "r425", "r426", "r501", "r518", "r660" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.sharecare.com/role/NetLossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r211", "r226", "r227", "r228" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rates on cash and cash equivalents", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r444" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r26" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "shcr_EnterpriseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "EnterpriseMember", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Enterprise", "label": "Enterprise [Member]", "documentation": "Enterprise" } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r698" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r698" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r773" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r698" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r772" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r698" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r698" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r698" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r698" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r147", "r173", "r174", "r175", "r195", "r196", "r197", "r200", "r207", "r209", "r230", "r269", "r275", "r319", "r374", "r375", "r376", "r384", "r385", "r409", "r410", "r411", "r412", "r413", "r415", "r424", "r445", "r446", "r447", "r448", "r449", "r450", "r465", "r529", "r530", "r531", "r551", "r624" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r741" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r705", "r716", "r726", "r751" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r702", "r713", "r723", "r748" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r747" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Re-measurement of warrant liabilities", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r9" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r429", "r430", "r434" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r429", "r430", "r434" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value Hierarchy for Assets and Liabilities Measured at Fair Value", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances." } } }, "auth_ref": [ "r19", "r75", "r76", "r123" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r310", "r336", "r337", "r338", "r339", "r340", "r341", "r430", "r476", "r477", "r478", "r666", "r667", "r676", "r677", "r678" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class [Axis]", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r76", "r122" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r429", "r430", "r431", "r432", "r435" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r428" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r310", "r336", "r341", "r430", "r476", "r676", "r677", "r678" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r310", "r336", "r341", "r430", "r477", "r666", "r667", "r676", "r677", "r678" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r310", "r336", "r337", "r338", "r339", "r340", "r341", "r430", "r478", "r666", "r667", "r676", "r677", "r678" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class [Domain]", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r12" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in liability", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r12", "r76" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes to the Warrant Liability and Contingent Consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r12", "r76" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Re-measurement of contingent consideration", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r433" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofChangestotheWarrantLiabilityandContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r12" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r310", "r336", "r337", "r338", "r339", "r340", "r341", "r476", "r477", "r478", "r666", "r667", "r676", "r677", "r678" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r428", "r435" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Financial Liabilities Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "shcr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 }, "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "negatedLabel": "Total intangible assets, accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r155", "r288" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r109" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remainder of 2024", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r109" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r109" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r109" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r285", "r287", "r288", "r290", "r483", "r484" ] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated future amortization expense:", "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r108", "r484" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r483" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r45", "r48" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforIntangibleAssetsDetails", "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r108", "r483" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Definite-lived, intangible assets", "label": "Finite-Lived Intangible Assets, Net [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Life", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r483" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r709", "r720", "r730", "r755" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r96", "r603" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r94" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r154", "r283", "r497", "r665", "r683", "r800", "r807" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r107" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r284" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillRollForward", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax benefit (expense)", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r92", "r127", "r233", "r247", "r251", "r253", "r502", "r511", "r662" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r291", "r293", "r608" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r293", "r608" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.sharecare.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r190", "r379", "r381", "r382", "r383", "r386", "r390", "r391", "r392", "r545" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax benefit (expense)", "negatedLabel": "Income tax benefit (less than)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r133", "r142", "r208", "r209", "r239", "r380", "r387", "r519" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r481", "r786" ] }, "shcr_IncreaseDecreaseInFairValueOfWarrantLiabilitiesAndContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "IncreaseDecreaseInFairValueOfWarrantLiabilitiesAndContingentConsideration", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrant liability and contingent consideration", "label": "Increase (Decrease) in Fair Value Of Warrant Liabilities And Contingent Consideration", "documentation": "Increase (Decrease) in Fair Value Of Warrant Liabilities And Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r777", "r786" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r286", "r289" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets not subject to amortization", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r110" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible\u00a0assets\u00a0not\u00a0subject\u00a0to\u00a0amortization", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r46", "r110" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r712", "r720", "r730", "r747", "r755", "r759", "r767" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r765" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r701", "r771" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r701", "r771" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r701", "r771" ] }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsGrossExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails_1": { "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill", "weight": 1.0, "order": 1.0 }, "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total intangible assets, cost", "label": "Intangible Assets, Gross (Excluding Goodwill)", "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill." } } }, "auth_ref": [ "r154" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Total intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r43", "r47" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intangible assets", "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestAndDebtExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndDebtExpenseAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income:", "label": "Interest and Debt Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r77", "r129", "r176", "r237", "r453", "r609", "r694", "r840" ] }, "shcr_InterestExpenseNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "InterestExpenseNoncash", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Interest Expense, Noncash", "documentation": "Interest Expense, Noncash" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r183", "r186", "r187" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r97", "r236" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r25", "r189", "r265", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r400", "r403", "r404", "r439", "r578", "r661", "r696", "r817", "r827", "r828" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r90", "r126", "r510", "r683", "r789", "r798", "r825" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r27", "r152", "r189", "r265", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r400", "r403", "r404", "r439", "r683", "r817", "r827", "r828" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities at fair value", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r75" ] }, "shcr_LifeSciencesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "LifeSciencesMember", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Life Sciences", "label": "Life Sciences [Member]", "documentation": "Life Sciences" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r158" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r296", "r297", "r298", "r299", "r343", "r480", "r526", "r570", "r571", "r630", "r631", "r632", "r633", "r641", "r649", "r650", "r664", "r668", "r679", "r685", "r819", "r829", "r830", "r831", "r832", "r833", "r834" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r739" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r739" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r296", "r297", "r298", "r299", "r343", "r480", "r526", "r570", "r571", "r630", "r631", "r632", "r633", "r641", "r649", "r650", "r664", "r668", "r679", "r685", "r819", "r829", "r830", "r831", "r832", "r833", "r834" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest in subsidiaries", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r33", "r125", "r189", "r265", "r300", "r302", "r303", "r304", "r307", "r308", "r439", "r509", "r582" ] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest", "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r758" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r821" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r766" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r740" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r185" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r185" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r101", "r102", "r103" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to Sharecare, Inc.", "terseLabel": "Net income (loss) attributable to Sharecare, Inc.", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r93", "r103", "r128", "r150", "r169", "r171", "r175", "r189", "r199", "r202", "r203", "r204", "r205", "r208", "r209", "r221", "r233", "r247", "r251", "r253", "r265", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r426", "r439", "r514", "r600", "r622", "r623", "r662", "r694", "r817" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss attributable to noncontrolling interest in subsidiaries", "netLabel": "Net income (loss) attributable to noncontrolling interest in subsidiaries", "terseLabel": "Less: Net loss attributable to noncontrolling interests in subsidiaries", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r73", "r121", "r169", "r171", "r208", "r209", "r513", "r784" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss available to common stockholders, basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r182", "r202", "r203", "r204", "r205", "r212", "r213", "r222", "r225", "r233", "r247", "r251", "r253", "r662" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss available to common stockholders, diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r182", "r214", "r217", "r218", "r219", "r220", "r222", "r225" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Standards Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r739" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r709", "r720", "r730", "r747", "r755" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r737" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r736" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r747" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r766" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r766" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r68", "r319", "r791", "r792", "r793", "r841" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r98" ] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingCostsAndExpensesAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and operating expenses:", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r233", "r247", "r251", "r253", "r662" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, current", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r457" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r458", "r459" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Lease right-of-use assets expense", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r787" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Business and Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r82", "r104", "r105", "r119" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r26" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r165", "r683" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r156" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation", "terseLabel": "Currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r28" ] }, "shcr_OtherMiscellaneousIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "OtherMiscellaneousIncomeExpense", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Miscellaneous Income (Expense)", "documentation": "Other Miscellaneous Income (Expense)" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r103" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofOtherIncomeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other income", "totalLabel": "Total other income", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r99" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r739" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r707", "r718", "r728", "r753" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r710", "r721", "r731", "r756" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r710", "r721", "r731", "r756" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r735" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments for shares repurchased", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r37" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r100" ] }, "us-gaap_PaymentsToDevelopSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToDevelopSoftware", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalized internal-use software costs", "label": "Payments to Develop Software", "documentation": "The cash outflow associated with the development or modification of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization." } } }, "auth_ref": [ "r100" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r738" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r738" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r737" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r747" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r740" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r736" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r164", "r280", "r281", "r655" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of common stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r18" ] }, "shcr_ProductAndTechnologyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ProductAndTechnologyExpense", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Product and technology", "label": "Product And Technology Expense", "documentation": "Product And Technology Expense" } } }, "auth_ref": [] }, "shcr_ProductAndTechnologyExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ProductAndTechnologyExpenseMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and technology", "label": "Product And Technology Expense [Member]", "documentation": "Product And Technology Expense" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r254", "r482", "r520", "r521", "r522", "r523", "r524", "r525", "r652", "r669", "r684", "r778", "r815", "r816", "r820", "r836" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r254", "r482", "r520", "r521", "r522", "r523", "r524", "r525", "r652", "r669", "r684", "r778", "r815", "r816", "r820", "r836" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r150", "r169", "r171", "r184", "r189", "r199", "r208", "r209", "r233", "r247", "r251", "r253", "r265", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r398", "r401", "r402", "r426", "r439", "r502", "r512", "r550", "r600", "r622", "r623", "r662", "r680", "r681", "r695", "r784", "r817" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r776", "r812" ] }, "shcr_ProviderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ProviderMember", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provider", "label": "Provider [Member]", "documentation": "Provider" } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofAllowanceforDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for doubtful accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r181", "r278" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r735" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r735" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r296", "r297", "r298", "r299", "r335", "r343", "r369", "r370", "r371", "r479", "r480", "r526", "r570", "r571", "r630", "r631", "r632", "r633", "r641", "r649", "r650", "r664", "r668", "r679", "r685", "r688", "r813", "r819", "r830", "r831", "r832", "r833", "r834" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r296", "r297", "r298", "r299", "r335", "r343", "r369", "r370", "r371", "r479", "r480", "r526", "r570", "r571", "r630", "r631", "r632", "r633", "r641", "r649", "r650", "r664", "r668", "r679", "r685", "r688", "r813", "r819", "r830", "r831", "r832", "r833", "r834" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r702", "r713", "r723", "r748" ] }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableConvertiblePreferredStockMember", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable\u00a0Convertible Preferred\u00a0Stock", "verboseLabel": "Redeemable convertible preferred stock", "label": "Redeemable Convertible Preferred Stock [Member]", "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer." } } }, "auth_ref": [] }, "shcr_RedeemableConvertiblePreferredStockSeriesAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "RedeemableConvertiblePreferredStockSeriesAMember", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Series A Preferred Stock", "label": "Redeemable Convertible Preferred Stock, Series A [Member]", "documentation": "Redeemable Convertible Preferred Stock, Series A" } } }, "auth_ref": [] }, "shcr_RedeemableWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "RedeemableWarrantsMember", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share", "label": "Redeemable Warrants [Member]", "documentation": "Redeemable Warrants" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r342", "r469", "r470", "r573", "r574", "r575", "r576", "r577", "r597", "r599", "r629" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r191", "r192", "r469", "r470", "r471", "r472", "r573", "r574", "r575", "r576", "r577", "r597", "r599", "r629" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r604", "r605", "r608" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesContractLiabilitiesandDeferredRevenueNarrativeDetails", "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party, Type [Axis]", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r342", "r469", "r470", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r573", "r574", "r575", "r576", "r577", "r597", "r599", "r629", "r826" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related-Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r466", "r467", "r468", "r470", "r473", "r546", "r547", "r548", "r606", "r607", "r608", "r627", "r628" ] }, "shcr_RepaymentsOfCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "RepaymentsOfCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on financing lease obligations", "label": "Repayments Of Capital Lease Obligations", "documentation": "Repayments Of Capital Lease Obligations" } } }, "auth_ref": [] }, "shcr_ReportingUnitBasisDecreaseThresholdInAnnualForecastedRevenues": { "xbrltype": "percentItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ReportingUnitBasisDecreaseThresholdInAnnualForecastedRevenues", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis point decrease in annual forecasted revenues", "label": "Reporting Unit, Basis Decrease Threshold In Annual Forecasted Revenues", "documentation": "Reporting Unit, Basis Decrease Threshold In Annual Forecasted Revenues" } } }, "auth_ref": [] }, "shcr_ReportingUnitBasisIncreaseThresholdInWeightedAverageCostOfCapital": { "xbrltype": "percentItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ReportingUnitBasisIncreaseThresholdInWeightedAverageCostOfCapital", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis point increase in weighted average cost of capital", "label": "Reporting Unit, Basis Increase Threshold In Weighted Average Cost Of Capital", "documentation": "Reporting Unit, Basis Increase Threshold In Weighted Average Cost Of Capital" } } }, "auth_ref": [] }, "shcr_ReportingUnitPercentageOfDeclineInFairValueInEventOfDecreaseInAnnualForecastedRevenue": { "xbrltype": "percentItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ReportingUnitPercentageOfDeclineInFairValueInEventOfDecreaseInAnnualForecastedRevenue", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of decline in fair value, in event of decrease in annual forecasted revenue", "label": "Reporting Unit, Percentage Of Decline In Fair Value, In Event Of Decrease In Annual Forecasted Revenue", "documentation": "Reporting Unit, Percentage Of Decline In Fair Value, In Event Of Decrease In Annual Forecasted Revenue" } } }, "auth_ref": [] }, "shcr_ReportingUnitPercentageOfDeclineInFairValueInEventOfIncreaseInWeightedAverageCapital": { "xbrltype": "percentItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ReportingUnitPercentageOfDeclineInFairValueInEventOfIncreaseInWeightedAverageCapital", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of decline in fair value, in event increase in weighted average capital", "label": "Reporting Unit, Percentage Of Decline In Fair Value, In Event Of Increase In Weighted Average Capital", "documentation": "Reporting Unit, Percentage Of Decline In Fair Value, In Event Of Increase In Weighted Average Capital" } } }, "auth_ref": [] }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fair value in excess of book value", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "documentation": "Percentage of fair value of reporting unit in excess of carrying amount." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r193", "r194", "r309", "r313", "r472", "r657", "r658" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r703", "r714", "r724", "r749" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r704", "r715", "r725", "r750" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r711", "r722", "r732", "r757" ] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsScheduleofFairValueHierarchyforAssetsandLiabilitiesMeasuredatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r153" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails", "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails", "http://www.sharecare.com/role/NetLossPerShareNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "RSUs", "terseLabel": "Restricted Stock Units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r87", "r115", "r508", "r533", "r538", "r544", "r581", "r683" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r147", "r195", "r196", "r197", "r200", "r207", "r209", "r269", "r275", "r374", "r375", "r376", "r384", "r385", "r409", "r411", "r412", "r415", "r424", "r529", "r531", "r551", "r841" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesScheduleofRevenuesDisaggregatedbyRevenueSourceDetails", "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "verboseLabel": "Total Revenue", "netLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r234", "r235", "r246", "r249", "r250", "r254", "r255", "r256", "r331", "r332", "r482" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Revenue and Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r143", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r651" ] }, "shcr_RevenuePerformanceMeasurementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "RevenuePerformanceMeasurementPeriod", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement period", "label": "Revenue, Performance Measurement Period", "documentation": "Revenue, Performance Measurement Period" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesRemainingPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r139" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesRemainingPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesRemainingPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsatisfied performance obligations expected recognition period", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r140" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesRemainingPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r140" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesRemainingPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationPercentage", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesRemainingPerformanceObligationsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining performance obligations percentage to be recognized", "label": "Revenue, Remaining Performance Obligation, Percentage", "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue." } } }, "auth_ref": [ "r775" ] }, "shcr_RevenueSettlementProcessTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "RevenueSettlementProcessTerm", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPerformanceBasedRevenueNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement process term", "label": "Revenue, Settlement Process Term", "documentation": "Revenue, Settlement Process Term" } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets obtained in exchange for lease obligations", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r460", "r682" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r766" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r766" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Allowance for Doubtful Accounts", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expense and Other Current Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareNarrativeDetails", "http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r39" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potential Common Shares Equivalents Excluded from Computation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r39" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r796" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-Based\u00a0Compensation Expense for Employee and Nonemployee Options", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r62" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r45", "r48", "r483" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r45", "r48" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r665", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r20", "r110" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r20", "r110" ] }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Income", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r78", "r79", "r604", "r605", "r608" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Stock Unit Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r113", "r114", "r115", "r159", "r160", "r161", "r231", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r540", "r541", "r542", "r543", "r668", "r774", "r788" ] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock Option Activity", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Warrants Issued and Outstanding", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Future Amortization Expense for Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r48" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r697" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r699" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r240", "r241", "r242", "r243", "r244", "r245", "r255", "r663" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingAndMarketingExpenseMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofShareBasedCompensationExpenseforEmployeeandNonemployeeOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and marketing", "label": "Selling and Marketing Expense [Member]", "documentation": "Primary financial statement caption encompassing selling and marketing expense." } } }, "auth_ref": [ "r94" ] }, "shcr_SeriesAPreferredStockHolderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "SeriesAPreferredStockHolderMember", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock Holder", "label": "Series A Preferred Stock Holder [Member]", "documentation": "Series A Preferred Stock Holder" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled/forfeited (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r363" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r361" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning (in USD per share)", "periodEndLabel": "Outstanding, ending (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r358", "r359" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units - Weighted-Average Grant Date Fair Value per share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised/released (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r362" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercised/released (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised", "documentation": "Number of non-option equity instruments exercised by participants." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancelled/forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations", "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted", "documentation": "Net number of non-option equity instruments granted to participants." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning (in shares)", "periodEndLabel": "Outstanding, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r13", "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock Units - Number of Plan shares outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "shcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyVestingInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfQuarterlyVestingInstallments", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of quarterly installments", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Vesting Installments", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Quarterly Vesting Installments" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options, Additional Disclosures", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r365" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cancelled/forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r822" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled/forfeited (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r822" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r354" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning (in shares)", "periodEndLabel": "Outstanding, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r350", "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Outstanding - Number of Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, beginning (in USD per share)", "periodEndLabel": "Outstanding, ending (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r350", "r351" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Outstanding - Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and/or exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r367" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and/or exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r367" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and/or exercisable (in USD per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r367" ] }, "shcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardUnvestedLiability", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested liability", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Unvested Liability", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Unvested Liability" } } }, "auth_ref": [] }, "shcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardVoluntarilyElectedToForgoCashBaseSalaryPercentage": { "xbrltype": "pureItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVoluntarilyElectedToForgoCashBaseSalaryPercentage", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement by share-based payment award, voluntarily elected to forgo, cash base salary, percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Voluntarily Elected To Forgo, Cash Base Salary, Percentage", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Voluntarily Elected To Forgo, Cash Base Salary, Percentage" } } }, "auth_ref": [] }, "shcr_ShareBasedCompensationArrangementByShareBasedPaymentAwardVoluntarilyElectedToForgoCashBaseSalaryPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVoluntarilyElectedToForgoCashBaseSalaryPeriod", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation arrangement by share-based payment award, voluntarily elected to forgo, cash base salary", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Voluntarily Elected To Forgo, Cash Base Salary, Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Voluntarily Elected To Forgo, Cash Base Salary, Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails", "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised/released (in USD per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r355" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in USD per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r354" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r117" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and/or exercisable, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r367" ] }, "shcr_SharecareBrasilServiciosDeConsultoriaLtdaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "SharecareBrasilServiciosDeConsultoriaLtdaMember", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sharecare Brasil Servicios de Consultoria, Ltda", "label": "Sharecare Brasil Servicios de Consultoria, Ltda [Member]", "documentation": "Sharecare Brasil Servicios de Consultoria, Ltda" } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock and Stockholders' Equity", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r112", "r116" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r144", "r159", "r160", "r161", "r189", "r215", "r216", "r223", "r225", "r231", "r232", "r265", "r300", "r302", "r303", "r304", "r307", "r308", "r311", "r312", "r314", "r315", "r317", "r439", "r540", "r541", "r542", "r543", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r580", "r601", "r624", "r642", "r643", "r644", "r645", "r646", "r774", "r788", "r795" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r11", "r31", "r147", "r173", "r174", "r175", "r195", "r196", "r197", "r200", "r207", "r209", "r230", "r269", "r275", "r319", "r374", "r375", "r376", "r384", "r385", "r409", "r410", "r411", "r412", "r413", "r415", "r424", "r445", "r446", "r447", "r448", "r449", "r450", "r465", "r529", "r530", "r531", "r551", "r624" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r195", "r196", "r197", "r230", "r482", "r539", "r562", "r572", "r573", "r574", "r575", "r576", "r577", "r580", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r593", "r594", "r595", "r596", "r597", "r599", "r602", "r603", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r689" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r195", "r196", "r197", "r230", "r482", "r539", "r562", "r572", "r573", "r574", "r575", "r576", "r577", "r580", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r593", "r594", "r595", "r596", "r597", "r599", "r602", "r603", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r624", "r689" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r706", "r717", "r727", "r752" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockCompensationPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockCompensationPlanMember", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareScheduleofPotentialCommonSharesEquivalentsExcludedfromComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options and restricted stock units", "label": "Share-Based Payment Arrangement [Member]", "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": [ "r797" ] }, "shcr_StockIssuedDuringPeriodSharesRestrictedStockUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "StockIssuedDuringPeriodSharesRestrictedStockUnits", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued upon vesting of restricted stock units (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Units", "documentation": "Stock Issued During Period, Shares, Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT", "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofStockOptionsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options exercised (in shares)", "negatedTerseLabel": "Exercised/released (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r84", "r85", "r115", "r355" ] }, "shcr_StockIssuedDuringPeriodValueRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "StockIssuedDuringPeriodValueRestrictedStockUnits", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued upon vesting of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Units", "documentation": "Stock Issued During Period, Value, Restricted Stock Units" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options exercised", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r11", "r31", "r115" ] }, "shcr_StockRepurchasedDuringPeriodRelatedToExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "StockRepurchasedDuringPeriodRelatedToExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsShares", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units (in shares)", "label": "Stock Repurchased During Period Related To Exercise Of Stock Options And Vesting Of Restricted Stock Units, Shares", "documentation": "Stock Repurchased During Period Related To Exercise Of Stock Options And Vesting Of Restricted Stock Units, Shares" } } }, "auth_ref": [] }, "shcr_StockRepurchasedDuringPeriodRelatedToExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "StockRepurchasedDuringPeriodRelatedToExerciseOfStockOptionsAndVestingOfRestrictedStockUnitsValue", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock repurchased related to tax withholding for exercised employee stock options and vested restricted stock units", "label": "Stock Repurchased During Period Related To Exercise Of Stock Options And Vesting Of Restricted Stock Units, Value", "documentation": "Stock Repurchased During Period Related To Exercise Of Stock Options And Vesting Of Restricted Stock Units, Value" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total Sharecare, Inc. stockholders\u2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r85", "r88", "r89", "r106", "r582", "r598", "r625", "r626", "r683", "r696", "r789", "r798", "r825", "r841" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r68", "r69", "r72", "r147", "r148", "r174", "r195", "r196", "r197", "r200", "r207", "r269", "r275", "r319", "r374", "r375", "r376", "r384", "r385", "r409", "r410", "r411", "r412", "r413", "r415", "r424", "r445", "r446", "r450", "r465", "r530", "r531", "r549", "r582", "r598", "r625", "r626", "r647", "r695", "r789", "r798", "r825", "r841" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.sharecare.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r474", "r475" ] }, "shcr_SulAmricaServiosDeSadeSASulAmricaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "SulAmricaServiosDeSadeSASulAmricaMember", "presentation": [ "http://www.sharecare.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sul Am\u00e9rica", "label": "Sul Am\u00e9rica Servi\u00e7os de Sa\u00fade S.A. (Sul Am\u00e9rica) [Member]", "documentation": "Sul Am\u00e9rica Servi\u00e7os de Sa\u00fade S.A. (Sul Am\u00e9rica)" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponents" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Components", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r781" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r746" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/BalanceSheetComponentsDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/BalanceSheetComponentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued taxes", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r24" ] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Technology\u00a0\u2013 features/content", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": [ "r21" ] }, "us-gaap_TemporaryEquityByClassOfStockTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityByClassOfStockTable", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary Equity, by Class of Stock [Table]", "label": "Temporary Equity, by Class of Stock [Table]", "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable." } } }, "auth_ref": [ "r22", "r51" ] }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityCarryingAmountAttributableToParent", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Series A redeemable convertible preferred stock, $0.0001 par value; 5,000,000 shares authorized; 5,000,000 shares issued and outstanding, aggregate liquidation preference of $50,000 as of March\u00a031, 2024 and December\u00a031, 2023", "periodStartLabel": "Redeemable convertible preferred stock, beginning balance", "periodEndLabel": "Redeemable convertible preferred stock, ending balance", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r300", "r302", "r303", "r304", "r307", "r308", "r377", "r506" ] }, "us-gaap_TemporaryEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLineItems", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Temporary Equity [Line Items]", "label": "Temporary Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityLiquidationPreference": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityLiquidationPreference", "crdr": "credit", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable convertible preferred stock, aggregate liquidation preference", "label": "Temporary Equity, Liquidation Preference", "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityNumberOfSharesRedemptionValueAndOtherDisclosuresAbstract", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Convertible Preferred Stock", "label": "Temporary Equity, Other Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquityParOrStatedValuePerShare", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable convertible preferred stock, par value (in USD per share)", "label": "Temporary Equity, Par or Stated Value Per Share", "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable." } } }, "auth_ref": [ "r22", "r51" ] }, "us-gaap_TemporaryEquitySharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesAuthorized", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable convertible preferred stock, shares authorized (in shares)", "label": "Temporary Equity, Shares Authorized", "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r83" ] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFREDEEMABLECONVERTIBLEPREFERREDSTOCKANDSTOCKHOLDERSEQUITYDEFICIT" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable convertible preferred stock, shares issued (in shares)", "periodStartLabel": "Redeemable\u00a0convertible preferred stock, beginning balance (in shares)", "periodEndLabel": "Redeemable\u00a0convertible preferred stock, ending balance (in shares)", "label": "Temporary Equity, Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r83" ] }, "us-gaap_TemporaryEquitySharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TemporaryEquitySharesOutstanding", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Redeemable convertible preferred stock, shares outstanding (in shares)", "label": "Temporary Equity, Shares Outstanding", "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r83" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r738" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r745" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r130", "r131", "r132", "r259", "r260", "r262" ] }, "us-gaap_TradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeNamesMember", "presentation": [ "http://www.sharecare.com/role/GoodwillandOtherIntangibleAssetsScheduleofFiniteLivedandIndefiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trade name", "verboseLabel": "Indefinite-lived, trade names", "label": "Trade Names [Member]", "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r65" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r765" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r767" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.sharecare.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r768" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r769" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r767" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r767" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r770" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r768" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r764" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.sharecare.com/role/NatureofBusinessandSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r40", "r41", "r42", "r134", "r135", "r137", "r138" ] }, "shcr_WarrantEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "WarrantEquityMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails", "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity Warrants", "terseLabel": "Equity", "label": "Warrant, Equity [Member]", "documentation": "Warrant, Equity" } } }, "auth_ref": [] }, "shcr_WarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "WarrantLiability", "crdr": "credit", "calculation": { "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liabilities", "label": "Warrant Liability", "documentation": "Warrant Liability" } } }, "auth_ref": [] }, "shcr_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "WarrantLiabilityMember", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails", "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Liability Warrants", "terseLabel": "Liability", "label": "Warrant, Liability [Member]", "documentation": "Warrant, Liability" } } }, "auth_ref": [] }, "shcr_WarrantLiabilityOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "WarrantLiabilityOutstanding", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityScheduleofWarrantsIssuedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants outstanding (in shares)", "label": "Warrant Liability, Outstanding", "documentation": "Warrant Liability, Outstanding" } } }, "auth_ref": [] }, "shcr_WarrantPrivateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "WarrantPrivateMember", "presentation": [ "http://www.sharecare.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants", "label": "Warrant, Private [Member]", "documentation": "Warrant, Private" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expiration period (in years)", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r824" ] }, "shcr_WarrantsAndRightsOutstandingVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "WarrantsAndRightsOutstandingVestingPeriod", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants vesting period (in years)", "label": "Warrants And Rights Outstanding, Vesting Period", "documentation": "Warrants And Rights Outstanding, Vesting Period" } } }, "auth_ref": [] }, "shcr_WarrantsEarnedButUnisssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "WarrantsEarnedButUnisssued", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants earned but not issued (in shares)", "label": "Warrants, Earned But Unisssued", "documentation": "Warrants, Earned But Unisssued" } } }, "auth_ref": [] }, "shcr_WarrantsReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.sharecare.com/20240331", "localname": "WarrantsReservedForFutureIssuance", "presentation": [ "http://www.sharecare.com/role/CommonStockandStockholdersEquityNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants reserved for future issuance (in shares)", "label": "Warrants Reserved For Future Issuance", "documentation": "Warrants Reserved For Future Issuance" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r214", "r225" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.sharecare.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average common shares outstanding, basic (in shares)", "netLabel": "Weighted-average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r212", "r225" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://www.sharecare.com/role/NetLossPerShareScheduleofBasicandDilutedNetLossPerShareAttributabletoCommonStockholdersDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(1)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(2)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)-(4)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(27)", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.E.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r679": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r680": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r681": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r682": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r683": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r694": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r774": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//210/tableOfContent" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 70 0001816233-24-000111-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001816233-24-000111-xbrl.zip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�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�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end XML 72 shcr-20240331_htm.xml IDEA: XBRL DOCUMENT 0001816233 2024-01-01 2024-03-31 0001816233 us-gaap:CommonClassAMember 2024-01-01 2024-03-31 0001816233 shcr:RedeemableWarrantsMember 2024-01-01 2024-03-31 0001816233 2024-05-06 0001816233 2024-03-31 0001816233 2023-12-31 0001816233 shcr:RedeemableConvertiblePreferredStockSeriesAMember 2024-03-31 0001816233 shcr:RedeemableConvertiblePreferredStockSeriesAMember 2023-12-31 0001816233 2023-01-01 2023-03-31 0001816233 us-gaap:RedeemableConvertiblePreferredStockMember 2023-12-31 0001816233 us-gaap:CommonStockMember 2023-12-31 0001816233 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001816233 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001816233 us-gaap:RetainedEarningsMember 2023-12-31 0001816233 us-gaap:NoncontrollingInterestMember 2023-12-31 0001816233 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001816233 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001816233 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001816233 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001816233 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001816233 us-gaap:RedeemableConvertiblePreferredStockMember 2024-03-31 0001816233 us-gaap:CommonStockMember 2024-03-31 0001816233 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001816233 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001816233 us-gaap:RetainedEarningsMember 2024-03-31 0001816233 us-gaap:NoncontrollingInterestMember 2024-03-31 0001816233 us-gaap:RedeemableConvertiblePreferredStockMember 2022-12-31 0001816233 us-gaap:CommonStockMember 2022-12-31 0001816233 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001816233 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001816233 us-gaap:RetainedEarningsMember 2022-12-31 0001816233 us-gaap:NoncontrollingInterestMember 2022-12-31 0001816233 2022-12-31 0001816233 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001816233 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001816233 2022-01-01 2022-12-31 0001816233 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember us-gaap:RetainedEarningsMember 2022-12-31 0001816233 srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2022-12-31 0001816233 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001816233 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001816233 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001816233 us-gaap:RedeemableConvertiblePreferredStockMember 2023-03-31 0001816233 us-gaap:CommonStockMember 2023-03-31 0001816233 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001816233 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001816233 us-gaap:RetainedEarningsMember 2023-03-31 0001816233 us-gaap:NoncontrollingInterestMember 2023-03-31 0001816233 2023-03-31 0001816233 us-gaap:RelatedPartyMember 2023-12-31 0001816233 us-gaap:RelatedPartyMember 2024-03-31 0001816233 srt:MinimumMember 2024-01-01 2024-03-31 0001816233 srt:MaximumMember 2024-01-01 2024-03-31 0001816233 shcr:EnterpriseMember 2024-01-01 2024-03-31 0001816233 shcr:EnterpriseMember srt:MinimumMember 2024-01-01 2024-03-31 0001816233 shcr:EnterpriseMember srt:MaximumMember 2024-01-01 2024-03-31 0001816233 2024-04-01 2024-03-31 0001816233 shcr:EnterpriseMember 2023-01-01 2023-03-31 0001816233 shcr:ProviderMember 2024-01-01 2024-03-31 0001816233 shcr:ProviderMember 2023-01-01 2023-03-31 0001816233 shcr:LifeSciencesMember 2024-01-01 2024-03-31 0001816233 shcr:LifeSciencesMember 2023-01-01 2023-03-31 0001816233 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001816233 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001816233 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001816233 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001816233 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001816233 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001816233 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001816233 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0001816233 shcr:WarrantPrivateMember 2024-03-31 0001816233 shcr:ContingentConsiderationLiabilityMember 2023-12-31 0001816233 shcr:ContingentConsiderationLiabilityMember 2024-01-01 2024-03-31 0001816233 shcr:ContingentConsiderationLiabilityMember 2024-03-31 0001816233 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-03-31 0001816233 us-gaap:TradeNamesMember 2024-03-31 0001816233 us-gaap:CustomerRelationshipsMember 2024-03-31 0001816233 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-03-31 0001816233 shcr:ComputerSoftwareProjectsInProcessIntangibleAssetMember 2024-03-31 0001816233 us-gaap:TradeNamesMember 2024-03-31 0001816233 shcr:WarrantLiabilityMember 2024-03-31 0001816233 shcr:WarrantEquityMember 2024-01-01 2024-03-31 0001816233 shcr:WarrantEquityMember 2024-03-31 0001816233 srt:MinimumMember shcr:WarrantEquityMember 2024-03-31 0001816233 srt:MaximumMember shcr:WarrantEquityMember 2024-03-31 0001816233 shcr:ContractualAndEarnoutArrangementsMember 2024-03-31 0001816233 2023-01-01 2023-12-31 0001816233 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001816233 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001816233 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001816233 us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0001816233 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0001816233 us-gaap:SellingAndMarketingExpenseMember 2024-01-01 2024-03-31 0001816233 us-gaap:SellingAndMarketingExpenseMember 2023-01-01 2023-03-31 0001816233 shcr:ProductAndTechnologyExpenseMember 2024-01-01 2024-03-31 0001816233 shcr:ProductAndTechnologyExpenseMember 2023-01-01 2023-03-31 0001816233 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-03-31 0001816233 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001816233 us-gaap:RestrictedStockUnitsRSUMember 2023-05-31 0001816233 us-gaap:RestrictedStockUnitsRSUMember 2023-05-31 2023-05-31 0001816233 shcr:SharecareBrasilServiciosDeConsultoriaLtdaMember shcr:SulAmricaServiosDeSadeSASulAmricaMember 2024-03-31 0001816233 shcr:SulAmricaServiosDeSadeSASulAmricaMember shcr:CustomerMember 2024-01-01 2024-03-31 0001816233 shcr:SulAmricaServiosDeSadeSASulAmricaMember shcr:CustomerMember 2023-01-01 2023-03-31 0001816233 shcr:CustomerBoardOfDirectorsRelatedMember 2023-01-01 2023-03-31 0001816233 shcr:CustomerBoardOfDirectorsRelatedMember 2023-12-31 0001816233 shcr:SeriesAPreferredStockHolderMember 2023-01-01 2023-03-31 0001816233 shcr:SeriesAPreferredStockHolderMember 2023-12-31 0001816233 shcr:DirectorAffiliatedCustomerMember 2023-12-31 0001816233 shcr:DirectorAffiliatedCustomerMember 2023-01-01 2023-03-31 0001816233 us-gaap:StockCompensationPlanMember 2024-01-01 2024-03-31 0001816233 us-gaap:StockCompensationPlanMember 2023-01-01 2023-03-31 0001816233 us-gaap:RedeemableConvertiblePreferredStockMember 2024-01-01 2024-03-31 0001816233 us-gaap:RedeemableConvertiblePreferredStockMember 2023-01-01 2023-03-31 0001816233 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0001816233 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0001816233 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001816233 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 shares iso4217:USD iso4217:USD shares pure shcr:installment 0001816233 --12-31 2024 Q1 false http://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member P6M P6M http://www.sharecare.com/20240331#WarrantLiability 10-Q true 2024-03-31 false 001-39535 SHARECARE, INC. DE 85-1365053 255 East Paces Ferry Road NE, Suite 700 Atlanta GA 30305 404 671-4000 Common Stock, par value $0.0001 per share SHCR NASDAQ Warrants, each warrant exercisable for one share of common stock, each at an exercise price of $11.50 per share SHCRW NASDAQ Yes Yes Accelerated Filer false true false false 362409958 100320000 128187000 8348000 8544000 124936000 128173000 2213000 2262000 9875000 6007000 2814000 3178000 240158000 267807000 2751000 3375000 13599000 13863000 130263000 136552000 191860000 192037000 578631000 613634000 45530000 45388000 55516000 65706000 5735000 5517000 106781000 116611000 317000 403000 586000 519000 7171000 8032000 114855000 125565000 0.0001 0.0001 5000000 5000000 5000000 5000000 5000000 5000000 50000000 50000000 58205000 58205000 0.0001 0.0001 600000000 600000000 358572273 358572273 353430357 353430357 36000 35000 1168869000 1157737000 -2551000 -2263000 -760460000 -725373000 405894000 430136000 -323000 -272000 405571000 429864000 578631000 613634000 90861000 116295000 51121000 67890000 13558000 15348000 14544000 20808000 34907000 34121000 13331000 14781000 127461000 152948000 -36600000 -36653000 1274000 1680000 217000 430000 368000 429000 1425000 1679000 -35175000 -34974000 -31000 31000 -35144000 -35005000 -57000 -346000 -35087000 -34659000 -0.10 -0.10 -0.10 -0.10 354208908 354208908 352923217 352923217 -35144000 -35005000 -282000 307000 -35426000 -34698000 -51000 -289000 -35375000 -34409000 5000000 58205000 353430357 35000 1157737000 -2263000 -725373000 -272000 429864000 40278 24000 24000 7674863 1000 -1000 0 27000 27000 13866000 13866000 -57000 -57000 -288000 6000 -282000 2573225 2784000 2784000 -35087000 -35087000 5000000 58205000 358572273 36000 1168869000 -2551000 -760460000 -323000 405571000 5000000 58205000 354463620 35000 1120024000 -2794000 -595820000 1155000 522600000 281042 282000 282000 1759615 14000 14000 -1055000 -1055000 10406000 10406000 -346000 -346000 250000 57000 307000 214984 396000 396000 -34659000 -34659000 131000 131000 5000000 58205000 356289293 35000 1130199000 -2544000 -631534000 866000 497022000 -35144000 -35005000 13331000 14781000 68000 254000 0 451000 0 68000 566000 1138000 -379000 -138000 13596000 9969000 -36000 59000 -151000 -2120000 -2842000 1387000 3747000 5795000 -10422000 -10608000 -635000 794000 218000 703000 -19591000 -23498000 51000 368000 5135000 4806000 -5186000 -5174000 2784000 131000 24000 1023000 285000 370000 -3045000 522000 -45000 72000 -27867000 -28078000 128187000 182508000 100320000 154430000 151000 236000 626000 1336000 0 1695000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:1.5pt">Nature of Business and Significant Accounting Policies</span><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sharecare, Inc. (“Sharecare” or the “Company”) was founded in 2009 to develop an interactive health and wellness platform and began operations in October 2010. Sharecare’s virtual health platform is designed to help people, patients, providers, employers, health plans, government organizations, and communities optimize individual and population-wide well-being by driving positive behavior change. The platform is designed to connect each stakeholder to the health management tools they need to drive engagement, establish sustained participation, increase satisfaction, reduce costs, and improve outcomes. Sharecare bridges scientifically validated clinical programs with content to deliver a personalized experience for its members, beginning with the RealAge® test, Sharecare’s health risk assessment that shows members the true age of their body, capitalizing on people’s innate curiosity of how “young” they are to draw them into the platform. The Sharecare platform provides members with a personalized action plan to guide and educate them on the habits and behaviors making the biggest impact, both positive and negative, on their RealAge. Sharecare provides the resources members need to manage their health through lifestyle or disease management and coaching programs, such as diabetes management and smoking cessation, well-being solutions, such as financial health and anxiety management; care navigation tools such as find-a-doctor, prescription savings, clinical decision support, medical records, home care, and more. In January 2023, Sharecare launched Sharecare+, a digital-first, comprehensive advocacy solution designed to deliver value through benefits navigation, clinical engagement, virtual care, and chronic case and utilization management. Additionally, Sharecare provides secure, automated release of information, audit and business consulting services to streamline the medical records process for medical facilities. Sharecare delivers value via its provider, enterprise, and life sciences channels. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation Policy</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”). The consolidated financial statements include the accounts of Sharecare, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company’s chief operating decision maker is its chief executive officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance and allocating resources for the entire company.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim Consolidated Balance Sheet as of March 31, 2024 and the Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit), and Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are unaudited. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hese unaudited interim consolidated financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. In management’s opinion, the unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company’s consolidated results of operations and cash flows for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023. The results of operations for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are not necessarily indicative of the results to be expected for the full fiscal year or any other future interim or annual periods. The information contained within the unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s annual financial statements for the year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these unaudited interim consolidated financial statements in conformity with GAAP requires the use of management estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include goodwill, revenue recognition, stock-based compensation, and income taxes. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash deposits are held with well-known financial institutions and may exceed federally insured limits. The Company grants credit to its customers in the normal course of business and generally requires no collateral from its customers.</span></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires management to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 — Quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 — Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities that may be measured at fair value on a non-recurring basis relate primarily to the Company’s tangible fixed assets and other intangible assets. For these assets, the Company does not periodically adjust the carrying value to fair value except in the event of an impairment. When the Company determines that an impairment has occurred, the carrying value of the asset is reduced to its fair value and an impairment charge is recorded within operating loss in the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net, consists of trade accounts receivable which are due under normal trade terms requiring payment, typically within 45 days from the invoice date. The allowance for doubtful accounts is based on management's estimate for expected credit losses for outstanding trade accounts receivable and is recorded as an offset to accounts receivable. Changes in the allowance for doubtful accounts are classified as general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. The Company determines expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, and adjusts based on expectations of changes in macro-economic conditions and customer-specific information that may impact the collectability of outstanding receivables. The Company reassesses the adequacy of the allowance for doubtful accounts each reporting period. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the allowance for doubtful accounts are as follows (in thousands):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts – beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts written off and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts – ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,348 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,426 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with certain acquisitions, the Company has recognized current and noncurrent contract liabilities, representing off-market values associated with certain wellness program royalty agreements. Amortization of these contract liabilities was $0 and $0.5 million for three months ended March 31, 2024 and 2023, respectively, all of which was included within cost of revenues in the Consolidated Statements of Operations and Comprehensive Loss. Additionally, the Company has recognized certain contract liabilities due to a former related party in the amount of $17.5 million, related to service agreements, which is included in accrued expenses and other current liabilities in the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records contract liabilities, which consist of deferred revenue and contract billings in excess of earned revenue, pursuant to ASC 606.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues arise from contracts that permit upfront billing and the collection of fees covering the entire contractual service period, which is generally <span style="-sec-ix-hidden:f-328">six</span> to twelve months and in advance of the satisfaction of the performance obligations identified within the related contract. As of March 31, 2024 and December 31, 2023, such fees were $5.7 million and $5.5 million, respectively. The Company recognized $1.2 million of revenue during the three months ended March 31, 2024 that was included in deferred revenue at December 31, 2023.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Revenue</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as customer cost savings, and/or clinical outcomes improvements (performance-based). The Company uses the most likely amount method to estimate variable consideration for these performance guarantees. The Company includes in the transaction price some, or all, of a variable consideration amount only to the extent that it is not probable that a significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company utilizes customer data to measure performance. Performance-based fees subject to refund that the Company has not recognized as revenues are generally due to either: (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that it is not probable that the Company will meet the relevant performance target(s). As of March 31, 2024 and December 31, 2023, such fees included within deferred revenue were $4.8 million and $4.9 million, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that performance measures are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs <span style="-sec-ix-hidden:f-336">six</span> to eight months after the end of a contract year, performance-based fees are reconciled and settled. Approximately $1.5 million and $1.2 million of revenues recognized during the three months ended March 31, 2024 and 2023, respectively, were performance-based. As of March 31, 2024 and 2023, the cumulative amount of performance-based revenues that had met the criteria for recognition and had been recognized but had not yet been settled with customers, totaled $1.9 million and $6.5 million, respectively. During the three months ended March 31, 2024, $0.7 million of revenue was recognized, which related to services provided prior to December 31, 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations represent contracted revenues that are non-cancellable and have not yet been recognized due to unsatisfied or partially satisfied performance obligations. This includes deferred revenues and amounts that will be invoiced and recognized as revenues in future periods. As of March 31, 2024, future estimated revenue related to </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations with terms of more than one year that are unsatisfied or partially unsatisfied at the end of the reporting period was approximately $61.2 million. As of March 31, 2024, the Company expects to recognize revenue on approximately 91% of these unsatisfied performance obligations over the following 24 months and the remainder thereafter.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregated Revenue</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s revenues disaggregated by revenue source (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enterprise</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,861 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, other income (expense) consisted of the following (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re-measurement of contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re-measurement of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company (“EGC”), the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are applicable to private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company has elected to use this extended transition period under the JOBS Act until such time as the Company is no longer considered to be an EGC. The adoption dates discussed below reflect this election.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The new ASU requires public business entities, on an annual basis, to provide a tabular rate reconciliation (using both percentages and reporting currency amounts) of (1) the reported income tax expense (or benefit) from continuing operations, to (2) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal (national) income tax rate of the jurisdiction (country) of domicile using specific categories and separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold. A public business entity is required to provide an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes of the reconciling items and the judgment used in categorizing the reconciling items. For each annual period presented, the ASU requires all reporting entities to disclose the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign. It also requires additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The ASU requires that all reporting entities disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU is effective for public entities for annual periods beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2023, the FASB issued ASU No. 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments in this update address the requirement for a public entity to disclose its significant segment expense categories and amounts for each reportable segment. A significant segment expense is any significant expense incurred by the segment, including direct expenses, shared expenses, allocated corporate overhead, or interest expense that is regularly reported to the chief operating decision maker and is included in the measure of segment profit or loss. The disclosure of significant segment expenses is in addition to the current specifically-enumerated segment expenses required to be disclosed, such as depreciation and interest expense. If a public entity does not disclose any significant segment expenses for a reportable segment, it is required to disclose narratively the nature of the expenses used by the chief operating decision maker to manage the segment's operations. The ASU is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures as it pertains to the Company’s single reportable segment.</span></div> <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation and Consolidation Policy</span></div>The Company’s consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and pursuant to the regulations of the U.S. Securities and Exchange Commission (“SEC”).<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying interim Consolidated Balance Sheet as of March 31, 2024 and the Consolidated Statements of Operations and Comprehensive Loss, Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit), and Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are unaudited. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hese unaudited interim consolidated financial statements are presented in accordance with the rules and regulations of the SEC and do not include all disclosures normally required in annual consolidated financial statements prepared in accordance with U.S. GAAP. In management’s opinion, the unaudited interim consolidated financial statements have been prepared on the same basis as the annual financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Company’s consolidated results of operations and cash flows for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2023. The results of operations for the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are not necessarily indicative of the results to be expected for the full fiscal year or any other future interim or annual periods. The information contained within the unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s annual financial statements for the year ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> The consolidated financial statements include the accounts of Sharecare, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company’s chief operating decision maker is its chief executive officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance and allocating resources for the entire company.</span></div> <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these unaudited interim consolidated financial statements in conformity with GAAP requires the use of management estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include goodwill, revenue recognition, stock-based compensation, and income taxes. The Company bases its estimates on historical experience, known trends, and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span></div> <div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash deposits are held with well-known financial institutions and may exceed federally insured limits. The Company grants credit to its customers in the normal course of business and generally requires no collateral from its customers.</span></div> <div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximates fair value due to their short-term nature.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures financial assets and liabilities at fair value at each reporting period using a fair value hierarchy that requires management to maximize the use of observable inputs and minimize the use of unobservable inputs. Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between willing market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 1 — Quoted prices in active markets for identical assets or liabilities</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 2 — Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities</span></div><div style="margin-top:8pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Level 3 — Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities that are Measured at Fair Value on a Non-recurring Basis</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities that may be measured at fair value on a non-recurring basis relate primarily to the Company’s tangible fixed assets and other intangible assets. For these assets, the Company does not periodically adjust the carrying value to fair value except in the event of an impairment. When the Company determines that an impairment has occurred, the carrying value of the asset is reduced to its fair value and an impairment charge is recorded within operating loss in the Consolidated Statements of Operations and Comprehensive Loss.</span></div> <div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Doubtful Accounts</span></div>Accounts receivable, net, consists of trade accounts receivable which are due under normal trade terms requiring payment, typically within 45 days from the invoice date. The allowance for doubtful accounts is based on management's estimate for expected credit losses for outstanding trade accounts receivable and is recorded as an offset to accounts receivable. Changes in the allowance for doubtful accounts are classified as general and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. The Company determines expected credit losses based on historical write-off experience, an analysis of the aging of outstanding receivables, customer payment patterns, and adjusts based on expectations of changes in macro-economic conditions and customer-specific information that may impact the collectability of outstanding receivables. The Company reassesses the adequacy of the allowance for doubtful accounts each reporting period. <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the allowance for doubtful accounts are as follows (in thousands):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts – beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,544 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts written off and other adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(607)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allowance for doubtful accounts – ending balance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,348 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,426 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8544000 7197000 411000 1869000 607000 640000 8348000 8426000 <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div>In connection with certain acquisitions, the Company has recognized current and noncurrent contract liabilities, representing off-market values associated with certain wellness program royalty agreements. Amortization of these contract liabilities was $0 and $0.5 million for three months ended March 31, 2024 and 2023, respectively, all of which was included within cost of revenues in the Consolidated Statements of Operations and Comprehensive Loss. Additionally, the Company has recognized certain contract liabilities due to a former related party in the amount of $17.5 million, related to service agreements, which is included in accrued expenses and other current liabilities in the Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023. 0 500000 17500000 17500000 <div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records contract liabilities, which consist of deferred revenue and contract billings in excess of earned revenue, pursuant to ASC 606.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenues arise from contracts that permit upfront billing and the collection of fees covering the entire contractual service period, which is generally <span style="-sec-ix-hidden:f-328">six</span> to twelve months and in advance of the satisfaction of the performance obligations identified within the related contract. As of March 31, 2024 and December 31, 2023, such fees were $5.7 million and $5.5 million, respectively. The Company recognized $1.2 million of revenue during the three months ended March 31, 2024 that was included in deferred revenue at December 31, 2023.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Revenue</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain contracts place a portion of fees at risk based on achieving certain performance metrics, such as customer cost savings, and/or clinical outcomes improvements (performance-based). The Company uses the most likely amount method to estimate variable consideration for these performance guarantees. The Company includes in the transaction price some, or all, of a variable consideration amount only to the extent that it is not probable that a significant reversal in the amount of cumulative revenue recognized will occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company utilizes customer data to measure performance. Performance-based fees subject to refund that the Company has not recognized as revenues are generally due to either: (1) data from the customer is insufficient or incomplete to measure performance; or (2) interim performance measures indicate that it is not probable that the Company will meet the relevant performance target(s). As of March 31, 2024 and December 31, 2023, such fees included within deferred revenue were $4.8 million and $4.9 million, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that performance measures are not met by the end of the measurement period, typically one year, some or all of the performance-based fees are required to be refunded. During the settlement process under a contract, which generally occurs <span style="-sec-ix-hidden:f-336">six</span> to eight months after the end of a contract year, performance-based fees are reconciled and settled. Approximately $1.5 million and $1.2 million of revenues recognized during the three months ended March 31, 2024 and 2023, respectively, were performance-based. As of March 31, 2024 and 2023, the cumulative amount of performance-based revenues that had met the criteria for recognition and had been recognized but had not yet been settled with customers, totaled $1.9 million and $6.5 million, respectively. During the three months ended March 31, 2024, $0.7 million of revenue was recognized, which related to services provided prior to December 31, 2023. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations represent contracted revenues that are non-cancellable and have not yet been recognized due to unsatisfied or partially satisfied performance obligations. This includes deferred revenues and amounts that will be invoiced and recognized as revenues in future periods. As of March 31, 2024, future estimated revenue related to </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations with terms of more than one year that are unsatisfied or partially unsatisfied at the end of the reporting period was approximately $61.2 million. As of March 31, 2024, the Company expects to recognize revenue on approximately 91% of these unsatisfied performance obligations over the following 24 months and the remainder thereafter.</span></div> P12M 5700000 5500000 1200000 4800000 4900000 P1Y P8M 1500000 1200000 1900000 6500000 700000 61200000 0.91 P24M <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s revenues disaggregated by revenue source (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Enterprise</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,960 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Life Sciences </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,474 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,861 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,295 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 46960000 70193000 28427000 28974000 15474000 17128000 90861000 116295000 <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2024 and 2023, other income (expense) consisted of the following (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re-measurement of contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re-measurement of warrant liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -294000 -138000 -85000 0 -11000 291000 368000 429000 <div style="margin-bottom:12pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company (“EGC”), the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are applicable to private companies (that is, those that have not had a registration statement declared effective under the Securities Act of 1933, as amended (the “Securities Act”), or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company has elected to use this extended transition period under the JOBS Act until such time as the Company is no longer considered to be an EGC. The adoption dates discussed below reflect this election.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In December 2023, the FASB issued ASU No. 2023-09 "Income Taxes (Topic 740): Improvements to Income Tax Disclosures." The new ASU requires public business entities, on an annual basis, to provide a tabular rate reconciliation (using both percentages and reporting currency amounts) of (1) the reported income tax expense (or benefit) from continuing operations, to (2) the product of the income (or loss) from continuing operations before income taxes and the applicable statutory federal (national) income tax rate of the jurisdiction (country) of domicile using specific categories and separate disclosure for any reconciling items within certain categories that are equal to or greater than a specified quantitative threshold. A public business entity is required to provide an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes of the reconciling items and the judgment used in categorizing the reconciling items. For each annual period presented, the ASU requires all reporting entities to disclose the year-to-date amount of income taxes paid (net of refunds received) disaggregated by federal (national), state, and foreign. It also requires additional disaggregated information on income taxes paid (net of refunds received) to an individual jurisdiction equal to or greater than 5% of total income taxes paid (net of refunds received). The ASU requires that all reporting entities disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign, and income tax expense (or benefit) from continuing operations disaggregated by federal (national), state, and foreign. </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ASU is effective for public entities for annual periods beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In November 2023, the FASB issued ASU No. 2023-07 "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." The amendments in this update address the requirement for a public entity to disclose its significant segment expense categories and amounts for each reportable segment. A significant segment expense is any significant expense incurred by the segment, including direct expenses, shared expenses, allocated corporate overhead, or interest expense that is regularly reported to the chief operating decision maker and is included in the measure of segment profit or loss. The disclosure of significant segment expenses is in addition to the current specifically-enumerated segment expenses required to be disclosed, such as depreciation and interest expense. If a public entity does not disclose any significant segment expenses for a reportable segment, it is required to disclose narratively the nature of the expenses used by the chief operating decision maker to manage the segment's operations. The ASU is effective for public entities for fiscal years beginning after December 15, 2023, and interim periods in fiscal years beginning after December 15, 2024. We are still evaluating the impact on our financial statement disclosures as it pertains to the Company’s single reportable segment.</span></div> Fair Value Measurements<div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial instruments consist of cash equivalents, accounts receivable, accounts payable, accrued liabilities, warrant liabilities, and contingent consideration liabilities. Cash equivalents are comprised of money market funds stated at amortized cost, which approximates fair value at the balance sheet dates, due to the short period of time to maturity. Accounts receivable, accounts payable, and accrued liabilities are stated at their carrying value, which approximates fair value due to the short time to the expected settlement date. The warrant liabilities and contingent consideration liabilities are recorded at estimated fair value.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value hierarchy for assets and liabilities measured at fair value as of March 31, 2024 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  <span style="-sec-ix-hidden:f-375">Warrant liabilities</span> </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Contingent consideration – other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The warrants issued during the initial public offering by Falcon Capital Acquisition Corp. “FCAC” and the warrants issued by FCAC simultaneously with its initial public offering in a private placement, are both classified within Level 1 as they are publicly traded and have an observable market price in an active market. Additionally, the warrant liabilities are exercisable for one share of common stock at an exercise price of $11.50.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration is classified within Level 3 as it is valued using certain unobservable inputs. The fair value of the contingent consideration is estimated based on the Company’s stock price and number of shares expected to be issued related to acquisitions in prior years and are estimated using a Monte Carlo simulation with inputs for the Company’s stock price, expected volatility, risk-free rate, first and second earnout hurdles and expected term. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a schedule of changes to the contingent consideration — other liabilities classified as Level 3 for the periods presented (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re-measurement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair value hierarchy for assets and liabilities measured at fair value as of March 31, 2024 (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents at fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,470 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  <span style="-sec-ix-hidden:f-375">Warrant liabilities</span> </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">  Contingent consideration – other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10470000 0 0 10470000 10470000 0 0 10470000 317000 0 0 317000 0 0 101000 101000 317000 0 101000 418000 1 11.50 <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a schedule of changes to the contingent consideration — other liabilities classified as Level 3 for the periods presented (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 3pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Re-measurement of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 395000 294000 101000 Balance Sheet Components<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Expenses and Other Current Liabilities</span></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31,<br/>2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,304 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,546 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,235 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued media costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,684 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liability due to the Series A Preferred Stockholder</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,496 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses due to the Series A Preferred Stockholder</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,084 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,516 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,706 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024 and December 31, 2023, accrued expenses and other current liabilities consisted of the following (in thousands):</span> 17304000 15546000 10506000 16235000 2506000 5168000 1509000 1837000 1684000 1826000 17496000 17496000 3255000 6084000 1256000 1514000 55516000 65706000 Goodwill and Other Intangible Assets<div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived, intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology – features/content</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived, intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,955 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,463 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software projects in process</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived, trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets not subject to amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,755 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,492)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the changes in the carrying amount of the Company’s goodwill for the period presented (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,860 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and intangible assets deemed to have indefinite lives are not amortized but are subjected to annual tests of impairment. The Company tests goodwill and indefinite-lived intangible assets for impairment annually in the fourth quarter and between annual tests if an event occurs or circumstances change that would indicate that it is more likely than not that the carrying amount may be impaired. The Company </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initially evaluates qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment is not conclusive, a quantitative assessment of the fair value of a reporting unit is performed to test goodwill for impairment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using a combination of income and market approaches. There have been no impairments of goodwill since the Company’s inception.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result of the sustained decline in the Company’s stock price and associated market capitalization, the Company performed an impairment test during the first quarter of 2024. The fair value of the reporting units for goodwill impairment testing was determined using both an income approach and market approach. The income approach was based on discounted projected future (debt-free) cash flows for each reporting unit. The discount rates applied to these cash flows were based on the weighted average cost of capital for each reporting unit, which takes market participant assumptions into consideration. For the market approach, we used both the guideline public company and similar transaction methods. The guideline public company method analyzes market multiples of revenue and EBITDA for a group of comparable public companies. Under the similar transactions method, valuation multiples are calculated utilizing actual transaction prices and revenue and EBITDA data from target companies deemed similar to the reporting unit. As a result of the interim test, the fair values of each of our reporting units exceeded their respective book values in excess of approximately 10%, and the Company determined there was no impairment. An increase of 100 basis points in the weighted average cost of capital or a decrease of 100 basis points in annual forecasted revenues would have resulted in a 3% and 9% decline in the fair value, respectively of our reporting units which would not have resulted in impairment. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets during the three months ended March 31, 2024 and 2023 totaled $12.7 million and $14.0 million, respectively. Amortization expense is included in depreciation and amortization in the Consolidated Statements of Operations and Comprehensive Loss.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a schedule of estimated future amortization expense for intangible assets as of March 31, 2024 (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,463 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived, intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology – features/content</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived, intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,955 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,463 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software projects in process</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived, trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets not subject to amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,755 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,492)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets and the related accumulated amortization for each class of intangible asset as of March 31, 2024 were as follows (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="21" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Definite-lived, intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology – features/content</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,926 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,549 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,091)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,458 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,849 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,121)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,728 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,631 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,001 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total definite-lived, intangible assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,955 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,492)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,463 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets not subject to amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software projects in process</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,770 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite-lived, trade names</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets not subject to amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,800 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total intangible assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343,755 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(213,492)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,263 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 62926000 29650000 33276000 P7Y2M12D 3549000 2091000 1458000 P3Y3M18D 77849000 41121000 36728000 P8Y2M12D 189631000 140630000 49001000 P1Y9M18D 333955000 213492000 120463000 4770000 4770000 5030000 5030000 9800000 9800000 343755000 213492000 130263000 <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the changes in the carrying amount of the Company’s goodwill for the period presented (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,037 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,860 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 192037000 -177000 191860000 0.10 100 100 0.03 0.09 12700000 14000000 <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a schedule of estimated future amortization expense for intangible assets as of March 31, 2024 (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2024</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,239 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,932 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,463 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 33671000 31239000 17572000 10104000 6932000 20945000 120463000 Income TaxesAs a result of the Company’s history of net operating losses, the Company has provided for a full valuation allowance against its deferred tax assets, with the exception of its German and French operations. For the three months ended March 31, 2024, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income. For the three months ended March 31, 2023, the Company recognized income tax benefit of less than $0.1 million, primarily due to tax on foreign income. Common Stock and Stockholders’ Equity<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with debt and equity financings and certain partnership arrangements, the Company may issue warrants. Warrants classified as liabilities generally vest immediately and are exercisable upon issuance and have an expiration of seven years from the date of issuance. Warrants classified as equity generally vest after three years from the date of issuance and have an expiration of seven years from the date of issuance.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the following warrants to purchase common stock were issued and outstanding:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise Price<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.21 - $5.61</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,433,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.50</span></div></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also entered into, and may in the future enter into, contractual arrangements with certain customers and other parties and earnout arrangements in connection with acquisitions that, in each case, provide for the issuance of warrants and/or common stock upon the achievement of specified milestones. As of March 31, 2024, these agreements provide for the issuance of up to 3,238,675 shares of common stock and 6,353,577 warrants to purchase shares of common stock. With respect to these arrangements, there were 52,589 warrants earned but not issued as of March 31, 2024.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Payments</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise Price </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Plan shares outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,218,339</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,007,766 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,089,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,278)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,674,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,685,153)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,492,908</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,761,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and/or exercisable as of March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,764,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and/or exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,902,493</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the exercise price of the underlying common stock option award and the estimated fair value of the Company’s common stock. Vested but unissued restricted stock units as of March 31, 2024 and December 31, 2023 were immaterial. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for employee and nonemployee options and restricted stock units included in the Consolidated Statements of Operations and Comprehensive Loss is as follows for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,844 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally, share-based compensation costs, reflected within additional paid-in capital in the Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three months ended March 31, 2024 and 2023, included approximately $0.2 million and $0.4 million related to capitalizable internally developed software activities, respectively.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2023, each of the principal executive officer, principal financial officer, other named executive officers, and certain eligible employees of the Company voluntarily elected to forgo up to 25% of their cash base salary for the next 12 months, and in lieu thereof received restricted stock units (“RSUs”) with a value equal to the cash amount they elected to forego over the 12-month period. In consideration for forgoing guaranteed cash compensation, each individual will receive an additional number of RSUs with a value equal to 25% of the amount of cash salary they have elected to forgo. The RSUs were issued in June 2023 and will vest in four equal quarterly installments over the next 12 months, subject to the individual’s continued employment. The ability of the named executive officers and other eligible employees to make such election to forgo guaranteed cash compensation and receive RSUs in lieu thereof was approved by the Compensation and Human Capital Committee of the Company’s board of directors. The unvested RSUs are classified as a liability. As of March 31, 2024, there was $0.4 million of unvested RSUs classified as a liability and recorded to accrued expenses and other current liabilities in the Consolidated Balance Sheets. As such, share-based compensation costs, reflected within additional paid-in capital in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the three</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended March 31, 2024 does not reflect the cost associated with these awards. Upon vesting of these RSUs, amounts will be reclassified from liability to equity.</span></div> P7Y P3Y P7Y <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the following warrants to purchase common stock were issued and outstanding:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise Price<br/>per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.21 - $5.61</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,433,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.50</span></div></td></tr></table></div> 1278746 4.21 5.61 17433334 11.50 3238675 6353577 52589 <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise Price </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Plan shares outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,218,339</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,007,766 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,089,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,278)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,674,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,685,153)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,492,908</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,761,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and/or exercisable as of March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,764,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and/or exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,902,493</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option and restricted stock unit activity, prices, and values during the three months ended March 31, 2024 are as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Restricted Stock Units</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise Price </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic Value<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Plan shares outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of December 31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,218,339</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.87</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,007,766 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,089,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.03 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised/Released</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,278)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,674,699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled/Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,685,153)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(661,764)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of March 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,492,908</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,761,162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and/or exercisable as of March 31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,764,072</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and/or exercisable as of December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,902,493</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 92218339 3.01 P5Y10M13D 1256000 49007766 1.93 0 0 15089859 1.03 40278 0.59 7000 7674699 2.38 2685153 2.40 661764 1.85 89492908 3.03 P5Y6M29D 260000 55761162 1.62 73764072 1.88 P5Y2M26D 260000 73902493 1.89 P5Y5M26D 1256000 <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for employee and nonemployee options and restricted stock units included in the Consolidated Statements of Operations and Comprehensive Loss is as follows for the three months ended March 31, 2024 and 2023 (in thousands):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales and marketing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product and technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,468 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,962 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,844 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,969 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 204000 111000 1508000 828000 1664000 1068000 10468000 7962000 13844000 9969000 200000 400000 0.25 P12M P12M 0.25 4 P12M 400000 Commitments and Contingencies<div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Matters</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is subject to litigation in the normal course of business. The Company is of the opinion that, based on the information presently available, the resolution of any such legal matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. The Company has accrued for losses that are both probable and estimable. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also party to investigations and legal disputes and losses related to certain matters that are reasonably possible, but at this time, we cannot estimate a loss or range of losses.</span></div> Related-Party Transactions<div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sul América Serviços de Saúde S.A. (Sul América), is a customer of and owns a 49% interest in Sharecare Brasil Servicios de Consultoria, Ltda. As of the year ended December 31, 2023, the Company ended the services contract with this related party and ceased operations of Sharecare Brasil Servicios de Consultoria, Ltda. Revenues recognized for the three-month period ended March 31, 2024 and 2023 from Sul América totaled $0.3 million and $1.3 million, respectively. For the three-month period ended March 31, 2024, the revenues recognized represent variable termination fee revenue, which was previously contrained and for which uncertainty about the variable amount to be received was resolved. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Series A Preferred Stock is held by a customer that also had an employee serving on the Sharecare Board. During the three month period ended June 30, 2023, the board member ceased employment with the customer. Subsequent to the board member’s termination of employment with the customer, this customer was no longer considered a related party. Revenues recognized for this customer for the three months ended March 31, 2023 totaled $6.2 million. As of December 31, 2023, $13.0 million in receivables were outstanding from this related party. </span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, we entered into a revenue contract with the Series A Preferred Stockholder to provide patient advocacy services. We also entered into separate agreements to purchase distinct goods and services. These agreements are now subject to a dispute. Separate from the above disclosed amounts for this related party, revenues recognized related to these distinct services for the three months ended March 31, 2023 totaled $10.6 million. Additionally, revenue for the three months ended March 31, 2023, included $0.4 million of amortization of contract assets. For the three months ended March 31, 2023, cost of sales totaled $10.9 million. Amounts paid under the agreements that were not determined to be distinct were recorded as a reduction of revenues.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, there were $34.3 million in receivables and $51.1 million in accounts payable and accrued expenses recorded in connection with these distinct agreements. Additionally, in 2022 the Company acquired certain intellectual property which was determined to be distinct and recorded an intangible asset, which is being amortized over its estimated useful life. The unamortized balance of intangible asset was $3.1 million as of December 31, 2023. As of March 31, 2024, the receivables, accounts payable, and accrued expenses balances recorded in connection with these distinct agreements remained unchanged.</span></div>The Company has a customer that was a related party for the year ended December 31, 2023 due to an affiliation with a member of the Sharecare Board. This member was nominated during the first quarter of 2023 and has subsequently ceased employment with the customer. This customer is no longer considered a related party as of December 31, 2023. As of December 31, 2023, $1.0 million in receivables were outstanding from this related party and revenues recognized for the three months ended March 31, 2023 totaled $0.7 million. 0.49 300000 1300000 6200000 13000000 10600000 400000 10900000 34300000 51100000 3100000 1000000 700000 Net Loss Per Share<div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests in subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,087)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,659)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,208,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,923,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s potential dilutive securities, which include stock options and restricted stock units, redeemable convertible preferred stock, and contingently issuable shares, have been excluded from the computation of diluted net loss per share for the three-months ended March 31, 2024 and 2023, as they are anti-dilutive and the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common share equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,660,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,951,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,660,077 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,951,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, stock options of 89.1 million that have exercise prices in excess of the average market price of common shares for the three months ended March 31, 2024 and restricted stock units of 53.5 million as of March 31, 2024 are not included in the calculation of potentially dilutive securities, but could become dilutive in future periods.</span></div><div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the prior period, stock options of 73.7 million that have exercise prices in excess of the average market price of common shares for the three months ended March 31, 2023 and restricted stock units of 32.5 million as of March 31, 2023 are not included in the calculation of potentially dilutive securities.</span></div> <div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):</span></div><div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,005)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests in subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss available to common stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,087)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,659)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354,208,908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,923,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -35144000 -35005000 -57000 -346000 -35087000 -35087000 -34659000 -34659000 354208908 354208908 352923217 352923217 -0.10 -0.10 -0.10 -0.10 The Company excluded the following potential common share equivalents presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:<div style="margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.200%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,660,077 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,951,366 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redeemable convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,660,077 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,951,366 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2660077 30951366 5000000 5000000 7660077 35951366 89100000 53500000 73700000 32500000 Subsequent Events<div style="margin-top:8pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers events or transactions that occur after the balance sheet date, but before the consolidated financial statements are issued, to provide additional evidence relative to certain estimates or identify matters that require additional disclosures. The Company evaluated subsequent events through, May 9, 2024, the date on which the consolidated financial statements were available to be issued, noting no such material events.</span></div> false false false false